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 Population aging in Canada is associated with a rising burden of heart failure (HF), a 
condition associated with substantial morbidity, mortality and health service use. HF 
management involves pharmacotherapy, exercise, dietary restrictions and symptom monitoring. 
First-line combination pharmacotherapy for HF consists of an angiotensin converting enzyme 
inhibitor (ACE inhibitor) or angiotensin receptor blocker (ARB) in conjunction with a β-
adrenergic receptor blocker (β-blocker). This combination therapy can reduce mortality, improve 
symptoms and reduce health service use. However, evidence about the benefits of these therapies 
has been derived from randomized controlled trials in younger patients from acute care and 
specialty clinic settings. Little work has explored outcomes among older individuals and those in 
the community setting. In purposely studying an older cohort of individuals with HF, the goals of 
this research were three-fold: to comprehensively describe their sociodemographic, clinical and 
service use characteristics; to describe rates of usage of first-line HF pharmacotherapy and 
correlates of non-use; and to examine the outcomes of mortality, long-term care (LTC) 
admission, long-stay hospitalization, admission, new cognitive decline and new functional 
decline as well as predictors of these outcomes. To achieve these aims, this work made use of the 
extensive data available through the Resident Assessment Instrument – Home Care (RAI-HC) 
database in Ontario. The RAI-HC is mandated for use in Ontario to assess all long-stay home 
care clients (those expected to receive home care service for at least 60 days). This assessment 
contains over 300 items about sociodemographic and clinical characteristics, diagnoses, service 
use and geriatric conditions, such as functional abilities and cognition. The study samples 
included long-stay home care clients older than 65 years of age. 
 The descriptive analyses (N=264,030) demonstrated that older home care clients with HF 
iv 
 
are a more complex group than home care clients without HF, with more comorbidity and higher 
use of medications and health care services. From the analyses examining pharmacotherapy use 
(N=176,860), rates of use of first-line pharmacotherapy were low, with only 30% of clients with 
HF receiving recommended combination first-line therapies, a similar proportion receiving no 
therapies and the remainder receiving at least one therapy. The multivariate analyses revealed 
that hypertension and diabetes mellitus diagnoses affect first-line therapy use. Regardless of 
clinical subgroup, use of these therapies was less likely among older clients and those with 
functional impairment, airway disease or behavioural symptoms. Longitudinal analyses were 
done using Cox proportional hazards regression modeling (N=9,283) in which individuals were 
followed for nine months after each RAI-HC assessment. Results from these analyses showed 
that female gender and living alone reduced the risk of all outcomes except LTC admission, 
while age over 85 years generally increased the risk of all examined outcomes. Comprehensive 
clinical indicators, the Changes in Health, End-stage disease, Signs and Symptoms (CHESS) 
scale and Method for Assigning Priority Level (MAPLe) algorithm, increased the risk of all 
outcomes except new cognitive decline. ACE inhibitor use was protective of LTC admission and 
functional decline, but not mortality, long-stay hospitalizations or cognitive decline. 
The complexity of older individuals with HF could impair self-care abilities and points to 
the need for initiatives to help such individuals manage their care at home with appropriate 
support and services. The low rates of use of first-line pharmacotherapy among older home care 
clients with HF highlights the need for better understanding of which factors affect prescribing 
practices. Better evidence, that is more applicable to older individuals with HF, is needed about 
the therapeutic benefits of first-line therapies to help enhance the evidence base and improve 
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 Heart failure (HF) is a chronic disease in which precipitating factors such as valvular or 
pericardial disease and systolic or diastolic left ventricular dysfunction increase the risk of 
clinical signs and symptoms of low cardiac output and systemic or pulmonary congestion. HF 
prevalence among Canadians exceeds 500,000 and is highest among those over age 65. HF is 
associated with high levels of morbidity and mortality, reduced quality of life, impaired 
functional ability and increased health service use. Management of HF is complex and involves 
dietary restrictions, exercise recommendations, monitoring of symptoms and pharmacotherapy.  
 Pharmacotherapies are recommended based on evidence from clinical trials, a research 
method considered to be the gold standard in medical literature. HF management has benefitted 
greatly from such trials and many medications are recommended in managing this disease. 
Pharmacotherapy for HF with reduced ejection fraction includes use of angiotensin converting 
enzyme (ACE) inhibitors, β-adrenergic receptor blockers (β-blockers), angiotensin II type I 
receptor blockers (ARB), aldosterone antagonists (AA) and digoxin. Trials of these medications 
have demonstrated effectiveness in improving HF outcomes. However, the majority of 
individuals in potential need of such therapies are not necessarily comparable to participants 
included in clinical trials. Selection criteria generally favour recruitment of younger individuals 
with less comorbidity and outcomes studied may not reflect the treatment goals of older 
individuals. Individuals with HF are often older, have more comorbidity and more concomitant 
medication use than trial participants. This disconnect means there is relatively little evidence 
upon which to base therapy for this population. Evidence suggests that older individuals are less 
likely to receive recommended pharmacotherapies although they may benefit from them. 
Pharmacotherapy use in older adults requires consideration of dosing, polypharmacy, 
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comorbidities and adherence. Underuse of therapy in older individuals could reflect poor disease 
management due to insufficient evidence of therapeutic benefit specific to this population. Better 
evidence upon which to base management in this cohort would help expand knowledge and 
quality of care in this area. 
 Much chronic disease management occurs in the community setting rather than in the 
acute health care system. Managing HF is representative of chronic disease management and is 
very complex. Medication therapy, exercise, dietary restrictions and education about changing 
symptoms are all components of care. Once needs are too great to be met through family support 
and home care services, transitions to long-term care occur. Understanding the needs of 
individuals with HF in the home care sector may help to allocate care more appropriately, but 
has been under-investigated.  
 Pharmacotherapy is an important component of care and understanding patterns of 
medication use as well as barriers to treatment is essential. Much evidence about rates of 
pharmacotherapy use comes from patients managed in specialized clinic settings. Whether such 
use is similar among older, community-dwelling individuals, who are predominantly managed 
by general physicians, is unknown. Patterns of medication use as well as factors that could be 
potential barriers to use are important to understand, but have been under-studied.  
 Perhaps more important is to understand whether medications recommended for 
treatment of younger individuals represented in clinical trials have similar effectiveness in older 
populations. Creating a more realistic picture of care in older populations with more medication 
use and more comorbidity would provide a more relevant sample on which to base clinical 
practice recommendations. However, the pre-eminence of clinical trial evidence has so far 
precluded research initiatives into population-based cohort studies. Arguably, such studies could 
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supplement evidence from clinical trials by examining the effects of proven therapies in more 
diverse patient populations. Further, many trials examine mortality and hospitalizations as 
outcomes. In older populations, quality of life outcomes, such as functional and cognitive 
decline, may be more important therapeutic goals. Understanding more diverse outcomes among 
older, complex patients would help inform clinical management. 
 Assessment instruments like the Resident Assessment Instrument-Home Care (RAI-HC) 
can help examine the care needs of individuals with HF, medication use and barriers to 
medication use, and outcomes of treatment over time. There are a number of strengths to 
performing pharmacoepidemiologic research using these tools, including comprehensive 
assessment of geriatric conditions, clinical and service use factors; size of the data set; and the 
longitudinal nature of the data collected. 
 This work will utilize Ontario RAI-HC data linked with Ontario Association of 
Community Care Access Centres (OACCAC) administrative data in a novel way to inform 
clinical management of HF. This research aims to provide evidence upon which to base 
management of older individuals with HF and assist with care planning and chronic disease 
management strategies. This work is well-aligned with recent health care movements towards 
promoting aging in the home environment and will allow the system to provide better care to 
older individuals. It is hoped that this research will be applicable to other chronic diseases and 
further enhance the care of aging populations. 
1.1 Search Strategy 
 Retrieval of the clinical trials relevant to HF pharmacotherapies and other components of 
treatment was done by searching the electronic databases Science Direct, Medline, Web of 
Science and ClinicalTrials.gov (1980-2009); the websites of the Canadian Cardiovascular 
4 
 
Society, the American College of Cardiology, and the European Society of Cardiology; and the 
online journal issues of Heart, Canadian Journal of Cardiology, the Journal of Cardiac Failure, 
the European Heart Failure Journal, Journal of the American Geriatrics Society and the Journal 
of the American Medical Association. The inclusion of older articles allowed identification of 
early RCTs in the field. The search strategy combined the following terms: heart failure 
(congestive, left-sided, right-sided), cardiac failure, pharmacotherapy, cardiovascular drugs, 
trials, ACE inhibitors, beta-1 adrenergic blocking agents, aldosterone antagonists, angiotensin II 
type 1 receptor antagonists, sartans and digoxin. Article bibliographies were reviewed and 
additional relevant references, irrespective of their publication date, were obtained. Major 
clinical trials for each of the 5 therapeutic classes of interest were reviewed and summarized in 
Tables 1-5 (Appendix G). Many excellent review articles and meta-analyses were identified, and 






2.1 The Prevalence and Burden of Heart Failure 
 
Cardiovascular diseases are the leading causes of morbidity and mortality worldwide, 
responsible for 16.7 million deaths annually. (1) HF is one such disease and is a major public 
health problem in Canada associated with high morbidity and mortality and substantial burden 
on the health care system. HF, as defined by the Canadian Cardiovascular Society (CCS), is a 
“complex syndrome in which abnormal heart function results in, or increases the subsequent risk 
of, clinical symptoms and signs of low cardiac output and or pulmonary or systemic congestion”. 
(2) An estimated 500,000 Canadians live with HF and its prevalence increases with age. By age 
80, the lifetime risk of HF development is approximately 20%. (2,3) Population aging and 
improved survival of individuals with hypertension and myocardial infarction (MI), two 
important risk factors for HF, are contributing to rising HF prevalence. (3,4,5) More worrisome, 
prevalence of HF among individuals over 65 years is anticipated to double over the next 30 
years. (5,6)  
 Despite advances in the overall treatment and management of HF, survival and quality of 
life remain poor. (7) In the United States and Canada combined, approximately 300,000 people 
die each year from HF. (8) Depending on age, symptom severity, heart dysfunction, and other 
factors, HF is associated with annual mortality rates as high as 50%, and 25-40% of patients will 
die within one year of diagnosis. (2,9) Five-year survival rates are approximately 50%. (2) 
Evidence suggests that median survival following hospital discharge for HF, age at death, and 
one-year and five-year survival rates have all improved since 1986. (10) 
In Canada, cardiovascular diseases are the most costly illness by diagnostic category, 
incurring $21.2 billion dollars in indirect and direct costs each year. (11) Expenditures on 
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cardiovascular medications and use of all drug classes, except nitroglycerin, have increased 
substantially in Canada over the past decade. (12) Diuretics, statins and ACE inhibitors were the 
most frequently used classes of medications, with costs associated with ACE inhibitors alone 
nearing $1 billion in 2006. (12) For HF, prescription medications and hospitalizations account 
for the majority of health system costs. (13) Health service utilization is especially high among 
older individuals with HF. Inpatient and outpatient costs associated with HF management make 
it one of the costliest health care problems in Canada. (14) One-year readmission rates as high as 
33-50% following index HF hospitalization were reported in two large Canadian studies. (14,15) 
An early study of patients hospitalized for HF found that 53% of readmissions were preventable. 
(16) Management of HF to reduce health care system use and improve quality of life for patients 
is necessary. 
2.2 Clinical Presentation and Diagnosis 
2.2.1 Disease Presentation 
 HF is a chronic condition characterized by bouts of worsening symptoms and signs, 
termed decompensation of chronic HF. (17) This decompensation can lead to frequent 
hospitalizations and physician visits in individuals with previously stable disease. (17,18) HF is 
considered to be stable if it is managed and individuals experience few or no signs and 
symptoms. In clinical practice, the signs and symptoms often associated with HF result from an 
elevation of pulmonary and systemic venous pressure of cardiac origin. (19) Typically, the 
following signs and symptoms are associated with the presence of HF: shortness of breath with 
exertion or when lying down, swelling of the lower extremities, reduced exercise tolerance, 
increased pressure in the jugular vein, and crackling sounds in the lungs during inspiration 
(Appendix A: Figure 1). (2,20) 
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 HF may present less typically in older persons, especially among those with concomitant 
functional impairment or frailty (Appendix A: Figure 2). (2) Such individuals often lead more 
sedentary lifestyles and may present with swelling in the hip region and no shortness of breath on 
exertion. (21) In individuals older than 80 years with HF, atypical symptoms include confusion, 
irritability, fatigue, anorexia, and reduced activity. (20) Further, behavioural changes including 
anxiety and depressed mood, as well as altered cognition, are more common in frail older 
individuals with HF and may be associated with symptomatic or undertreated HF. (22) These 
atypical symptoms can make identification of HF among older, frailer individuals difficult. 
2.2.2 Heart Failure Diagnosis 
 HF diagnosis is based on the presence of symptoms (Appendix A: Figure 1) and objective 
evidence of cardiac dysfunction, usually through echocardiography. (19,23) The additional 
criterion of favourable response to treatment directed at HF may also be used. (23) Ideally, 
diagnosis of HF should be done while symptoms are present. (19)  
2.2.3 Stages of Heart Failure 
 The most widely used classification system for severity and progression of HF is the New 
York Heart Association (NYHA) system. This system is based on functional measures, allowing 
movement between stages if HF is well managed with pharmacotherapy (Appendix B: Figure 1). 
(17,24) The American College of Cardiology and American Heart Association (ACC/AHA) 
guidelines for evaluating and managing HF also classify HF into four stages (Appendix B: 
Figure 2). (3,25) This classification system is based on physiological changes and the first stage 
identifies persons at high risk for HF development due to comorbid conditions. (3) Both systems 




2.2.4 Heart Failure with Reduced and Preserved Ejection Fraction 
 HF was thought to result from primarily dysfunction of the left ventricle (LV) during 
systole, impairing the heart‟s ability to pump enough blood to the circulation. Confirmation of a 
reduced ejection fraction (EF) during systole, shown to be below 40 % on an echocardiogram, is 
the definition of HF with reduced EF. (17) It is becoming clear, however, that systolic function 
may be preserved in HF. Termed „heart failure with preserved ejection fraction‟ (HFPEF), left 
ventricular ejection fraction (LVEF) is preserved, but the pressure needed to allow blood to fill 
the ventricle is higher. (26) As LV filling becomes compromised, pressure increases in the left 
atrium, pulmonary veins and capillaries, predisposing the individual to pulmonary congestion 
and HF. HF with preserved and reduced EF may not be mutually exclusive, and one or both may 
occur in the same individual. (27)  
 HFPEF increases in prevalence with age and is thought to account for more than 50% of 
HF cases in individuals older than 75 years. (19,25) It is more common in women, and 
individuals with chronic hypertension, coronary artery disease, and abnormal echocardiograms. 
HFPEF is associated with similar rates of mortality and rehospitalizations as HF with reduced 
EF. (26,28,29) 
2.2.5 Underlying Pathophysiology and Aging 
 The aging process contributes to structural changes in the heart which may be associated 
with HF. In the LV, aging increases both stiffness and wall thickness, reduces compliance and 
early diastolic filling, and impairs relaxation, all of which increase mechanical stress. (27) This 
stress can lead to extensive structural changes, rendering the failing heart unable to meet cardiac 
output demands to tissues despite adequate LV filling pressure. (27) While aging can lead to 
such changes that predispose individuals to HF development, other underlying pathologies also 
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play a role. For example, conditions such as hypertension, myocardial ischemia (resulting from 
coronary artery disease) and LV hypertrophy can all contribute to reduced ventricular function. 
(30) As the heart fails, delivery of blood and oxygen is reduced and vascular resistance increases. 
(20) These changes impair the heart rate response to stress, reduce compliance and contractile 
reserve and increase the pressure needed to pump blood from the heart (Appendix C: Figure 1). 
(20) 
 HF is characterized by prolonged stimulation of the sympathetic nervous system and 
renin-aldosterone-angiotensin (RAA) system activation (Appendix C: Figure 2). The resulting 
angiotensin II, norepinephrine and cytokines produced normally compensate for changes in 
arterial pressure and cardiac output, but in HF they precipitate cardiac muscle cell death, 
endothelial dysfunction, vasoconstriction and renal retention of sodium and water (Appendix C: 
Figure 3). (27,31) As heart muscle dies, the LV experiences further dysfunction and increased 
wall stress which further promotes pathogenic structural changes. (27) The overall result is an 
inability of the heart to respond to stressors such as ischemia, tachycardia, illness and physical 
exertion, and clinical events that are well-tolerated at younger ages can lead to HF in older 
persons. (20) The aging process, as well as the presence of age-related chronic conditions, 
contributes to structural cardiovascular changes that precede HF development in older 
individuals.  
2.3 Risk Factors 
 Among older populations, HF is often multi-factorial in nature. (27) Ischemic heart 
disease (IHD) is the predominant cause of HF in the Western world; other common etiologies 
include systemic hypertension, cardiomyopathies, valvular heart disease, LV hypertrophy, 
arrythmias, pericardial disease, and diabetes. (17,24,27) IHD and hypertension alone are 
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responsible for 70-80% of HF cases. (24,27) In older women with HFPEF, hypertension is the 
most common cause, while in older males it is IHD. (20) Given the relationship of HF to other 
cardiovascular conditions, investigators in the Physicians‟ Health Study in the United States 
examined whether lifestyle factors affect HF risk. (32) After more than 20 years of follow-up in 
20,900 men, this study found that maintaining a normal weight, not smoking, exercising 
regularly, moderating alcohol intake and consuming breakfast cereals and fruits and vegetables 
individually reduced HF risk and together reduced HF risk by 22% compared to men with none 
of these healthy habits. (32) Strategies targeting prevention of cardiovascular disease may 
ultimately affect HF incidence. However, in individuals who already have HF, non-adherence 
with medications and diet are the most common causes of exacerbations. (16) 
2.4 Comorbidities 
 With aging, the risk of developing chronic disease increases. In the Canadian National 
Population Health Survey, only 12% of participants aged 80 or older reported having no chronic 
conditions, while 41% of participants reported having three or more. (33) When examining HF in 
older populations, it is important to consider the implications of comorbidities. Anemia, 
cachexia, renal insufficiency, obstructive sleep apnea, chronic obstructive pulmonary disease 
(COPD), diabetes, hypertension and hyperlipidemia are all common in individuals with HF. 
(25,34,35) Such comorbidities have unfavourable implications for the prognosis of HF, play a 
role in the progression of HF and are often worsened by HF. (34) For example, anemia 
contributes to exercise intolerance and renal insufficiency worsens HF symptoms and prognosis 
and limits the use of pharmacotherapy. (25) A history of depression may affect HF prognosis by 
increasing the risk of mortality and cardiac events, reducing the likelihood of receiving cardiac 
procedures and education about HF management, and lengthening hospital stay. (36,37) Lastly, 
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the occurrence of comorbid conditions in individuals with HF very strongly affects quality of life 
and may impair self-care behaviours. (17)  
2.5 Disease Outcomes 
 Improper management of HF is associated with adverse outcomes including mortality, 
hospitalizations, functional decline, cognitive impairment, and caregiver burden. The potentially 
relevant outcome of long-term care (LTC) admission among older HF patients in the community 
has not been studied. Evidence suggests that proper pharmacologic management of HF may 
improve some of these outcomes. 
2.5.1 Mortality 
 HF is associated with significant morbidity and mortality, especially among older 
cohorts. (20) First-year mortality rates are as high as 50% and five-year survival is 
approximately 50%. (2) Whether HF mortality rates are similar between males and females is 
unclear, but overall, males and individuals with HF with reduced EF have shown greater 
improvements in mortality through pharmacotherapeutic interventions. (38,39) 
2.5.2 Hospitalizations  
 Probably the largest economic impact of HF comes through its association with increased 
health service use including hospitalizations. HF is the most common cause of hospitalizations in 
people over the age of 65 in the United States and is the primary discharge diagnosis of almost 
1,000,000 individuals annually. (8) In Canada, 50% of individuals with HF are readmitted to 
hospital in the year following HF diagnosis and more readmissions are seen among older 
individuals. (40) Non-adherence to drug therapy, non-adherence with dietary and exercise 
recommendations, living alone, post-hospitalization medication discrepancies, lack of cardiology 
consult at admission and pulmonary hypertension all increase the risk of rehospitalization for 
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HF. (41) In a large cohort study of patients presenting to a Canadian emergency department (ED) 
with acute HF, those who were not admitted were more likely to present again in the ED, be 
hospitalized and die within 30 days and one year. (42) 
2.5.3 Functional Decline 
 Individuals with HF are significantly more likely to be frail, and both conditions increase 
the likelihood of functional decline. (43,44) Individuals hospitalized for HF often experience 
functional decline, which can lead to a greater need for home and community care services. As 
function continues to decline, individuals are at increased risk of hospitalization for HF. Decline 
in both measures of activities of daily living (ADL) and instrumental activities of daily living 
(IADL) represent clinical changes that have been associated with increased mortality and poor 
health-related quality of life among older persons with HF. (45) Near the end of life, individuals 
with HF exhibit much variability in changes in NYHA class and physical limitations, but late-life 
illness is generally characterized by long-term functional limitations with episodic disease 
exacerbations (Appendix D). (46,47)  
2.5.4 Cognitive Impairment 
 Cognitive impairment is a common problem in HF thought to affect 20-50% of patients. 
(48-50) Cognitive impairment and HF share common risk factors including atherosclerosis, 
hypertension and diabetes. (48,49) In HF, it is thought that reduced cerebral blood flow due to 
systolic hypotension or microemboli-induced cerebral infarcts may lead to impaired cognition 
through deficits in memory, attention, processing speed, and learning. (21,49) Older individuals 
with HF seem more prone to developing chronic cognitive impairment and may develop acute 
and fluctuating impairment known as delirium, especially during decompensated HF. (22,49) 
Cognitive impairment in older individuals with HF can lead to difficulties in self-care including 
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non-adherence to therapy, medication mismanagement, failure to recognize early symptoms, 
rehospitalization, physical disability and increased mortality. (16,49-51) Optimization of HF 
therapy in older populations may improve cognitive function in a dose-dependent manner, and 
longitudinal studies of cognitive changes in HF have been identified as a gap in the current 
literature. (51,52) 
2.5.5 Caregiver Burden 
 Caregiver burden is another important outcome associated with HF. For caregivers of 
individuals with HF, disease management is extremely complex in terms of promoting self-care, 
monitoring dietary and exercise adherence, transporting patients to appointments, and monitoring 
for signs of decompensation. (53) Studies of caregiver burden in HF have found that patient age, 
comorbidity, disease severity and LVEF were not predictive of caregiver burden. (53,54) 
However, disruption of daily schedule and patient‟s loss of physical strength were associated 
with increased burden. (54) 
2.5.6 Other Outcomes 
 HF is associated with increased rates of depression and poorer quality of life, especially 
in older individuals. A community-based study of older individuals with HF (mean age 72 years) 
found that compared to gender-matched community-dwelling older controls, individuals with HF 
experienced significantly more depressive symptoms and reduced health-related quality of life 
(measured with the RAND-36 survey). (55) The diminished quality of life in HF has been linked 
to reduced physical, social and functional abilities as well as increased psychological distress. 
(55) 
2.6 Management of Heart Failure 
 As a chronic condition, the management of HF is complex and many therapeutic 
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strategies exist. Treatment options for the management of HF include neurohormonal modulation 
through pharmacotherapy, salt and fluid intake restriction, exercise therapy and surgical 
interventions. Many individuals with HF will benefit from a combination of these therapeutic 
options in management of their disease. 
2.6.1 Pharmacotherapy 
 Pharmacological management of HF is based on strong evidence from a large number of 
randomized controlled trials (RCTs), many of which focused on HF with reduced EF. A 
summary of these therapies is given in Figure 1 (Appendix E). There is much less evidence to 
support treatment of HFPEF. ACE inhibitor, β-blocker, ARB, AA and digoxin therapies are 
commonly used treatment options in HF management, in addition to diuretics.  
2.6.1.1 Heart Failure with Reduced Ejection Fraction 
 Most of the therapeutic options recommended in managing HF are recommended in the 
treatment of HF with reduced EF. ACE inhibitor, ARB and β-blocker therapies are 
recommended for use in most individuals with HF with reduced EF. AA and digoxin, both older 
therapies, are recommended for some subpopulations and new evidence of potential benefits is 
emerging. Diuretics are used extensively and hydralazine and isosorbide dinitrate therapy is used 
in specific patient populations (Appendix F: Table 1). The following table is a summary of the 
evidence of therapeutic benefits for ACE inhibitor, β-blocker, ARB, AA and digoxin therapies. 










Evidence of Therapeutic  









- improve survival, HF symptoms, NYHA   
  class, exercise capacity, HF hospitalizations  
  and HF development (58-63) 
- reduce recurrent MI and improve post-MI  
  survival (64-67) 
- some may improve cognitive impairment in  
   hypertensive adults (68) 
- 25% reduction in all- 
 cause mortality  
- 35% reduction in HF- 
  specific mortality or  
  hospitalization  
- improve NYHA class  
  (57,69) 
- benefits in severe HF (70) 
 
- inconclusive evidence  
  on cognitive benefits 
- frequent use of 
  composite endpoints 
- little research into  
  quality of life  
  outcomes, functional  






- improves NYHA class, not mortality (71) 
Candesartan 
- with ACE inhibitor therapy, reduces   
  cardiovascular death or hospitalization, but  
  more adverse events (72) 
- reduces CV death or HF hospitalization in  
  ACE inhibitor intolerant individuals (73) 
- equivalent to ACE inhibitors post-MI:  
  reduces all-cause mortality, recurrent MI  
  (74,75) 
 
- with β-blocker therapy,  
  some reduction in  
  morbidity and  
  hospitalizations (76) 
- not superior to ACE  
  inhibitors in reducing  
  mortality, but as effective  
  in reducing  
  hospitalizations (77,78) 
- frequent use of  
  combined endpoints 
- little research into  
  functional, cognitive  
  and quality of life  
  outcomes 
- not all therapies  
  investigated for all  






- improves exercise tolerance, quality of life  
  and NYHA class (79) 
- may reduce sudden death, but increase  
  hospitalizations (80) 
Carvedilol 
- improves symptoms, NYHA class, overall  
  well-being, but not exercise tolerance (81-85) 
- trend toward improved  
  survival (86,88,92) 
- improve NYHA class,  
  reduce all-cause mortality,  
  prolong exercise tolerance  
  time (93) 
- frequent use of  
  composite endpoints 
- no studies examining  
  functional status or  
  cognition 
- not all therapies  
  investigated for all  







Evidence of Therapeutic  





β-blocker  Carvedilol 
- reduces all-cause mortality, hospitalizations,  
  slows disease progression, may improve  
  survival over metoprolol (82,86-88) 
- reduces all-cause mortality and recurrent MI   
   post-MI (89) 
Metoprolol 
- increases exercise tolerance, quality of life,  
  improves NYHA class (87,90,91) 
- improves survival,  all-cause mortality and  
  hospitalization risk (86,87) 
  
AA No Spironolactone 
- reduces all-cause mortality, cardiac deaths, 
HF hospitalization (with use of ACE 
inhibitors, diuretics, digoxin) (94) 
- reduces renal function, quality of life (95) 
Eplerenone 
- reduces all-cause mortality, cardiovascular 
death or hospitalizations following MI (96) 
No - only mortality and  
  hospitalizations  
  endpoints examined  
- no research into  
  functional or cognitive  




- improves symptoms, functional class,  
  exercise capacity, LVEF, reduces heart rate  
  and body weight, may reduce hospitalizations  
  (97-99) 
 - reduces HF hospitalizations, not mortality,  
  even in older individuals (100) 
No - most evidence from  
  subgroup analysis,  
  especially for older  
  individuals 
- no research on  
  cognitive or functional  
  effects 
 
Abbreviations: AA = Aldosterone Antagonist, ACE = Angiotensin Converting Enzyme, ARB = Angiotensin Receptor Blocker, β–blocker 
= β-Adrenergic Receptor Blocker, CV = Cardiovascular, HF = Heart Failure, LVEF = Left Ventricular Ejection Fraction, MI = 
Myocardial Infarction, NYHA = New York Heart Association (functional classification), RCT = Randomized Controlled Trial  
a
Evidence-based therapies: Candesartan and Valsartan 
b




 The many benefits of ACE inhibitors, including improved survival and reduced 
hospitalizations, have been demonstrated in RCTs since the 1980s (see Appendix G: Table 1). 
ACE inhibitors show evidence of a class-effect, meaning that similar benefits have been 
observed with enalapril, captopril, ramipril, quinapril and lisinopril. (56,57) ACE inhibitors are 
recommended as first-line therapy for symptomatic HF with reduced EF (Appendix F). (2,3,101) 
 ARB therapies are also considered in managing HF, but are newer and only possibly 
confer survival benefits (see Appendix G: Table 2). (102) These therapies are primarily 
recommended for use in individuals who cannot tolerate ACE inhibitors, but in some cases, can 
be added to ACE inhibitor regimens. (2,3,101)  
 β-blocker therapy is another important component of pharmacotherapy for HF. Unlike 
ACE inhibitors, there is more variation in effectiveness seen with β-blockers (Appendix G: Table 
3). The cardioselective β-blockers metoprolol, carvedilol and bisoprolol have been shown to 
reduce all-cause mortality by approximately 35% and are considered evidence-based therapies. 
(86,87,103-105) Long-term use of β-blockers has been associated with improved symptoms and 
NYHA class in individuals with HF, although these benefits are seen after a longer treatment 
period than ACE inhibitor benefits. (102) β-blocker therapy should be used in conjunction with 
ACE inhibitor or ARB therapy as first-line treatment in most individuals with HF with reduced 
EF (Appendix F). (2,3,101) 
 In addition to ACE inhibitor, ARB, and β-blocker therapy in HF management, use of 
aldosterone antagonists and digoxin are recommended in some cases. Spironolactone is the 
predominantly used AA and has shown benefits when added to standard therapy regimens of 
ACE inhibitors, β-blockers and diuretics. However, spironolactone is only recommended for 




(Appendix F). (2,3,101,105) Digoxin is a symptomatic therapy for HF that suppresses renin 
secretion by the kidneys and increases contractility. (97,106) It does not improve survival, but is 
recommended for use in individuals with HF with reduced EF who remain symptomatic despite 
optimal therapy (Appendix F). (2,101) Clearly the pharmacotherapy regimen for HF with 
reduced EF is complex. However, management of this type of HF has benefitted greatly from the 
large number of clinical trials and well-established clinical guidelines exist. 
2.6.1.2 Heart Failure with Preserved Ejection Fraction 
 HFPEF is now recognized as a common condition, especially among older individuals. 
Unlike HF with reduced EF, treatment for HFPEF is not well established. Non-pharmacological 
management of HFPEF is similar to that of HF with reduced EF. Daily weight monitoring, diet 
and lifestyle modifications, patient education and close follow-up are key components of care 
(107,108) and exercise training may be beneficial. (3) 
 There is less evidence about which pharmacotherapies should be used to treat HFPEF and 
no evidence-based therapies exist that improve clinical outcomes (Appendix H). (108) Treatment 
strategies for HFPEF are based on extrapolations from effective strategies used to treat HF with 
reduced EF and a small number of trials have examined the effect of these therapies in the 
treatment of HFPEF in older individuals. Such trials indicate that while β-blocker therapy may 
be beneficial in improving all-cause mortality or cardiovascular hospitalizations over placebo 
(109), ACE inhibitor and ARB therapies do not. (110,111) Further, while some ARBs 
(candesartan and losartan) have demonstrated effectiveness in improving exercise tolerance, 
quality of life and HF-related hospitalizations (112-114), others (irbesartan and valasartan) have 
shown less benefit. (111,115) Subgroup analyses from the Digitalis Investigation Group trial 




total cardiovascular mortality, did reduce HF hospitalizations, and led to an increase in unstable 
angina leading to more cardiovascular hospitalizations overall. (100) Finally, there is some 
research into management of HFPEF from cohort studies. A large cohort study in Ontario 
examined the effects of ACE inhibitor, β-blocker, spironolactone and digoxin therapy in 
individuals with EF above and below 50%. (116) None of these therapies reduced mortality or 
hospitalization rates in individuals with HFPEF. (116) A smaller subgroup analysis examined the 
effectiveness of pharmacotherapy in patients older than 80 years, finding no association between 
ARB, β-blocker, digoxin, statin or diuretic therapy and improved survival or hospitalizations. 
(117) 
 Despite the lack of clear evidence about effective therapies in the management of 
HFPEF, ACE inhibitor and β-blocker therapy are recommended for symptom relief in 
individuals with controlled hypertension. (2,3) Digoxin use should be avoided in most 
circumstances, unless required for heart rate control. (2,3)  
2.6.1.3 Therapeutic Benefits in Older Individuals 
 HF management has benefitted greatly from results of well-designed clinical trials. 
However, many trials from which the evidence was generated excluded older (aged 75 +) 
subjects. Exclusion of older individuals from such trials has a number of limitations and 
implications for HF management. Although age is the number one risk factor for cardiovascular 
events, approximately 40% of cardiovascular medicine trials exclude older individuals. (118) 
Increasing life expectancies and increasing age of patients have not yet resulted in increased 
interest to provide best quality, evidence-based care for older individuals. (119) The 




prescribing to elderly populations small, even though such individuals are the largest consumers 
of prescription medications. (120) 
 To enhance care for elderly individuals, more and better data are needed and clinical 
trials designed appropriately for elderly individuals have been called for. (118,121) Trial 
participants and older persons with comorbidities may have different risk-to-benefit ratios with 
respect to therapy and this may prevent uptake of evidence-based care. (120) Thus, sometimes 
even with evidence, older persons do not receive quality care, and cohort studies on real patients 
with comorbidities would build the evidence base. (119) Despite the fact that most trials of HF 
pharmacotherapies have excluded older individuals, current treatment recommendations for HF 
are the same for older and younger individuals. Some smaller, observational studies have 
examined treatment effects in older populations, and subgroup analyses of older subjects from 
the larger trials have also been published. 
 Enough evidence exists for some to conclude that older individuals with HF benefit from 
ACE inhibitor therapy and should not be denied treatment. (122) Whether benefits are as great as 
those seen among younger individuals is more questionable. (70) Subgroup analyses and 
observational studies have found up to 41% reductions in mortality for older individuals, 
suggesting that benefits of ACE inhibitors seen in RCTs extend to older individuals. (122-125) 
Despite these potential benefits, increasing age has been shown to be an independent predictor of 
not receiving ACE inhibitor therapy. (123-125) Among older long-term care residents, ACE 
inhibitor therapy significantly reduced the rate of functional decline, independent of comorbidity 
or baseline physical function. (126) Thus ACE inhibitor therapy appears to have some benefit 
even in older populations. 




Older individuals may be more prone to side effects of ACE inhibitor therapy, including coughs 
and rash, and therefore ARBs may be acceptable alternates to ACE inhibitor therapy in this 
cohort. (56) Subgroup analyses have found differing results on mortality, but valsartan and 
candesartan therapy are associated with improved NHYA class, LVEF, signs and symptoms of 
HF, hospitalizations and quality of life in older and younger age groups. (71,74)  
 The utility of β-blocker therapy in older populations has also been explored through 
subgroup analyses of larger trials and observational cohort studies. Subgroup analyses from trials 
of metoprolol and bisoprolol suggest mortality benefits in older individuals, except in those with 
severe renal impairment (127,128) and nebivolol reduced all-cause mortality and hospitalizations 
compared to placebo, but less effect was seen in the subgroup older than 75 years. (110) Cohort 
studies have found that all-cause mortality and HF-specific mortality were reduced at both high 
and low doses of β-blockers. (123) Lastly, in older individuals with HFPEF, there is some 
evidence of mortality benefits of β-blockers, overall suggesting that β-blockers be used to treat 
HF with preserved and reduced EF. (82,86,87,103,129) 
 The effectiveness of AA therapy in older populations is not well established. From the 
RALES study, adverse events declined significantly in all age groups, including a pre-defined 
subgroup of individuals older than 67 years. (93) However, a later population-based study of 
older individuals with HF (mean age 78 years) showed increased rates of hyperkalemia-
associated morbidity and mortality with spironolactone use, although this may have been due to 
inappropriate dosing or monitoring. (130) 
 It is well recognized that the therapeutic index of digoxin is narrow, especially for older 
individuals. (25) In post-hoc analysis, age was an independent predictor of total mortality, all-




suspected digoxin toxicity and withdrawal from digoxin therapy (131), even at low serum 
digoxin concentrations (0.5-0.9 ng/mL). (100) Lastly, in older hospitalized individuals, cognitive 
performance improved significantly with digoxin therapy. (132)  
2.6.1.4 Other Issues in Heart Failure Pharmacotherapy in Older Individuals 
 Clearly there are many limitations of the current evidence in terms of applicability to 
older populations. There are also many unique considerations that must be taken into account 
when deciding how to manage HF in older individuals. These include underuse and dosing, 
polypharmacy, adverse drug events, adherence and comorbidities. These factors extend beyond 
HF and are applicable to pharmacotherapy generally in older populations. 
 Underuse and Dosing of Heart Failure Pharmacotherapies 
 HF pharmacotherapies are underused in older HF populations. Even if therapies are 
prescribed, doses often fall short of those recommended from clinical trials. (56) Possibly due to 
less evidence about their clinical benefit in older individuals, ACE inhibitors and β-blocker 
therapies are underused in both primary care and specialty care settings. (40,122,133-135) 
Reasons identified for underuse of ACE inhibitors and β-blockers include underestimation of 
morbidity and mortality in HF, underestimation of benefits of therapy, concerns about adverse 
events, and age. (135) Use of ACE inhibitor, ARB and β-blocker therapies have improved over 
time, while use of older therapies such as digoxin have declined. (136) Use of ACE inhibitor or 
ARB therapies has been found to be as high as 83% among individuals deemed ideal for ACE 
inhibitor therapy across all age groups. (137,138) β-blocker use is usually lower than ACE 
inhibitor use in older cohorts and has been found to be as low as 10% among older individuals. 
(133,135) Age, comorbidity, COPD and a history of bradycardia were all identified as barriers to 




as ACE inhibitor therapy, were more likely to receive β-blockers. (123) Further, 
contraindications to β-blocker use, as well as side effects like fatigue and exercise intolerance, 
are more common in older individuals and limit the use of these therapies. (110) However, even 
if contraindications to therapy exist, ACE inhibitor therapy has been shown to be beneficial 
(139,140) and β-blocker therapy is recommended in individuals with stable pulmonary disease. 
(2) Thus, underuse of HF pharmacotherapy is prevalent, and while it may be justified in some 
cases, it may partially reflect resistance by providers in managing older individuals. 
 In addition to underuse of HF pharmacotherapy, under-dosing is also prevalent in older 
populations. Normally, ACE inhibitors are prescribed at lower doses and progressively titrated to 
higher doses to attain recommended dosages from clinical trial evidence. (137) In geriatric 
medicine, titration to the maximum tolerated dose is recommended. (2) However, many studies 
have shown that ACE inhibitors and β-blockers are often used at suboptimal doses, especially 
among older individuals. (133,137,138) Renal impairment, hypotension and low creatinine 
clearance were all identified as reasons for lower dosing of ACE inhibitors in these studies. 
(133,137,138) Alternately, under-dosing may represent physician reluctance to try higher doses 
in older individuals. (133) Consequences of suboptimal dosing have only been explored 
minimally. While some benefits are seen with lower doses of ACE inhibitors or β-blockers (141), 
optimal benefit is seen at recommended doses. (142) Further exploration into underuse and 
suboptimal dosing to determine effects on adverse outcomes may improve care and quality of 
life and reduce costs.  
Polypharmacy and Adverse Drug Events 
 Polypharmacy, the use of multiple medications, is common among older individuals due 




involves multiple medications and one study reported an average of seven medications in 
recently discharged individuals with HF. (143) With use of increasing numbers of medications, 
the potential for side effects and drug-drug interactions also increases. (56) The number of 
prescribed medications is the strongest risk factor for adverse drug events, independent of age. 
(144) Concomitant use of four drugs increases the risk of adverse events by 50%-60% and this 
risk approaches 100% with eight to nine prescribed medications. (144) 
 Many age-related physiological changes occur that can potentially alter the effects of 
medications and increase the risk of drug-drug interactions and adverse drug events. Renal 
function decreases with age, putting older individuals at risk for hypotension, renal failure and 
hyperkalemia. (56) Further, aging is associated with reductions in drug metabolism and clearance 
through the cytochrome P-450 family of enzymes. (144) Elimination half-lives generally 
increase with age, making the timing between doses of medication important considerations in 
older individuals. (144) Lastly, reduced skeletal muscle mass, decreased total body water and 
reduced intravascular volume all lead to a smaller area of distribution for medications in older 
individuals. (25) As a result of such physiological changes, clearance of ACE inhibitors, β-
blockers and digoxin is affected. (25,144) ACE inhibitor dosing should be adapted to renal 
function, and monitoring of serum potassium and creatinine to detect impaired renal function 
should be done regularly. (25) Polypharmacy also increases the risk of drug-digoxin interactions, 
which can lead to reduced clearance, making older individuals more susceptible to digoxin 
toxicity, a clinical diagnosis that can lead to delirium. (145,146) Concerns over adverse drug 
events, including toxicities and side effects, are important barriers to prescribing HF medications 






 In older populations, adherence with prescribed drug therapy can affect therapeutic 
benefit. The World Health Organization defines adherence as „the extent to which a person‟s 
behaviour (taking medications, following diet, and/or executing lifestyle changes) coincides with 
agreed recommendations from a health care provider‟. (148) This definition reflects the 
importance of patients being in agreement with therapeutic recommendations. Comorbidity, 
depression, poor social support and social isolation may all reduce adherence with drugs, diet 
and exercise recommended in older individuals with HF. (20,149) Medication adherence rates as 
high as 73%-90% have been reported among HF patients discharged from hospital and self-
reports. (143,150) Most individuals recall receiving advice on exercise and dietary restrictions as 
well; however, individuals with lower recall were shown to take fewer HF medications. (150)  
 The presence of cognitive impairment may have detrimental effects on adherence. Like 
HF, the prevalence of CI increases with age and the co-occurrence of these conditions is 
becoming more common. (52) Multiple small, cross-sectional studies have shown that cognitive 
impairment is highly prevalent in recently discharged individuals with HF, that it correlates with 
severity of NYHA symptoms, and that a history of chronic HF is associated with a greater risk of 
chronic cognitive impairment or dementia. (49,151) Cognitive impairment can interfere with the 
ability of individuals to recognize their illness and reduce adherence with prescribed therapies, 
including medications, leading to frequent hospitalizations. (144)  
 Persistence, the length of time that individuals are adherent with therapy, is also 
important to consider when treating older individuals. (148,152) Persistence with cardiovascular 
therapies generally decreases over time, with 12-month adherence rates found to be 63% 




recommended HF pharmacotherapy give insight into covariates of persistence, reasons for 
discontinuing therapy and the relationship between persistence and outcomes. (158-160) A large 
five-year follow-up study found persistence rates of ACE inhibitors/ARBs and β-blockers to be 
79% and 65%, respectively. (159) Multiple drug therapy and more severe HF were associated 
with persistence and discontinuation was significantly associated with increased mortality. (159) 
A smaller cohort study of individuals from a specialized HF clinic found that β-blocker use at 6, 
12, and 24 months was maintained between 69 and 74%. (158) Even in individuals with COPD 
who did not exhibit wheezing, 86% were able to tolerate therapy to the end of follow-up with 
careful observation. (158) Failure to restart therapy following hospitalization, more advanced 
symptoms, spironolactone use, no ACE inhibitor use, adverse drug reactions and medical reasons 
are common reasons for discontinuing therapy. (158,160)  
Comorbidities 
 Among older populations, the presence of comorbidity is common. Comorbidities 
including anemia, renal insufficiency, diabetes, COPD and arthritis can play a role in the 
progression of HF and be worsened by HF. Management of HF can also affect other conditions. 
For example, diuretics can aggravate urinary incontinence issues and dietary restrictions can 
affect nutritional disorders. (25) Therapy with diuretics, vasodilators, and β-blockers can worsen 
hypotension and increase fall risk. (25) Frailty also worsens HF symptoms and quality of life, 
and can be worsened during hospitalizations leading to greater fall risk. (25) 
 The presence of comorbidity also has great influence on rates of prescription of HF 
pharmacotherapy. Renal dysfunction (serum creatinine greater than 170 µmol/L) is more 
common in older age and reduces ACE inhibitor and spironolactone use in individuals with HF. 




dysfunction, diabetes and respiratory disease were not significant predictors of ACE inhibitor use 
in individuals with HF. (133) Asthma, pulmonary disease and respiratory diseases (and 
consequent bronchodilator and steroidal therapies) can reduce the likelihood of receiving β-
blocker therapy by up to 50%. (133,150)  
 Some conditions also increase the likelihood of receiving therapy. Diabetics are more 
likely to receive ACE inhibitor, but not β-blocker therapy. (133) Individuals with IHD, 
hypertension and atrial fibrillation are more likely to receive both ACE inhibitor and β-blocker 
therapy. (150) While comorbidity should flag the need for careful management and monitoring, 
it should not necessarily be a reason to withhold effective therapy.  
2.6.1.5 Limitations of Evidence for Pharmacotherapy 
 Participants in clinical trials for HF pharmacotherapy are not representative of the 
individuals most likely to need therapy. Namely, older individuals with comorbidity represent 
the majority of patients with HF, but have generally been excluded from clinical trials. Trial 
participants are a highly select group that tend to be younger, male, and have HF with reduced 
EF as their sole or primary diagnosis. (161) Meanwhile, in the community, individuals with HF 
are older, more equally distributed by gender, have multiple comorbidities, take many 
concomitant medications and have high rates of HFPEF. (161) The limited generalizability of 
clinical trial findings to elderly populations has been noted, as has the potentially incorrect 
application of results from such trials in treating older individuals. (121) Nonetheless, guideline 
recommendations for HF are based on these clinical trials and generally apply to all individuals 
with HF with reduced EF regardless of age. (56) Study design, exclusion criteria, and relevant 
outcomes of interest all limit the value of clinical trial data in recommending care to older 




Study Design and Exclusion Criteria 
 Most studies of HF pharmacotherapy have been large, randomized, double blind, 
placebo-controlled trials, providing high quality evidence of interventions compared to placebo 
or standard therapy. (149) However, the generalizability of this evidence to HF patient 
populations is questionable. RCTs are the most rigorous method by which to evaluate the 
effectiveness of medical interventions like pharmacotherapy. (149) Often, trials do not enroll 
sufficient numbers of older persons to have enough power to examine individual outcomes. 
Some evidence about the benefits of pharmacotherapy in older populations comes from subgroup 
analyses of larger clinical trials, a weaker type of study design. Further evidence has come from 
prospective cohort studies in older individuals with HF. (123,130,162) While this study design is 
not considered as rigorous as an RCT, the results may be more relevant to the community-
dwelling HF population, providing valuable evidence on which to base practice. 
 Many RCTs exclude older persons, especially those older than 75 years. (56,81,83,86,90) 
The average age of participants in HF RCTs is approximately 66 years, versus an average age of 
75 years for the general population with HF; most community-dwelling individuals with HF 
would not qualify for trials. (122,141,163) Encouragingly, a review of RCTs of coronary 
syndromes found that the proportion of subjects over 75 years increased four-fold in 1991-2000 
compared to 1966-1990, but concluded that older individuals are still under-represented. (164) 
Exclusion of older participants may be due to physician beliefs that age is associated with 
inferior outcomes or investigator concerns that many competing causes of adverse events could 
mask treatment benefits. (118,163) Some have begun to question whether chronological age is an 
appropriate criterion for determining participation in clinical trials or if physical ability, organ 




entry, while increasing the generalizability of results. (165,166) However, older individuals may 
not be willing to participate in RCTs due to age, illness, mobility, physical limitations, 
comorbidity, other appointments and care-giving roles. (167) So, while enrolling a more diverse 
cohort of older individuals in trials would add to the evidence base and extend generalizability, 
the feasibility of such studies may be questionable.  
 Many trials of HF pharmacotherapy have included only participants with impaired LVEF, 
usually below 35 or 40% (Appendix G), and this is another big difference between trial and 
community populations. (168) Women are more likely to have HFPEF and this selection 
criterion indirectly excludes many of them from trials. (161,163,167) Exclusion of individuals 
with HFPEF may partially account for the age differences observed between trial participants 
and the typical HF patient population. (122,161,167) More evidence is needed to guide 
management of individuals with HFPEF, who represent a large proportion of older patients. 
From the limited trials that have examined HFPEF, it can be seen that women and older 
individuals are more likely to be represented (Appendix H). 
 The presence of comorbidity also affects who is enrolled in HF trials. Presence of other 
comorbid conditions may increase the likelihood of competing causes of adverse outcomes, 
making trial organizers hesitant to enroll individuals with multiple comorbidities. (163,168) 
Additionally, individuals with multiple comorbidities often use many medications, another 
common exclusion criterion. (122,168) Impaired renal function is often an exclusion criterion, 
but worsens HF prognosis and is deserving of evidence to support disease management. (122)  
 Almost all major RCTs of HF therapy have been done in Western, industrialized 
countries. Whether results are applicable to non-Western populations, where HF burden is 




and older individuals may receive poorer care, increasing the risk of adverse outcomes. 
(169,170) However, a cohort study involving younger individuals with HF found similar rates of 
ACE inhibitor and β-blocker use among men and women and no difference in mortality rates 
was observed between those on optimal medication therapy. (171) Further, most trials studied 
individuals with NYHA class II-IV HF (see Appendix G). This means that therapeutic effects in 
people with more advanced HF have been better established than for those with milder HF, who 
may benefit more from pharmacotherapy to delay disease progression. Lastly, many trials recruit 
individuals from secondary and tertiary care centers, which likely leads to selection bias, 
increasing the likelihood of enrolling individuals receiving optimal HF management. (141) 
Outcomes of Interest 
 Most clinical trials of HF pharmacotherapy examine all-cause mortality as the main 
outcome of interest. However, large numbers of individuals need to be enrolled to reach enough 
outcomes for adequate power. A common solution involves combining endpoints, but this 
strategy can mask the magnitude of therapeutic benefits associated with each outcome. (122,172) 
The applicability of such endpoints in individuals with severe disease or those who are frail is 
questionable. In older populations, improved functional independence, quality of life, symptom 
reduction and prevention of hospitalizations may be more valued than incremental survival 
benefits. More recent trials are starting to reflect some of these other treatment benefits by 
examining secondary endpoints like improvements of NYHA class, exercise tolerance and 
progression of HF. (122) From Tables 1-5 in Appendix G, it can be seen that many of the trials 
for therapies for HF with reduced EF examined all-cause mortality and use of the composite 
endpoint of all-cause mortality and all-cause hospital admission was common. Some trials 




HFPEF (Appendices G and H). (83,90,98,111) Long-term medication toxicity may be another 
more appropriate endpoint in older populations who are continuing to live longer with chronic 
illness. (173) 
2.6.1.6 Physician Perceptions and Awareness of Guidelines 
 Physician concerns over the applicability of clinical trial evidence to older individuals 
with HF and physician attitudes towards HF management have been the focus of much research. 
Specialists tend to prescribe HF therapy more than general physicians, who may have 
exaggerated concerns about treatment risk and side effects of HF pharmacotherapy. (122) 
Studies from primary care have demonstrated lower use of ACE inhibitor therapy in older 
individuals and those with comorbidities and polypharmacy because of perceived risk of adverse 
effects, lower perceived benefit, lack of confidence in the guidelines, difficulty of dose titration, 
monitoring and follow up, poor patient adherence, complexity of treatment, lack of diagnostic 
confidence, and difficulty applying RCT findings to older complex patients. (137,147,174) 
Further, while some work shows that application of therapeutic guidelines has improved (133), 
interventions to improve guideline adherence are less effective in older populations. (175) Age, 
gender and comorbidity have all been shown to affect whether individuals with HF receive 
guideline-recommended therapies. (170,176,177) 
2.6.1.7 Treatment Decisions in Older Individuals 
 Use of pharmacotherapy for HF management is lower among older individuals. ACE 
inhibitors and β-blockers are underused in older individuals in both primary care and specialty 
care settings. (52,122,133-135) Age and concerns over adverse events are cited as reasons 




prescribe such therapies in older cohorts. However, whether such decisions are based upon good 
evidence is debatable. 
 Age-related physiological changes that alter the pharmacokinetics of drug therapies by 
reducing drug clearance and area for distribution increase the potential for adverse drug 
reactions. (25,144) Thus, consideration of the potential risk of adverse drug reactions is 
necessary when treating older individuals. However, in any decision to prescribe or withhold 
therapy, potential risks and benefits must be evaluated. When considering potential benefits of 
therapy in older populations, physicians may not have good evidence available upon which to 
base decisions. Evidence of therapeutic benefit comes almost exclusively from RCTs. Exclusion 
criteria of such trials means that participants are dissimilar from the majority of HF patient 
populations based on age, LVEF, comorbidity and medication use. It is often up to physicians to 
decide whether therapeutic benefits observed in trials can be expected in older populations. 
Physicians have identified difficulty applying trial findings to their patients as a reason for lower 
use of HF pharmacotherapies in older patients. (137,149,174) 
 Further, from clinical trial work, the endpoints of mortality and hospitalizations (often 
combined) are most commonly used. (57,70,76-78,81,85-96) Outcomes of potentially greater 
relevance in older populations, such as functional ability, cognition, quality of life and symptom 
management, are often not studied. Thus, whether such therapies offer benefits applicable to 
older individuals is not well established. Some work from older cohorts seems to indicate that 
benefits of ACE inhibitor and β-blocker therapy observed in trial participants does extend to 





 There is also a dearth of information regarding outcomes of therapy over time, despite the 
fact that pharmacotherapy for HF will be used over the long-term. The CCS 2009 guidelines 
caution clinicians to balance the benefits of hypertension therapy in older individuals with the 
increased risk of side effects, especially in those with frailty or underlying comorbidity. (178) In 
summary, older individuals are less likely to receive HF pharmacotherapy, but the potential 
benefits of such therapy in this population are not well established. This means that while 
potential risks of treatment are well understood, potential benefits are not. To inform such 
decisions, research that establishes whether therapeutic benefit exists in older populations is 
needed. 
2.6.2 Restricting Salt and Fluid Intake 
 Limiting the intake of salt and fluids is recommended in HF to manage weight and 
control edema. The CCS guidelines recommend that individuals with symptomatic HF restrict 
their dietary salt intake to 2-3g/day and adhere to a „no-salt-added‟ diet. (2) In individuals with 
persisting fluid retention and congestion, daily fluid intake should be limited to 1.5-2 L/day. (2) 
Lastly, daily weight monitoring is important and medical attention should be sought if weight 
gain exceeding two kilograms in three days occurs. (101) 
2.6.3 Exercise Therapy 
 Another component of HF management is exercise therapy. Coats and colleagues (179) 
have shown that exercise training can improve exercise tolerance, oxygen consumption and HF 
symptoms. CCS guidelines recommend that all individuals with stable, NYHA class II-III HF 
with reduced EF should aim to exercise 2-5 times per week for 30-45 minutes. (2) Through 
interval training or steady state exercise, benefits include increased physical capacity, improved 




2.6.4 Surgical Interventions 
 Surgical interventions in HF management are less commonly used than the previously 
described therapies. Coronary artery bypass grafting (CABG) is a treatment option for 
individuals with multi-vessel disease, but may not be feasible in individuals with comorbid 
conditions. (6) Implantable devices, including defibrillators, can help with heart rate control in 
individuals with HF with advanced HF (LVEF < 30%) who are at increased risk for atrial 
fibrillation. (6) Cardiac resynchronization therapy may be beneficial in individuals with 
persisting HF symptoms and impaired cardiac conduction. (2) Lastly, surgical ventricular 
remodeling is an experimental treatment. (6) 
2.6.5 Chronic Disease Management and Heart Failure 
 In HF care, chronic disease management (CDM) programs have gained much recent 
attention and may enhance the quality of patient care. CDM programs generally refer to a 
multidisciplinary approach in which physicians and teams, consisting of nurses and possibly 
other health professionals, tailor and monitor care to individuals at all stages of HF. (181,182) 
Common components of CDM programs include education of patients and caregivers in self-care 
practices, case coordination (by clinical nurses or nurse practitioners), enhancement of self 
management skills, optimization of medication and follow-up with patients (Appendix E: Figure 
2). (182-184) Educating patients and caregivers about the symptoms, signs, diagnosis, treatment, 
dietary issues and role of exercise can help promote self management and redirect the burden of 
care away from the acute health care system. (182) 
 CDM programs for HF have been advocated to increase prescription of pharmacotherapy, 
increase adherence to dietary restrictions and medication therapy, and reduce hospitalizations. 




relieving symptoms, improving functional capacity and quality of life, and reducing acute 
exacerbations and unnecessary hospitalizations. (182) CDM programs may be especially 
beneficial to individuals with other comorbidities or other barriers to care. (182)  
2.6.5.1 Self-Care 
 An important goal of CDM programs is the promotion and facilitation of self-care 
practices through patient education. Self-care strategies include both self-maintenance and self-
management behaviours. Self-maintenance refers to adherence to prescribed therapies and health 
practices, while self-management includes recognition and evaluation of signs and symptoms of 
HF, implementation of a treatment option and evaluation of the treatment chosen (Appendix E: 
Figure 3). (187-189) Self-management requires learning skills, insight, judgment, problem-
solving and decision-making, and is more cognitively demanding than self-maintenance. A HF-
specific tool to help clinicians evaluate the self-management capabilities of their patients has 
been developed. (190) 
In HF, specific self-care behaviours include medication taking, symptom monitoring and 
adhering to dietary restrictions. CDM programs for HF strive to promote patient self-care and 
have been shown to improve quality of life and functional status, reduce unplanned and repeated 
hospitalizations and possibly reduce mortality. (182,191)
 
 Barriers to self-care include anxiety 
comorbidities, depression, sleep problems, cognitive impairment and poor health literacy. (189) 
There are no performance measures to address patient adherence to components of self-care in 
acute care settings, making it difficult for providers to know if education is working. (192)  
2.6.5.2 Research Evidence for Chronic Disease Management Programs 
 Research evidence is beginning to highlight important benefits of CDM programs for HF 




improve use of and adherence to pharmacotherapy, improve quality of life and prognosis and 
reduce resource use. (104,182-184) Improving adherence to drug therapy may in turn improve 
other outcomes including survival and reduction of hospitalizations in individuals with HF with 
reduced EF. (74,93,103,110) In Ontario, CDM is delivered to a large proportion of individuals 
with HF regardless of age, but some work found that males are more likely to receive CDM. 
(193) 
 Much research has examined interventions with coordinated CDM delivered through 
nurses and pharmacists. Such intensive interventions may reduce number of hospitalizations and 
number of days spent hospitalized related to HF in the short term (up to six months), but longer 
term benefits are questionable. (94,185) One recent meta-analysis (104) suggests that while 
targeted interventions reduce hospital readmissions, they do not affect mortality. Further, 
individuals with optimally treated, stable HF may be managed adequately through general 
practice, with HF clinics being useful in initial disease management. (194) 
2.6.5.3 Role of Home Care in Chronic Disease Management 
 Home care may play an important role in optimal management of HF, possibly in 
conjunction with or following, CDM programs. Home care may help overcome the underuse of 
disease-modifying therapies, especially in older persons (183), improve adherence to medication, 
diet and exercise recommendations and help maintain the benefits seen in CDM programs. (2,16) 
In older individuals, CDM programs may be more effective with some home care component or 
strategy to address comorbidities, and social and financial issues associated with HF. (184) The 
role for home care in CDM is not well-developed, but home care may be able to provide CDM 
services complementary or in addition to those offered in general practice. Coordinating care 




could improve disease outcomes and quality of life.  
2.7 Summary of Current Literature  
 Heart failure, with reduced or preserved EF, is common among older individuals and is 
associated with reduced survival, functional ability and quality of life, as well as increased health 
service use and caregiver burden. Chronic disease management programs can help older 
populations manage this complex disease. An important part of such programs, and a cornerstone 
of HF care, is pharmacotherapy. ACE inhibitors, β-blockers, ARB, AA and digoxin are all 
recommended for use in HF with reduced EF and while less evidence exists about the 
effectiveness of these therapies in HFPEF, there are some recommendations for use among these 
individuals. Pharmacotherapies for HF have been well-evaluated in RCTs. Benefits of 
pharmacotherapy include prolonged survival, reduced hospitalizations and improvements in 
symptom severity, function and exercise tolerance. ACE inhibitor and β-blocker therapies have 
shown the most beneficial effects in individuals with HF and reduced EF and are recommended 
for use in most individuals. 
 The representation of older individuals in clinical trials of HF pharmacotherapy is poor. 
The exclusion of older individuals, women, those with comorbidity and those on other 
medications limits the likelihood that evidence gained from RCTs will be applicable to larger HF 
populations in the community. Even when trials enroll older subjects, highly selective inclusion 
criteria continue to promote enrollment of individuals with less comorbidity and medication use. 
Another weakness of the current evidence in HF management is in managing HFPEF. 
Recommendations are sparse for all individuals, and effective therapies in older populations have 
not been well explored. However, emerging from the observational cohort studies in HFPEF 




trials enroll more women and do not usually limit EF above 40%. More cohort studies will begin 
to advance knowledge in this field, providing evidence for therapies in older populations. 
Excellent systematic reviews and meta-analyses of the larger trials for ACE inhibitors, β-
blockers and ARBs have been published and are invaluable in providing direction for the 
management of HF. 
 Whether older individuals with HF benefit from pharmacotherapy to the same degree as 
trial participants is not well established. Some evidence suggests that similar benefits are seen in 
older populations, particularly for ACE inhibitor therapy. However, the few studies examining 
therapeutic effects in older populations have many limitations. The cut-off ages remain low, and 
most of these studies still did not include very old individuals (age 80 or older). Difficulties in 
recruiting older adults may still be a barrier. Additionally, subgroup analyses of large trials can 
potentially add to knowledge about therapeutic effectiveness in older individuals, but are usually 
not adequately powered to provide statistically strong evidence. Further, many populations of 
older individuals with HF continue to be excluded from studies, including those receiving home 
care and those in institutions. Some of these populations may be captured in the post-
hospitalization studies, but nonetheless, this exclusion is a weakness of current research.  
 The CCS 2006 HF guidelines include recommendations for HF management in older 
individuals based on some smaller RCTs and observational data. (2) Recommendations are based 
on symptom control and mortality outcomes, which are applicable to older populations. 
However, effects of therapy on outcomes such as functional or cognitive decline have not been 
well explored, even though these quality of life outcomes may be of particular importance to 
older populations. Trials commonly use combined endpoints to observe statistically significant 




individual outcomes. Following older cohorts receiving therapy to examine benefits or adverse 
outcomes may be of the most utility in providing new evidence to inform practice. 
 Underuse and suboptimal dosing of HF therapies among older populations is problematic, 
suggesting suboptimal quality of care. Older individuals may only tolerate lower doses than 
those shown to be effective from RCTs, to adjust for reduced creatinine clearance. There is 
evidence that therapeutic benefit occurs even at suboptimal dosing, suggesting that underuse of 
these proven therapies is a more worrisome problem than suboptimal dosing. Many barriers at 
the physician level have been identified. Physicians may not feel recommendations are easy to 
follow, may disagree with recommendations or may be hesitant about perceived risks of HF 
therapy. Further understanding about the use of pharmacotherapy could be generated by 
exploring more patient-level factors, particularly across care settings. Additionally, the issues 
observed with pharmacotherapy for HF in older individuals apply to older individuals more 
broadly and not just those with HF. Thus, management of chronic conditions in older persons 
could benefit from some changes in trial design to ensure that the majority of those needing 
therapy are represented in the trials on which recommendations are based. Whether enough 
evidence about benefits in older populations exists to make informed treatment decisions is 
important. Observational cohort studies of therapies proven to be effective in younger cohorts 
would add to the knowledge base and build upon existing trial evidence.  
 Dissemination of knowledge about the most current evidence is challenging. Increasing 
knowledge uptake of smaller, observational trials in older individuals may also improve 
physician confidence in providing HF pharmacotherapy in this cohort. Furthermore, 
investigation of methods to improve adherence generally, and specifically among older 




cardiovascular medications have shown promising results. Linking persistence of therapy and 
non-use of therapy to outcomes is a logical research direction and ultimately examines quality of 
care. Thus, while management of HF has progressed over the past three decades, meeting the 
needs of older individuals, creating more comprehensive trials and ensuring effective knowledge 




3.0 STUDY CONTEXT AND RATIONALE 
3.1 Home Care in Ontario 
 The organizational structure of home care in Ontario is important in understanding the 
context in which this research is being conducted. The local health integration networks (LHIN) 
and community care access centres (CCAC) in the province and the provincial reimbursement 
plan for seniors‟ medications are important contextual components.  
3.1.1 The Structure of Home Care in Ontario 
Home care is becoming an increasingly important component of Ontario‟s health care 
continuum. Although Ontario had a trial home care program as early as 1958, home care in 
Canada was introduced in the 1970‟s. (1) In 1988, all provinces and territories established 
programs for both acute and long-term clients, and home care has since expanded rapidly. (2,3) 
Canadian health reform has seen the expansion of community care at the expense of hospital 
care, and the Romanow Report (2002) highlighted the increasing importance and necessity of 
such expansion. (4,5) Home care is not included as an essential service in the Canada Health Act, 
though some recommend its inclusion. (4,5) As such, there is no portability of home care 
services between provinces. (3) However, all provinces and territories have public funding and 
basic service provision to some degree. (3,6) Funding for home care has increased dramatically 
in the last two decades, but still represents only a small part of overall health care spending. (6) 
Further, more recent spending for home care services has not expanded as rapidly since the 
1990‟s. (7) 
Home care refers to the provision of a comprehensive range of coordinated health 
services in the home to enable individuals of all ages to remain at home with appropriate care 




chronic conditions to remain at home and also facilitate returns home following hospital stays. 
(8) Such services can often prevent, delay or substitute for long-term or acute care (9), and are 
intended to complement informal supports for individuals at home. The variability in home care 
policies is evident across Canada, with one example being the access to supportive services for 
individuals with chronic conditions. (3) 
 Most clients receive home care services in their own home, but some services are 
accessed by clients in LTC facilities or assisted or supportive housing facilities. Further, the 
majority of clients are long-stay, meaning they are expected to receive services for 60 days or 
more. (3) One study found that while the proportion of clients receiving home care did not 
change significantly, there was a large increase in the proportion of clients receiving nursing and 
specialty care in an eight-year period. (10) At any given time, the number of people receiving 
home care generally exceeds that getting facility-based services (11), with up to 5% of the 
national population receiving services. (3) In Ontario, over 5.5 million home care visits were 
delivered in 2005/2006, to approximately 600,000 clients. (12-14) Most of these visits (67%) 
involved personal support and homemaking services and nursing was provided in more than one-
quarter of visits. (14) It is expected that with current demographic and health care trends, the 
demand for home care services in Canada will continue to rise. (1) The population is aging, the 
prevalence of chronic conditions is rising and more individuals wish to remain at home for care. 
(1) Technological advances have facilitated the shift for home care services, as have trends 
towards shorter hospital stays, and shifts away from long-term care. (1) For these reasons, home 
care is likely to remain a vital component of the health care system. 
In Ontario, the 14 LHINs oversee the distribution of more than 20 billion health care 




province‟s 14 CCACs correspond to the geographic boundaries of each of the 14 LHINs. The 
CCACs are locally funded through the LHINs to provide access to government-funded home and 
community services and LTC in the province. (15) CCACs are the single point of access for 
individuals requiring home care services. CCAC case managers determine eligibility for home 
care services and arrange for health care professionals to provide a range of care including 
nursing services, personal support, physiotherapy, occupational therapy, social work, nutritional 
counseling and medical supplies and equipment. (16) CCACs also coordinate community 
support services for clients as needed. (16) In 2001, the Canadian Institute for Health 
Information (CIHI) developed the Home Care Reporting System to improve quality and 
accountability of home care services by providing a set of indicators allowing regional 
comparisons. (17) 
 The Ontario Ministry of Health and Long-Term Care (MOHLTC) launched the Aging at 
Home strategy in 2007, committing over 1 billion dollars to support seniors to live healthy and 
independent lives while remaining at home. (18) Specific goals of this initiative include avoiding 
premature admission to LTC facilities and hospitals, finding innovative ways to support seniors 
in the community, creating integration across the continuum of community-based services, 
supporting caregivers and promoting health system sustainability. This is a key initiative in 
alleviating the burden on existing inpatient and residential facilities and preparing for future 
increases in health service use. Even more recently, the MOHLTC announced that province-wide 
quality measures and a reporting system for home care will be introduced to ensure high-quality 
health care. (12)  
3.1.2 The Ontario Drug Benefit Plan and Formulary 




but programs in each province vary. In Ontario, the MOHLTC covers most of the cost of many 
drug products for seniors through the Ontario Drug Benefit (ODB) plan. (19) Seniors with valid 
Ontario health insurance who are 65 years and older are automatically eligible for coverage. (19) 
Medication costs are subsidized depending on marital status and income levels, with many 
seniors paying a $100 copayment each year, after which prescriptions cost $6.11. (19) The ODB 
formulary is a comprehensive list of drug products that are included in the provincial drug 
benefit program. As of September 2009, the Ontario formulary contained more than 3200 drug 
products. For most cardiovascular medications, including all medication classes indicated for HF 
management, there are few restrictions on use and many have interchangeable medications 
approved for use. (20) Table 1 in Appendix I provides a list of HF medications included in the 
provincial formulary.  
3.2 The Resident Assessment Instrument – Home Care 
 Across the care continuum, data about client needs and preferences are needed to 
improve care. interRAI instruments enable the collection of high-quality data to enhance care 
quality in many care settings. interRAI is an international, collaborative research network with 
members from more than 30 countries. This network strives to improve health care in vulnerable 
populations by promoting evidence-based clinical practice and policies based on high-quality 
data about individual needs and outcomes across the continuum of health care. Assessment tools 
developed by interRAI are designed for use in specific care settings and include a set of core 
items considered relevant to all settings. However, all assessments incorporate common clinical 
concepts, language and data collection methods to allow comparisons across care settings. 




Improvements have been made to standardized items and the new suite contains common items 
and definitions. (23)  
 interRAI instruments allow comprehensive, standardized data to be collected across 
many domains including sociodemographic characteristics, functional and cognitive status, 
psychological conditions, disease diagnoses and service use. Such data can then be used for 
individual care planning, measuring outcomes of interest and developing quality indicators.  
 interRAI has developed assessment instruments designed for use across the care 
continuum. The RAI-HC was designed for use in home care populations. This assessment 
instrument consists of over 300 questions designed to assess the needs, strengths and preferences 
of clients receiving home care services. The RAI-HC database contains detailed clinical and 
sociodemographic information including cognitive status, mood and behaviour patterns, informal 
support services, physical function, clinical diagnoses, medication use (both prescription and 
non-prescription) in the seven days prior to assessment and acute service utilization (including 
hospitalizations and ED visits) in the 90 days prior to assessment. (24) Embedded within the 
RAI-HC, Clinical Assessment Protocols (CAPs) help with further assessment and care planning, 
as well as needs analysis and patient safety analysis at an aggregate level. (25) This breadth of 
information creates a rich data source, which provides comprehensive information about home 
care client populations. Trained clinicians complete RAI-HC assessments and use clinical 
judgment in recording diagnoses. Accuracy of recorded information is routinely verified through 
discussions with physicians, family and caregivers. Assessors are trained to review medical 
records if necessary. The reliability and validity of the tool have been established previously and 
items contained within the RAI-HC, including key areas of functional and cognitive status, have 




 The RAI-HC is used in a number of provinces and territories in Canada and in 2003, the 
Ontario MOHLTC mandated the use of the RAI-HC to assess every long-stay home care client 
in the province. (3) The majority of clients expected to be long-stay receive a RAI-HC 
assessment within 14 days of initiation of home care services, regardless of whether they remain 
on service. Further, clients who were not expected to be long-stay are assessed by day 60 f they 
remain on service. Reassessments of clients who continue to receive services are done semi-
annually. While most long-stay clients are assessed in the community, some are assessed in 
hospital to facilitate placement into LTC facilities. Approximately 150,000 assessments are 
completed each year. Assessments are completed by trained assessors within each CCAC in the 
province; the CCACs transmit their assessment information (along with their administrative 
records and medication data) to the OACCAC. Through a data sharing agreement, the University 
of Waterloo receives data cuts from the OACCAC approximately every 6 months. Medication 
data are routinely collected at each assessment as part of normal clinical practice. The newer 
interRAI HC instrument is not yet in use in Canada, but mandates the use of standardized 
medications codes where they exist. (23) The RAI-HC and all interRAI instruments are available 
for purchase through www.interrai.org. 
3.2.1 Data Source 
The RAI-HC database has a number of strengths that make it an unparalleled choice for 
population health research. This database contains extensive and detailed clinical information 
about geriatric conditions such as functionsl and cognitive status, mood and behaviour patterns, 
clinical diagnoses, and medication use (both prescription and non-prescription). Further, 
information is routinely collected about informal support services and acute service utilization 




collection is mandated, no additional burden is placed on individuals to collect this information. 
Adding to the strengths of this data set, items for assessing presence of clinical diagnoses like HF 
are included in RAI-HC assessments. The validity of such information has been demonstrated. 
(30) Further, a number of summary health scales are embedded within the assessment and these 
scales have been validated for use with the RAI-HC. (26,28,31-34) The RAI-HC is mandated for 
use in Ontario, allowing census-level evaluation of the care needs of all long-stay home care 
clients in the province. This comprehensiveness means that the data are representative of the 
entire long-stay home care population in Ontario. Lastly, the RAI-HC has been used in Ontario 
since 2003. There are currently more than 1,000,000 assessments in the database and the 
longitudinal nature of these data allows for analysis of trends over time. In summary, this rich 
data source is second to none in Canada in size, comprehensiveness, representativeness and 
longitudinal nature.  
3.2.2 Outcome Measures 
 Many outcome measures can be generated from the longitudinal use of embedded scales 
(combinations of items) on interRAI instruments. In cross-sectional analysis, these scales can 
summarize client characteristics in a number of domains. The embedded scales automatically 
calculate scores for individual clients that help assess clinical status and care needs. This 
research will utilize five health index scales (outcome measures) for functional ability, cognition, 
depression and health instability. These are: 1) the Activities of Daily Living (ADL) self-
performance hierarchy scale (28), 2) the Instrumental Activities of Daily Living (IADL) capacity 
scale (26), 3) the Cognitive Performance Scale (CPS) (29,32), 4) the Depression Rating Scale 
(DRS) (33), and 5) the Changes in Health, End-stage disease and Signs and Symptoms (CHESS) 




and higher scores in each measure indicate more severe impairment. (26,28,31-34) The scales are 
described in detail below. 
The Activities of Daily Living Self-performance Hierarchy Scale 
 The ADL self-performance hierarchy scale is a 7-level scale (range from 0 – independent 
to 6 – most dependent) calculated based on the toileting, locomotion, eating and personal 
hygiene items from the RAI-HC. This scale accounts for the typical stages of ADL loss and has 
been validated against other scales. (26,28) 
The Instrumental Activities of Daily Living Capacity Scale 
 The IADL difficulty scale is a 7-level scale (range from 0 – no difficulty to 6 - great 
difficulty) calculated using the meal preparation, ordinary housework and phone use items from 
the RAI-HC. (26) This scale measures the capacity to perform IADLs, regardless of whether the 
opportunity to do so exists. 
The Cognitive Performance Scale 
 The CPS is used to measure cognitive function and is a 7-level scale (range from 0 - 
intact to 6 – very severe impairment) composed of items that measure short-term memory, 
cognitive skills for daily decision making, expressive communication and eating self-
performance. (32) The CPS has been validated against the Mini Mental State Exam. (29) 
The Depression Rating Scale 
 The DRS is a 15-level scale (range from 0 – no depressive symptoms to 14 – many 
depressive symptoms) based on seven RAI-HC items: negative statements; persistent anger; 
expressions of unrealistic fears; repetitive health and anxious complaints; facial expressions that 




Cornell depression scales and scores above three are generally interpreted to indicate possible 
depression. (33) 
The Changes in Health, End-stage Disease and Signs and Symptoms Scale 
 The CHESS is a 6-level scale (range from 0 – no instability to 5 – highest level of 
instability) that provides a measure of health instability and frailty. The CHESS score is created 
from subscores based on the presence of the following health symptoms: vomiting, dehydration, 
loss of appetite, weight loss, shortness of breath and edema. This subscale is then added to 
declines in cognitive or ADL functions, as well as end-stage disease items. It was a strong 
predictor of survival in an LTC population and is validated for use in the home care setting. 
(26,31,34) 
3.2.3 interRAI Research in Pharmacoepidemiology 
 The comprehensive information collected using interRAI instruments has been used 
extensively in geriatric research and to a smaller extent in pharmacoepidemiological research. 
Much of this work has examined older populations in the LTC and home care environments. The 
RAI-HC assessment has been used in many countries to examine pharmacotherapy use among 
older individuals receiving home care services. Patterns of use of antipsychotics, analgesics and 
outcomes of therapy have been described in European and Canadian home care populations. (35-
37) Much more work has examined medication use in LTC populations for diseases including 
Parkinson‟s, HF, dementia, hypertension and pain. (38,39,40-46) Some work has also examined 
patient outcomes related to medication therapy (25,39) and potentially inappropriate medication 
use. (47,48) It is clear that the comprehensive data collected using interRAI instruments can be 
used to undertake pharmacoepidemiological studies and inform clinical practice. In particular, 




attribute often lacking in databases traditionally used for pharmacoepidemiological studies. 
Nonetheless, little work has focused on outcomes over time and none has examined use of 
medications among community-dwelling individuals with HF receiving home care services. 
Thus, while interRAI instruments have the potential to contribute greatly to the field of 
pharmacoepidemiology for many chronic conditions, this potential is only beginning to be 
realized.  
3.3 Study Rationale  
Given the overall prevalence of chronic diseases like HF, as well as the many negative 
outcomes of such conditions, research in this area has the potential to be informative and wide-
reaching. The proposed research aims to address gaps in current knowledge about chronic 
disease management in HF in the community setting.  
3.3.1 Gaps in Current Knowledge 
Much work on pharmacotherapy in HF has come from RCTs and some from hospital and 
specialty clinic settings. Knowledge about disease characteristics and service needs of 
community-dwelling older persons with HF is lacking. Further, much research has examined the 
outcomes of mortality and hospitalizations, which may not be the only relevant outcomes among 
to older individuals with HF. There is evidence that therapies used to manage HF are underused 
in older populations, but again, most of this research involved hospitalized individuals or those 
receiving care through specialized clinics. This may not be representative of other sub-
populations of patients, particularly those receiving home care services. Further, little is known 
about potential barriers to implementing CDM programs for HF. Lastly, there is a dearth of 
evidence about the effectiveness of pharmacotherapy for HF in older individuals, and evidence 




3.3.2 Proposed Research 
This research will attempt to address some of the identified gaps in the current knowledge 
of pharmacotherapeutic management of HF. In doing so, there will be three main research areas, 
each of which will be described in detail in its own chapter of this dissertation. All analyses will 
make use of the extensive Ontario RAI-HC and OACCAC data available at the University of 
Waterloo. Application of the interRAI instruments to the area of outcomes of pharmacotherapy is 
novel in Ontario and Canada. All work will be retrospective and involve secondary data analysis 
of data contained within the databases at the University of Waterloo. Ethics approval was 
obtained from the Office of Research Ethics at the University of Waterloo (certificate #14761).  
3.3.2.1 A Profile of Older Community-Dwelling Home Care Clients with Heart Failure in 
Ontario 
A first step in beginning to understand therapeutic effectiveness in older populations is to 
characterize a more typical HF population than those represented in the current literature. This 
first initiative will characterize HF individuals who are receiving home care services with respect 
to sociodemographic and clinical characteristics, medication use and service use. This will not 
only create a comprehensive description of individuals in an increasingly important health care 
sector, but will add to the current literature, which currently under-represents older individuals 
with HF. This will be one of the first comprehensive studies of a representative population of 
older individuals in the community setting. Specifically, this research will: 
1) determine prevalence estimates of HF in long-stay home care clients; 
 
2) describe sociodemographic and clinical characteristics of long-stay home care clients       
   according to HF diagnosis; and 
 
3) examine informal supports and acute service use among long-stay home care clients  





3.3.2.2 Correlates of Non-Use of Pharmacotherapy in Heart Failure 
First-line pharmacotherapy, consisting of an ACE inhibitor or ARB in conjunction with a 
β-blocker, is recommended for most individuals with HF. It is well understood that older 
individuals in hospital, specialty practice and general practice settings are less likely than their 
younger counterparts to receive recommended therapies for HF. Whether this holds true for HF 
clients receiving home care services is unknown. Further, many provider-level factors associated 
with use of these therapies have been identified in the literature, but less is known about patient-
level factors. Understanding factors associated with medication use in this population can assist 
with care planning and help inform intervention strategies to overcome gaps in care. This 
research will examine use of ACE inhibitor, ARB and β-blocker therapy in the home care setting 
and examine factors associated with non-use of these therapies. Making use of the extensive 
sociodemographic and clinical variables available in the RAI-HC database, this research aims to:  
1) estimate the prevalence of ACE inhibitor, ARB and β-blocker therapy use among long-    
    stay home care clients with HF, and 
 
2) identify correlates of non-use of first-line pharmacotherapy among long-stay home care  
    clients with HF. 
 
3.3.2.3 Outcomes among Older Home Care Clients with Heart Failure  
The last research initiative will examine the outcomes of mortality, LTC admission, long-
stay hospitalization, functional decline and cognitive decline over time. The current literature 
with respect to such outcomes in older HF populations is sparse and predominantly focuses on 
the outcomes of mortality and hospitalizations. These five outcomes will be explored using the 
longitudinal data in the RAI-HC database. Proportional hazards regression analysis will be used 
to model time to each outcome. The ability to examine quality of life outcomes will provide 




outcomes in community-dwelling individuals with HF to date and will also answer key questions 
about factors associated with relevant geriatric outcomes. Specifically, this work will: 
1) determine rates of mortality, LTC admission, long-stay hospitalization, functional     
    decline and cognitive decline among long-stay home care clients with HF, and 
 
2) examine a comprehensive set of sociodemographic, clinical, medication and service use   
   factors potentially associated with each outcome.  
 
3.4 Research Goals 
 Using Ontario data, it is hoped that this work will generate evidence upon which to 
inform future policy and practice in home care. While this research focuses on chronic disease 
management of HF, this research model can be extended to other chronic diseases, generating 
future evidence. Research dissemination will be performed in a variety of ways, and will target 
diverse audiences. Early results have been presented at clinical and research-oriented 
conferences, as well as to policy-makers in a variety of networking forums. Manuscripts from 
early results have been published or are in press, and future work will be published once 
complete. Preliminary research findings were presented to key stakeholders in policy and across 
care-settings in May 2010. Ultimately, it is hoped that this research will inform new policies and 
practices to improve the delivery of chronic disease care in the community, eventually translating 
to improved quality of life for individuals with HF through interventions designed to target those 




4.0  A PROFILE OF OLDER COMMUNITY-DWELLING HOME CARE CLIENTS 
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This chapter is based on a study first reported in Chronic Diseases in Canada. The primary 
publication can be found at: Foebel AD, Hirdes JP, Heckman GA, Tyas SL, Tjam EY. A 
Profile of Older Community-Dwelling Home Care Clients with Heart Failure in Ontario.  





 Heart failure (HF) is a “complex syndrome in which abnormal heart function results in, 
or increases the subsequent risk of, clinical symptoms and signs of low cardiac output and/or 
pulmonary or systemic congestion.” (1) An estimated 500,000 Canadians live with HF (2) and its 
prevalence increases with age. (3) At age 80, both men and women have approximately a 20% 
lifetime risk of developing HF. (3) Population aging and improved survival of patients with 
hypertension and myocardial infarction, two important risk factors for HF, contribute to the 
rising prevalence of HF. (4,5) Already a substantial burden on the Canadian health care system, 
projections of the future burden of HF are worrisome: HF incidence is projected to double in 
Canada by 2025 due to population aging, with the most rapid growth in prevalence expected in 
those over 85 years old. (6,7) 
 Despite advances in the overall treatment and management of HF, survival and quality of 
life remain poor.  In Canada, 4,430 deaths were attributable to HF in 2004. (8) HF is associated 
with annual mortality rates as high as 50%, and 25% to 40% of patients will die within one year 
of diagnosis. (1,9) HF patients today are primarily 65 years or older and suffer from multiple 
comorbidities including hypertension, diabetes, arthritis, cognitive impairment and depression. 
(10,11) 
 The prevalence of HF translates into high costs to the Canadian health care system. The 
repeated hospitalizations, complex treatment regimen and cost of pharmacotherapy strain many 
components of health care including primary and specialty care, emergency departments (ED) 
and hospitals. (12) Among Canadians over 85 years of age, HF is responsible for more 
hospitalizations than ischemic heart disease or heart attack. (8) Readmission rates for disease 




because of poor clinical status, which may continue to worsen in hospital. Hospitalization itself, 
in fact, appears to lead to progressive functional decline and eventual placement into a long-term 
care (LTC) facility. (14-16) More than 10% of hospitalizations of older adults resulting in 
Alternate Level of Care designations are for cardiovascular disease, particularly HF, as are up to 
20% of transfers of LTC residents to hospital. (17,18) LTC residents hospitalized with HF may 
experience long ED waits and spend on average six days in hospital.
 
(18) Further, 7.4% of LTC 
residents hospitalized for HF remain in hospital as Alternate Level of Care patients awaiting 
transfer back to their LTC home. (18) Such admissions are often unsuitable and potentially 
preventable if HF were better managed in primary care. (19-23) Specifically, the health care 
system needs new approaches for the management of HF targeted towards reducing the risk and 
duration of hospitalizations. (7) 
 Effective management of HF is challenging as it involves complex pharmacotherapeutic 
regimens, periodic adjustment of medication doses, elaborate dietary and fluid intake regimens, 
exercise therapy, and ongoing patient education to ensure appropriate self-care. The Canadian 
Heart Health Strategy and Action Plan recommends the Chronic Disease Management (CDM) 
model as the preferred model for care delivery for cardiovascular disease. (24) A fundamental 
characteristic of CDM is patient-centered emphasis on disease self-care, which incorporates both 
self-maintenance and self-management. Self-maintenance requires adherence to prescribed 
treatments and health practices (25), while self-management builds on self-maintenance and 
includes recognition of signs and symptoms of HF, evaluation of the importance of these signs 
and symptoms, implementation of a treatment option and evaluation of the treatment chosen. 
(25,26) Self-management requires learning skills, insight, judgment, problem-solving and 




targeting HF strive to promote patient self-care and have been shown to improve quality of life 
and functional status, reduce unplanned and repeated hospitalizations and possibly reduce 
mortality. (27,28)
 
However, HF in older patients is often associated with multiple medical 
comorbidities and polypharmacy, as well as with depression and cognitive impairment, all of 
which can interfere with self-care and prevent patients from fully benefitting from CDM 
programs. (29,30) Further, there is no clear understanding of the ideal duration of such programs 
or the most effective mode of follow-up. (28,31) 
 Given the high prevalence of HF in populations over 65 years old, the acute health care 
system needs enhanced CDM for HF to ease the burden on itself. Working in partnership with 
primary care physicians and specialty HF clinics, home care is a potentially important 
component of CDM for HF and may also provide a means of follow-up beyond the initial 
program. (32) Developing methodologies to assess levels of risk, identify barriers to self-care 
and deliver specific community-based interventions to home care clients with HF would make a 
significant contribution to an overall CDM strategy for HF.
 
 HF is a common disease, but there is little research on the demographic and clinical 
characteristics, service use and needs of these clients in home care. This study seeks to 1) 
describe the sociodemographic and clinical characteristics of long-stay home care clients with 
HF and 2) examine service use among long-stay home care clients with HF to promote 
management at home with appropriate services.  
4.2 Methods 
4.2.1 Data Source 
 Sociodemographic, clinical and service use data were retrieved from the Ontario Resident 




assessments in Ontario, a province of approximately 13.2 million people. The RAI-HC evaluates 
the care needs of all long-stay home care clients in the province (i.e. those expected to receive 
services for longer than 60 days). The assessment consists of over 300 questions designed to 
generate Client Assessment Protocols (CAPs) that help with further assessment and care 
planning, as well as to provide outcome measures for cognition, depression and physical 
function. Trained clinicians conduct the RAI-HC assessments and use clinical judgment to 
record diagnoses. The accuracy of the recorded information is verified through discussions with 
physicians, family and caregivers, and assessors are trained to review medical records if 
necessary. The RAI-HC is considered both reliable and valid and the items contained within 
have excellent inter-rater and test-retest reliability. (33-36)
  
The RAI-HC database contains 
detailed clinical and demographic information accumulated in the previous seven days, including 
cognitive status, mood and behaviour patterns, informal support services, physical function, 
clinical diagnoses, prescription and non-prescription medication use, and acute service utilization 
in the 90 days prior to assessment, including hospitalizations and ED visits. This breadth of 
information provides a comprehensive description of all long-stay home care clients within 
Ontario.  
4.2.2 Sample 
 All home care clients aged 65 years or older who received their most recent RAI-HC 
assessment between January 2004 and December 2007 were eligible for this analysis, regardless 
of functional or cognitive status, or presence of comorbidity (N = 264,030). Using only the most 
recent assessment allowed for a prevalence sample, providing a comprehensive profile of HF 




included only clients assessed in the community. The Office of Research at the University of 
Waterloo provided ethics approval for the analyses of the anonymized data in the current study. 
4.2.3 Measures 
 The RAI-HC includes valid and reliable items to assess HF (as well as other conditions) 
(37); clients were defined as having HF if this condition was recorded in the assessment. Trained 
assessors routinely verify this information through self-report, discussions with caregivers and 
health providers, as well as review of medical records if necessary. Accuracy of the diagnostic 
and medication information collected using the interRAI instruments has also been established. 
(37)
 
Among individuals with HF in nursing homes and LTC facilities, the positive predictive 
value and sensitivity for the interRAI diagnosis of HF was greater than 0.80 compared to what is 
found with administrative databases. (37,38)
 
Clinical measures such as ejection fraction and New 
York Heart Association (NYHA) class were not available from this data source.  
 Based on previous literature and in consultation with a geriatrician (Dr. George 
Heckman), key sociodemographic and health-related variables were identified to describe the HF 
sample (1,11,29,40), including age, gender, living arrangement, marital status, caregiver 
presence, caregiver stress, health region within Ontario (as defined by the geographic boundaries 
of each of 14 Community Care Access Centres [CCACs], which align with Local Health 
Integration Networks in Ontario), daily pain, edema, falls, number of medications, shortness of 
breath, incontinence and presence of comorbidity. The following comorbidities were used in 
describing this sample: coronary artery disease (CAD), arthritis, diabetes, airway disease 
(including asthma, chronic obstructive pulmonary disease [COPD] and emphysema) and 
hypertension. The analysis also included five summary health scales for functional ability, 




self-performance hierarchy scale (range 0–6); 2) the Instrumental Activities of Daily Living 
(IADL) capacity scale (range 0–6); 3) the Cognitive Performance Scale (CPS) (range 0–6); 4) the 
Depression Rating Scale (DRS) (range 0–14); and 5) the Changes in Health, End-stage disease 
and Signs and Symptoms (CHESS) scale (range 0–5). (35,41-44) Each scale has been developed 
and validated for use with the RAI-HC, and higher scores in each measure indicate more severe 
impairment. (36,41-44) Service use in the seven days prior to assessment was captured with the 
RAI-HC assessment and use of nursing, homemaking, physiotherapy and meal services were 
analyzed. Hospitalizations, ED visits and use of emergent care (defined as any unplanned visit to 
a non-ED health provider) in the past 90 days were also investigated. 
4.2.4 Analysis 
 Scores from each of the five summary scales used (ADL, IADL, CPS, DRS and CHESS) 
were collapsed into three levels to differentiate between levels of impairment. Similarly, the 
variables for age, falls, hospitalizations, ED visits and use of emergent care were collapsed into 
three levels. Use of nursing, homemaking, physiotherapy and meal services in the home were all 
analyzed by comparing receipt of any service versus no services. Three classes of commonly 
used HF medications (angiotensin-converting enzyme inhibitors, angiotensin receptor blockers 
and beta-adrenergic receptor blockers) were excluded from the medication counts. Comorbidity 
and medication counts were collapsed into three and four levels, respectively. Differences in 
characteristics between groups were tested using unpaired, two-tailed t-tests and Satterthwaite‟s 
unequal variance assumption for continuous variables and chi-square tests for categorical 
variables (significance level p < .05). Stratification by age groups addressed potential 
confounding of observed age group differences with clinical and service use variables. All 





 Between January 2004 and December 2007, the RAI-HC assessed 264,030 unique clients 
and identified 39,247 home care clients with HF (14.9%) in total. The proportion of clients with 
HF in each CCAC varied significantly (p < .0001) (see Figure 4.1). The proportion of clients 
with HF was highest in the North East CCAC (19.5%) and lowest in the Central West CCAC 
(11.3%).  
 Table 4.1 lists the sociodemographic characteristics of clients according to the presence 
of HF. Given the size of the sample, most observed differences are statistically significant. 
Compared with clients without HF, those with HF are older (mean age 83.5 years vs. 81.8 years, 
standard deviation [SD] 7.5 and 7.6, respectively), less likely to be women and less likely to be 
living alone. More clients with HF have caregivers, but there is no significant difference in levels 
of caregiver stress. 
 Table 4.2 shows the clinical characteristics of home care clients by HF diagnosis. Again, 
due to the large sample size most observed differences are statistically significant; only clinically 
significant findings are reported here. HF clients have more complex functional needs than those 
without and exhibit more health instability (as measured by the CHESS scale); as expected, they 
also experience significantly higher levels of edema and shortness of breath. They have less 
cognitive impairment, as measured by the CPS scale, although the overall proportion of HF 
patients with some degree of cognitive impairment is high. Prevalence of depression or a history 
of falls in the previous 90 days does not differ by HF status.  
 HF clients use more medications and have more comorbid conditions than those without 
HF. After exclusion of three classes of medications recommended for the treatment of HF 




receptor blockers), the mean number of medications in the HF group is 9.3 (SD = 4.1) compared 
with 7.2 (SD = 2.9) for the group without. Further, 58.0% of the HF sample take 9 or more 
medications compared to only 35.0% of clients without HF. Almost half the clients with HF 
(45.1%) have five or more comorbid conditions, while only 26.5% of those without HF 
experience that level of comorbidity. Hypertension, arthritis, CAD, diabetes, osteoporosis and 
airway disease (including COPD) are the most prevalent comorbidities in the entire sample 
studied. Except for osteoporosis, rates of comorbidity are higher among clients with HF. 
Stratification was done to explore potential confounding by age (not shown) and apart from some 
variation in rates of depression and falls, there are no differences due to age for the clinical 
characteristics presented.  
 Clients with HF receive significantly more nursing, homemaking and meal services 
compared with the group without HF (see Table 4.3), though receipt of physiotherapy services is 
low in both groups. Home care clients with HF received an average of 1.3 days of nursing 
services in the seven days prior to RAI-HC assessment while clients without HF received an 
average of 1.0 days. HF clients are hospitalized more frequently, with 37.4% hospitalized at least 
once in the previous 90 days compared to only 26.1% of clients without HF. They also report 
significantly more ED visits and use more emergent care. Potential confounding by age was 













Figure 4.1: Variation in Prevalence of Heart Failure by Community Care Access Centre 




Abbreviations: C = Central , CCAC = Community Care Access Centre, CE = Central East,  
Ch = Champlain, CW = Central West, ESC = Erie St. Clair, HNHB = Hamilton Niagara  Haldimand 
Brant, MH = Mississauga Halton, NE = North East, NSM = North Simcoe Muskoka, NW = North West, 
SE = South East, SW = South West, TC = Toronto Central, WW = Waterloo Wellington 
    

































  % (n) % (n)  
Age 65-74 years  
75-84 years   
85+ years 
12.9 (4,639) 
  39.0 (14,060) 





<0.0001     
Gender Female   64.1 (25,140)   66.6 (149,563) <0.0001 
Married     35.0 (13,740) 38.1 (85,607) <0.0001 
Living Alone  32.7 (7,021) 34.5 (45,850) <0.0001 
Caregiver Available    87.3 (34,267)   85.9 (193,115) <0.0001 
Caregiver Stress      16.7 (6,535)   17.0 (38,238) 0.08 
 


































Table 4.2: Clinical Characteristics among Older Home Care Clients, Ontario 2004-2007 
(N=264,030) 
 






Clinical Characteristics  %  %   





















  2.2      (864) 
17.1 (6,704) 
80.7 (31,676) 












































Daily Pain  48.9 (17,648) 45.3 (94,028) <0.0001 
Edema  37.0 (14,510) 21.4 (48,071) <0.0001 
Shortness of Breath  46.5 (18,252) 21.2 (47,561) <0.0001 





24.8  (9,743) 
  7.3  (2,860) 
68.8 (154,603) 
24.0 (53,871) 




















































  1.1      (419) 
  9.1   (3,552) 
31.8 (12,496) 
58.0 (22,780) 








Abbreviations: ADL = Activities of Daily Living, CAD = Coronary Artery Disease, CHESS = Changes 
in Health, End-stage disease and Signs and Symptoms, CPS = Cognitive Performance Scale, DRS = 
Depression Rating Scale, HF = Heart Failure, IADL = Independent Activities of Daily Living 
a
 0 = no impairment; 1-2 = some functional impairment; 3+ = severe functional impairment
  
b





0 = cognitively intact; 1-2 = mild cognitive impairment; 3+ = cognitively impaired 
d 
0 = no indicators of depression; 1-2 = some indicators of depression; 3+ = indicators of probable 
depression 
e




 includes chronic obstructive pulmonary disease (COPD), emphysema and asthma 
h 




Table 4.3: Home Care and Acute Health Care Service Use among Older Home Care 
Clients, Ontario 2004-2007 (N=264,030) 
 






  %  %   
Home Care Service Use
a 
    
Any Nursing  39.4 (15,447) 29.8 (67,037) <0.0001 
Any Homemaking  46.3 (18,154) 40.3 (90,646) <0.0001 
Any Meals     20.8 (8,154) 18.4 (41,371) <0.0001 
Any Physiotherapy  7.8 (3,057)   9.0 (20,133) <0.0001 
Acute Health Care Service Use
b 
Number of Emergent Care visits 0 
1 
2+ 
 91.2 (35,772) 
 6.5 (2,565) 
      2.3 (910) 
92.9 (208,765) 
5.5 (12,417) 
    1.6 (3,601) 
 
<0.0001 
Number of ED visits 0 
1 
2+ 
  78.1 (30,655) 
16.0 (6,265) 
  5.9 (2,327) 
  81.7 (183,567)             
  14.2 (31,965) 
    4.1 (9,151) 
 
<0.0001 
Number of Hospitalizations 0 
1 
2+ 
  62.6 (24,547) 
  28.8 (11,314) 
  8.6 (3,386) 
74.0 (166,188) 
  22.5 (50,552) 




Abbreviations: ED = Emergency Department, HF = Heart Failure 
a 
measured in 7 days prior to assessment 
b 






 This study provides a comprehensive description of older home care clients with HF in 
Ontario. The extensive RAI-HC data allowed the examination of many sociodemographic and 
clinical characteristics as well as service use, both through home care and acute care services. 
These descriptors are useful in identifying care needs as well as patterns of service use among 
older, community-dwelling home care clients. These analyses are also useful in identifying areas 
for further study or intervention strategies.  
 The clustering of diseases that share risk factors with HF, such as diabetes, as well as the 
clustering of diseases that can precipitate HF, such as hypertension and CAD, is expected among 
clients with HF. These data show this clustering and provide an estimate of the co-occurrence of 
such conditions in this older cohort. The observed clustering of HF with other diseases of aging, 
such as arthritis and airway disease, indicates that this group is more complex medically. Further, 
these particular comorbidities may, in the setting of a history of HF, present additional 
therapeutic challenges (e.g. NSAIDs for arthritis) and diagnostic challenges (e.g. dyspnea from 
HF or airway disease). The complex needs of the HF group are also reflected in the significantly 
higher levels of medication use in this group, even after adjustment to exclude three classes of 
medications recommended for HF. This means that these clients need to be more active in 
monitoring for adverse drug events as a component of their self-care. 
 HF clients are significantly older than their counterparts without HF. Older home-care 
clients with HF exhibit more complex clinical characteristics than those without (Table 4.2); they  
have more health instability (as measured by the CHESS scale), are less able to look after 
themselves (impaired in instrumental and basic ADLs), and experience more daily pain, edema, 




clients, this symptom is not universal in this group, likely because such individuals are frail and 
present atypically, especially among older populations. (1,45,46) However, it may also be 
possible that such hallmark symptoms are not present in the sample due to proper management 
of HF through pharmacotherapy and other treatment modalities. The significantly higher 
prevalence of daily pain and incontinence among the HF group may represent common yet 
underappreciated HF manifestations (1,45), as may the overall higher prevalence of other 
comorbid conditions in this group.  
 Clients with HF are less likely to be severely cognitively impaired than clients without 
HF, though rates of cognitive impairment are still high among both groups. Cognitive 
impairment in persons with HF is associated with poorer outcomes including a greater risk of 
mortality and hospitalization and consequently institutionalization. In a cross-sectional study 
such as this, people with HF and concomitant cognitive impairment may be so unable to look 
after themselves that they have been referred to more intensive care settings. (30) Alternately, 
cognitive impairment may be underestimated through CPS scores, as IADL impairment is also 
prevalent among clients with HF, reflecting the presence of executive dysfunction common in 
this population. (30) Atypical symptoms of HF in older populations may include alterations in 
mood and behavioural symptoms, but the similar rates of depression among HF and non-HF 
clients do not support this interpretation. (46,47) History of falls is also similar between the two 
groups (Table 4.2) and fall prevalence is lower than reported in similar populations. (48) These 
results indicate that the clinical complexity of HF clients receiving home care services is more 
distinguishable from non-HF clients through functional characteristics such as ADL and IADL 




 Given the clinical characteristics and medical complexity of home care clients with HF, it 
is likely that there are many barriers to self-care. An indirect indication of difficulty with self-
care may be the high rates of access to an informal caregiver. It is possible that without 
caregivers, clients with HF are at higher risk of death or placement to a LTC facility and are thus 
less likely to be seen in this home care sample.  
 Managing multiple medical conditions and medications, and dealing with depression, 
cognitive impairment and functional decline are likely all barriers to effective self-care. 
Cognitive impairment and depressive symptoms are present in 51.7% and 37.0% of clients with 
HF, respectively. Clinic-based CDM programs may not be designed to overcome such barriers to 
self-care and the care setting may be inappropriate for such persons with HF. Functional 
impairment is high among home care clients with HF and may limit access to clinic-based 
programs. Further, having to schedule and attend numerous appointments for follow-up of 
multiple chronic conditions with many care providers may also be a barrier to attending clinic-
based programs. Transitional care programs for seniors, in which specially trained Advanced 
Practice Nurses help coordinate care and enhance the self-care skills of patients with HF and 
their caregivers reduce readmission rates after discharge from hospital. (49) However, the 
extension of such programs to frail home care clients with HF has not been evaluated. Home care 
may be a more suitable setting than LTC facilities in which to provide CDM for these medically 
complex clients. (50) interRAI assessment instruments used in the home care setting can offer 
risk assessment for adverse outcomes, identify barriers to self-care and provide a potential 
platform for CDM delivery. 
 The geographic variation in HF prevalence is an interesting finding. Due to the 




differences are due to variability between raters in recording diagnoses. Given that HF risk 
increases with age, the age structures of the client bases of each CCAC may explain some of this 
variation. HF prevalence, however, is not highest in the CCACs with the oldest populations. 
Thus, such variations may indicate differences in access to home care services for older 
individuals with HF or, conversely, different management strategies for HF on the part of the 
CCAC. Some CCACs may be more likely to push for LTC admission for clients with HF, while 
others may promote more aggressive management within the home. There are other implications 
of such variations in HF prevalence and such profiles could help CCACs prioritize service 
planning, initiate chronic disease management strategies and re-allocate staffing as necessary.  
 This descriptive work demonstrates that HF is prevalent among older home care clients in 
Ontario and that clients with HF are clinically complex, using home care and acute care more 
frequently than their counterparts without HF. There are some limitations to this work. First, the 
cross-sectional study design allows a snapshot of this sample during a given time period, but 
does not allow any assessment of the temporality of the associations observed. For example, it is 
not known whether use of services followed or preceded HF diagnosis. Further, when examining 
hospitalizations, ED use or emergent care use, the reason for the health care service encounter 
was not collected. These data indicate, however, that the more clinically complex clients with HF 
do indeed use more services both in the home and in the broader health care system. 
Additionally, these data do not include information regarding HF severity, which may influence 
service use, although the CHESS scale embedded within the RAI-HC allows some assessment of 
health instability and can be predictive of mortality in LTC patients. (51) Clients with HF scored 
significantly higher on this item, indicating more disease instability overall. Another limitation is 




representative of other populations, either in institutions or in the community, that do not seek 
out or receive referrals for home care services. Lastly, given the demographics of this sample, it 
is likely that HF with preserved ejection fraction (HFPEF) is prevalent. HFPEF is more common 
in women and is thought to account for more than half of HF cases in those older than 75 years. 
(52,53) Given that almost 80% of the sample with HF was older than age 75, HFPEF likely 
affects a large proportion of these clients. This could not be verified from the data set used, but is 
worth noting as it has implications for CDM. There is much less evidence about the effectiveness 
of pharmacotherapy in the management of HFPEF compared to HF with reduced ejection 
fraction. Other aspects of HF management, however, are applicable to both populations. As 
better treatment modalities are identified for HFPEF, CDM programs will need to adapt 
accordingly. 
 This research has unique strengths. It provides a clear picture of the burden of HF in 
home care clients in Ontario and allows regional differences to be identified. It makes use of the 
extensive information available in the RAI-HC assessment to richly describe the clinical 
characteristics, presence of other diseases and service use in this population. Lastly, it assesses 
all long-stay home care clients in Ontario; since the number of HF clients identified in this 
sample is quite large, it was possible to fully describe the clinical and functional characteristics 
of HF clients. 
 These results depict home care clients with HF as a complex, high-needs group with high 
rates of medication use, frequent use of health care services and many potential barriers to self-
care, as shown by the high levels of functional impairment, cognitive impairment, depression, 
comorbidity and medication use. Any new CDM strategy for home care clients with HF should 




although programs would need to be designed to avoid undue caregiver stress. Targeting 
intervention strategies to improve self-care skills may significantly reduce the burden on other 
parts of the health care system. Improving communication between primary care providers, 
geriatric or cardiology consultants, and home care could allow such vulnerable populations to 
remain at home and independent. Such interventions would align well with the Aging at Home 
Strategy in Ontario, as well as with the Comprehensive Canadian Heart Health Strategy and 
Action Plan. An initial step to such strategies may be to identify and target the highest-needs 
individuals for such interventions. This work has provided a potentially important first step in 




5.0  CORRELATES OF NON-USE OF PHARMACOTHERAPY IN HEART FAILURE 
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 5.1 Introduction 
 HF currently affects over 500,000 Canadians and its prevalence among persons 65 years 
and older is expected to double over the next three decades. (1-3) HF is a leading cause of 
hospital admissions among older Canadians and the associated inpatient and outpatient costs 
make it one of the most clinically burdensome and expensive health care problems in Canada. (4)
 
In the United States and Canada alone, more than five million individuals have an HF diagnosis 
and the costs of the disease exceed $20 billion (USD) annually. (5)
 
 Pharmacotherapy is a cornerstone of successful HF management, in addition to dietary 
and exercise modifications and proper clinical follow up. The Canadian Cardiovascular Society 
(CCS) Consensus Conference Guideline recommendations state that combination therapy 
consisting of an ACE inhibitor and β-blocker should be offered to all HF patients with reduced 
left ventricular ejection fraction (LVEF). (2)  For patients with intolerance to ACE inhibitors, the 
CCS Guidelines recommend the use of ARB therapy. (2) The CCS Guidelines also recommend 
that ACE inhibitors and β-blockers also be offered to most patients with HF and preserved 
LVEF, while recognizing the relative paucity of clinical trials addressing this condition. (2) This 
combination therapy forms a cornerstone upon which other therapies, such as digoxin, 
spironolactone, or nitrates and hydralazine, may be prescribed to patients with significant and 
persistent symptoms. (2) Patient-related factors and the presence of absolute contraindications 
and intolerance will ultimately influence prescriber decisions regarding HF therapy.  
 The clinical trials on which these recommendations are based generally excluded older 
patients or those with multiple comorbid conditions, although data from small clinical trials and 
numerous observational studies suggest that these recommendations are applicable to all adult 




improve survival post-hospitalization, reduce the risk of functional decline, and improve 
cognition, particularly in patients with reduced LVEF. (11-13) β-blocker therapy has also been 
shown to reduce mortality and hospitalizations in older HF patients. (14,15) Despite these 
potential benefits, uptake of guideline recommendations is low in older patients and underuse of 
both ACE inhibitors and β-blockers has been documented. (16) Older patients may be less likely 
to receive the recommended therapy due to concern over greater risk of adverse drug events, 
such as dizziness, hypotension and falls; contraindications; polypharmacy; titration of therapy; 
and lack of confidence in guidelines based on non-elderly populations. (17-22) Whether patient 
characteristics influence such prescribing is poorly understood and the extent to which Canadian 
HF guidelines are followed in the community is unclear.  
 Individuals with HF who receive home care services in Ontario represent a clinically 
complex group at high risk of health service utilization and institutionalization. (23) Further, 
with a push towards shorter hospital stays in both the U.S. and Canada, more individuals with 
HF are discharged earlier, increasing the burden on home care service providers. (24,25) As 
such, these patients are in regular contact with regulated health care professionals in the primary 
care setting and represent a group who might benefit from a targeted chronic disease 
management program designed specifically for home care clients with HF. However, 
implementing such a program would require a greater understanding of the clinical 
characteristics and patterns of medication use in this complex and precarious population than is 
known currently.  
 This research aimed to describe clients‟ clinical characteristics and home care service 
use, and determine the utilization and clinical/service use correlates of first-line HF 





5.2.1 Study Design and Data Source 
This population-level, cross-sectional study was based on data from long-stay home care 
clients in all 14 health regions in Ontario, a Canadian province of approximately 13.2 million 
people. Ontario‟s Resident Assessment Instrument-Home Care (RAI-HC) database is a 
repository of all RAI-HC assessments, which identify care needs of all long-stay home care 
clients in Ontario. This RAI-HC is mandated for use in Ontario and many other regions across 
Canada, as well as internationally in 12 other countries including the United States. (26) The 
RAI-HC includes over 300 questions designed to generate Clinical Assessment Protocols (CAPs) 
to guide care planning, as well as outcome measures for cognition, depression and physical 
function. Assessments are conducted by case managers (usually nurses or social workers) who 
receive standardized training in the completion of the RAI-HC and use professional judgment to 
record disease diagnoses and to verify accuracy of this information through discussions with 
physicians, other health professionals, family, and caregivers, and review of medical records 
when necessary. The reliability and validity of the tool have been established previously. (27-29) 
RAI-HC items have excellent inter-rater and test-retest reliability, including in key areas of 
functional and cognitive status. (30)
 
The RAI-HC database contains detailed clinical and 
sociodemographic information, including cognitive status, mood and behavioral patterns, 
informal support services, physical function, clinical diagnoses and symptoms, service utilization 
in the 90 days prior to assessment and use of non-prescription and prescription drugs in the past 
seven days. Diagnostic accuracy of information recorded on RAI assessments has been shown to 
be high when compared with administrative data. (31,32)
 
The breadth of information creates a 




 All home care clients aged 65 years or older receiving their first RAI-HC assessment 
between January 2004 and December 2007 were included in the study, regardless of functional 
status,  cognitive status or presence of comorbidity (n=176,860). The Office of Research at the 
University of Waterloo provided ethics approval for the analyses of the anonymized data in the 
current study.  
5.2.2 Measures 
 Clients were defined as having HF if it was recorded in the RAI-HC by the assessing 
nurse clinician. Among individuals in nursing homes and long-term care facilities in Ontario, a 
diagnosis of HF on the RAI was shown to have greater than 80% sensitivity compared to 
administrative databases. (31,32) First-line combination therapy, in accordance with the CCS 
Guidelines, was defined as use of ACE inhibitor and/or ARB therapy in conjunction with a β-
blocker. Henceforth, the term therapy will refer to this first-line pharmacotherapy. Table 5.1 lists 
the medications included for analysis. While some therapies are recommended for use based on 
evidence from clinical trials, others are not. (33,34) Certain therapies (ACE inhibitors: captopril, 
enalapril, ramipril, lisinopril; β-blockers: carvedilol, bisoprolol; ARBs: candesartan, valsartan) 
are specifically recommended by the CCS Consensus Conference Guidelines because they were 
evaluated in large clinical trials. (2) As evidence suggests that providers are often unaware of this 
distinction, (35) however, drug class was considered more important than specific therapies. 
Medications used in the previous seven days were manually recorded from medication containers 
at the time of assessment and the case managers verified information with clients and caregivers, 
as well as through review of medical records. Medications were transcribed electronically, 
allowing for many variations of medication names. Identification of variants of each medication 




Table 5.1: Heart Failure Medications Included in Analyses of Older Home Care Clients, 
Ontario 2004-2007 
 



























          
Abbreviations: ACE = Angiotensin Converting Enzyme, ARB = Angiotensin Receptor Blocker, 




 Potential predictors of HF pharmacotherapies, selected based on clinical relevance and 
previous research, were explored as possible correlates of therapy. (2,7,17,32) These included 
age, gender, education, living arrangement, marital status, caregiver distress, presence of 
comorbidity (including coronary artery disease [CAD], arthritis, diabetes mellitus, and 
hypertension), health regions within Ontario (the 14 Local Health Integration Networks [LHIN]), 
daily pain, edema, use of acute care services, end stage disease, self-rated health, shortness of 
breath, and year of assessment. Presence of airway disease (including chronic obstructive 
pulmonary disease [COPD], asthma and emphysema), number of medications, adherence with 
prescribed medications and falls - all of which are potential barriers to therapy - were also 
included in the analyses, as was receipt of nursing, homemaking and physical therapy services. 
Other measures included four summary health index measures for functional ability, cognition, 
depression and health instability. These were: 1) the Activities of Daily Living (ADL) self-
performance hierarchy scale (range 0-6), 2) the Cognitive Performance Scale (CPS) (range 0-6), 
3) the Depression Rating Scale (DRS) (range 0-14), and 4) the Changes in Health, End-stage 
disease and Signs and Symptoms (CHESS) score (range 0-5). Each measure has been developed 
and validated for use with the RAI-HC and higher scores in each measure indicate more severe 
impairment. (28,30,36,37)
 
Behavioural symptoms were a composite measure of the presence of 
any of the following characteristics on the RAI: wandering, verbally abusive, physically abusive, 
socially inappropriate or disruptive behaviour, and resisting care. 
5.2.3 Analysis 
 
 HF prevalence and use of HF medications were summarized using descriptive statistics. 
Differences between groups were tested using t-tests for continuous variables and chi-square 




were first identified using bivariate analyses and evidence from the literature and then included 
in subsequent multivariable logistic regression analyses. Two-way interaction effects were tested 
at p<0.05 and models were stratified by significant effect modifiers. The criterion for statistical 
significance for entry of variables in the final models was set to alpha=0.05 and selected 
variables were examined in multivariable analyses using regression models with stepwise 
elimination. Alternative forms of the models were examined to rule out order of entry/deletion 
effects. Model fit was assessed using standard lack of fit and regression diagnostics. All analyses 
were conducted using SAS software (version 9.2, SAS Institute Inc., Cary, NC). 
5.3 Results 
 Between January 2004 and December 2007, 176,860 initial RAI-HC assessments were 
completed. A total of 21,968 home care clients with HF (12.4%) were identified. Clients with HF 
were significantly older and less likely to be female, married or cognitively impaired than clients 
without HF (Table 5.2). HF clients were also significantly more likely to exhibit functional 
(ADL) impairment and health instability (as seen with CHESS scores), have higher numbers of 
current medications and comorbid conditions and report more use of nursing and homemaking 
services. Use of specific HF medications was less frequent in clients without HF; however, over 
one-quarter of HF clients (n=6,287) received none of the HF therapies, whereas only 28% were 
receiving recommended combination therapy. Of the clients with HF who received β-blocker 
therapy, approximately one-quarter were receiving evidence-based therapy. Usage of other HF 
medications is depicted in Table 5.2.  
 Table 5.3 lists the differences observed between HF clients receiving no HF therapy and 
those receiving at least one medication. Clients receiving any therapy were significantly more 




and cognitively impaired, exhibited more health instability and depression, and were taking 
fewer medications. Clients receiving therapy were significantly more likely to have received 
nursing and physical therapy services in the past week, although the differences observed were 
small. Over the four-year period, the proportion of clients with HF who received no therapy 
declined from 31.4% to 25.2% (Table 5.4). While functional impairment could reduce the ability 
to access medications, only a small proportion of those with ADL impairments (scores of 2 or 
more on the ADL hierarchy scale) reported no medication use (data not shown). 
 Table 5.5 summarizes the results of the multivariable analyses stratified by hypertension 
status, which was a significant effect modifier. Among clients without hypertension, the presence 
of either CAD or diabetes mellitus was associated with an increased likelihood of receiving 
therapy, whereas functional impairment, behavioural symptoms and airway disease were 
associated with non-receipt of therapy. Age, gender, health region, depressive symptoms, health 
instability, and number of medications and comorbidities were not significantly associated with 
non-receipt of therapy in this group. In hypertensive clients, use of therapy varied by diabetic 
status. Among hypertensive clients with concomitant diabetes mellitus, functional impairment, 
airway disease and age over 85 years were associated with non-receipt of therapy. Gender, health 
region, depressive symptoms, health instability, and numbers of medications and comorbid 
conditions were not significantly associated with therapy in this group. Among hypertensive 
clients without diabetes mellitus, functional impairment and presence of airway disease were 
associated with non-receipt of therapy, while presence of CAD was associated with an increased 
likelihood of receiving therapy. In all models, receipt of home care services (nursing, 





Table 5.2: Sociodemographic, Clinical, Pharmacotherapy and Service Use Characteristics 
of Older Home Care Clients, Ontario 2004-2007 (N = 176,860) 
 
 
 HF Sample 
(N = 21,968) 
% (n) 
Non-HF Sample 
(N = 154,898) 
% (n) p value 





Mean Age in years (SD) 
65-74 years   
75-84 years   
85+ years 
15.3 (3,369) 
45.1 (9,897)  
39.6 (8,702)  
 
   82.8   (7.2) 
21.0 (32,454)  
47.7 (73,904)  
31.3 (48,540)  
 
81.2   (7.3) 
 
<0.001 
Gender Female   58.8 (12,905)  64.1 (99,221)  <0.001 
Married   37.9 (8,321)  39.6 (61,397)  <0.001 
Living Alone  33.4 (7,329)  35.4 (54,828)  <0.001 
Clinical Characteristics     




3+   
  55.8 (12,263)  
25.0 (5,477)  
19.2 (4,215)  
61.1 (94,542)  
23.3 (36,004)  
15.7 (24,273)  
 
<0.001 
CPS score b 0   
1-2 
3+   
  46.2 (10,143)  
42.1 (9,250)  
11.7 (2,572)  
44.1 (68,298)  
41.4 (64,191)  
14.5 (22,376)  
 
<0.001 
DRS score c 0 
1-2   
3+   









  0 
1-2   
3+   
11.9 (2,604) 
  57.9 (12,710) 
30.2 (6,646) 
22.3 (34,536)  
62.2 (96,222)  
15.5 (24,071)  
 
<0.001 
Behavioural Symptoms  10.0 (1,903)  12.7 (20,049) <0.001 










  8.4 (1,839) 
  54.5 (11,967) 
37.2 (8,162) 


















   59.1 (12,975)  
 46.7(10,258)  
43.3 (9,510)  
30.4 (6,673)  
26.5 (5,810)  
19.8 (4,345)  
16.7 (3,657)  
52.5 (81,243)  
44.5 (68,894)  
21.5 (33,367)  
21.2 (32,861)  
13.8 (21,330)  
17.9 (27,669)  



















    2.4 (533)  
  12.6 (2,767)    
  34.4 (7,554)  
  50.6 (11,114)    
    8.44 (4.0) 
3.7 (5,789)  
27.6 (42,703) 
38.7 (59,972)  
30.0 (46,434) 







 HF Sample 
(N = 21,968) 
% (n) 
Non-HF Sample 
(N = 154,898) 
% (n) p value 
Pharmacotherapy     
Use of First-Line 
HF Medications 
ACE inhibitor + β-blocker 
ARB + β-blocker 
ACE inhibitor + ARB 
ACE inhibitor + ARB + β-
blocker 
ACE inhibitor only 









     4.2 (931) 
     0.7 (153) 
 
0.8 (171)  
 22.1 (4,844)    
  46.6 (10,211)  
4.3 (952)  
16.3 (3,587)  
44.3 (9,732)  
 25.9
 i
 (2,523)  
28.6 (6,287)  
10.5 (16,267)  
2.3 (3,596) 
     0.6 (887) 
 
     0.4 (645)  
19.5 (30,147)  
31.0 (47,946)  
4.8 (7,450)  


















  62.8 (13,804)  
 1.5 (2,297)  
23.8 (5,224)  
14.3 (22,075)  
1.8 (2,823)  
5.8 (8,963)  
 
<0.001 
Service Use     







33.9 (6,835)  
35.9 (7,228)  
11.1 (2,230)  
 25.3 (37,007)  
 31.4 (45,964)  





Abbreviations: ACE = Angiotensin Converting Enzyme, ADL = Activities of Daily Living, ARB = 
Angiotensin Receptor Blocker, β-blocker = β-Adrenergic Receptor Blocker, CAD = Coronary 
Artery Disease, CHESS = Changes in Health, End-stage disease and Signs and Symptoms, CPS = 
Cognitive Performance Scale, DRS = Depression Rating Scale EB = Evidence-based, HF = Heart 
Failure, SD = Standard Deviation 
 a 
0 = no impairment; 1-2 = some functional impairment; 3+ = severe functional impairment
 
b 
0 = cognitively intact; 1-2 = mild cognitive impairment; 3+ = cognitively impaired 
c 
0 = no indicators of depression; 1-2 = some indicators of depression; 3+ = indicators of probable 
depression 
 d 
0 = no health instability; 1-2 = some health instability; 3+ = moderate to high health instability
 
e 
excludes HF  
f
 includes chronic obstructive pulmonary disease (COPD), emphysema and asthma 
g 
excludes ACE inhibitor, β- blocker and ARB  therapies 
h 
Evidence-based β-blocker therapy (bisoprolol or carvedilol)  
i 
(%) shown is a proportion of the Any β-blocker group 
j 
no ACE inhibitor, β- blocker or ARB use 
k  







Table 5.3: Sociodemographic, Clinical, Pharmacotherapy and Service Use Characteristics 
of Older Home Care Clients with Heart Failure by Pharmacotherapy Status, Ontario 2004-
2007 (N = 21,968) 
 
  No First-line 
Pharmacotherapy 









Sociodemographic Characteristics     
Age  85+ years 44.8 (2,814) 37.6 (5,888) <0.001 
Gender Female 58.7 (3,687) 58.8 (9,218) 0.90 
Married   35.3 (2,219) 38.9 (6,102) <0.001 
Clinical Characteristics     
Functional Impairmenta  40.7 (2,558) 30.0 (4,703) <0.001 
Cognitive Impairmentb        14.8 (929) 10.5 (1,643) <0.001 
Depressionc        14.8 (931) 13.6 (2,125) 0.02 
Unstable Healthd    33.0 (2,071) 29.2 (4,575) <0.001 















       2.2 (0.6) 
 7.3 (1,147) 
    54.0 (8,463) 
38.7 (6,071) 
 
     2.3 (0.6) 
 
<0.001 













   47. 5 (7,452) 
   46.2 (7,244) 
   33.2 (5,213) 
























       7.2 (4.6) 
    0.04 (7) 
9.1 (1,421) 
   36.9 (5,782) 
   54.0 (8,471) 
 
8.9   (3.6) 
 
<0.001 
Service Use     










  34.1 (5,040) 
 35.7 (5,280) 





Abbreviations: CAD = Coronary Artery Disease, SD = Standard Deviation 
a 




score of 3 or more on the Cognitive Performance Scale (CPS) = cognitive impairment 
c 





 score of 3 or more on the Changes in Health, End-stage disease and Signs and Symptoms (CHESS) 
scale = moderate to high health instability 
e
 excludes HF 
f 
includes chronic obstructive pulmonary disease (COPD), asthma and emphysema
 
g
 excludes ACE inhibitor, β-blocker and ARB  therapies 
h 





Table 5.4: Prevalence Estimates of No First-Line Pharmacotherapy Use among Older 





2004 31.4 (1,664)  
2005 29.4 (1,772)  
2006 28.1 (1,619)  
2007 25.2 (1,232) 







Table 5.5: Multivariable Analysis of Predictors of No First-Line Pharmacotherapy among 
Older Home Care Clients with Heart Failure, Ontario 2004-2007 (N = 21,968) 
 
Model 1:                           Non-Hypertensive Clients 
Covariate 






 1.39 (1.26, 1.53) <0.001 
Behavioural Symptoms 1.44 (1.24, 1.68) <0.001 
CAD
 
0.66 (0.60, 0.73) <0.001 
Airway Disease
b 
1.36 (1.23, 1.50) <0.001 
Diabetes Mellitus 0.55 (0.49, 0.61) <0.001 
                                        Hypertensive Clients 
Model 2:                                with Diabetes Mellitus 
Covariate 






1.73 (1.46, 2.04) <0.001 
Airway Disease
b 
1.77 (1.49, 2.10) <0.001 
Age 75-84
c 
1.15 (0.93, 1.42) 0.24 
Age 85+
c 
1.60 (1.27, 2.03) <0.001 
Model 3:                                without Diabetes Mellitus 
Covariate 
Odds Ratio 









1.54 (1.37, 1.73) 




In each model, above variables were included simultaneously (all variables were adjusted for each other). 
 
Abbreviations: CAD = Coronary Artery Disease, CI = Confidence Interval 
a 
score of 2 points or more on the ADL Hierarchy Scale 
b 
includes chronic obstructive pulmonary disease (COPD), emphysema and asthma 
c







 The results of this study provide a depiction of patterns of HF medication use in a 
representative population of vulnerable community-dwelling seniors. In this study of 21,968 
older home care clients with HF, nearly 30% (n=6,287) were not receiving any first-line HF 
therapies, potentially leaving them at risk of further functional decline, worsening of HF 
symptoms and increased service use. Previous studies suggest that underuse of such therapies 
may occur due to patient non-adherence, possible treatment bias or physicians‟ concerns about 
potential side effects and contraindications, especially in older vulnerable patients. Consistent 
with previous studies, this study shows that advanced age and the presence of airway disease 
(including COPD) were associated with non-use of therapy. Ageism in prescribing HF therapies 
has been documented in the literature (17) and while Canadian HF guidelines caution the use of 
β-blocker therapy in individuals with untreated COPD, therapies are recommended for those 
with stable disease. (2) Novel associations identified in this study included a reduced likelihood 
of HF therapy use among selected clients with functional impairment and behavioural symptoms. 
Taken together, these findings appear to support previous work which demonstrated that those at 
the highest risk of outcomes are the least likely to receive therapy. (38) The modest increase in 
the use of therapy for HF over the four-year period may reflect partial uptake of two sets of 
guidelines published in Canada in 2003 and 2006 – including one focusing on the management 
of heart disease in older patients. (2,39) Nonetheless, as evidence supporting the use of ACE 
inhibitor and β-blocker in HF management has been available for over a decade, the high 





 In Ontario, persons aged 65 and older are eligible for prescription coverage under the 
Ontario Drug Benefit Plan, and thus these results are likely not explained by cost barriers. Older 
home care clients with HF are a vulnerable population, and the association of functional 
impairment with non-use of therapy suggests that prescribing physicians may have concerns 
about precipitating adverse events, such as falls. While concerns over postural hypotension and 
fall risk have been raised as reasons for withholding therapy in other studies (17), having had one 
or more falls (in the 90 days prior to assessment) was not found to be related to medication use in 
this study. Cognitive impairment and depressive symptoms were common among clients with 
HF, and although not found to be associated with medication use in this study, their presence 
may complicate adherence to therapy. The presence of behavioural symptoms was found to be a 
predictor of non-receipt of HF therapy. Such symptoms often occur in patients with vascular 
cognitive impairment and may represent a proxy for impaired executive function that impedes 
the ability of these patients to properly manage their medications. (40) Executive dysfunction 
may be captured to a degree by the CPS; however, behavioural symptoms, and not CPS scores, 
were found to be associated with use of therapy. Alternatively, underuse among such patients 
may reflect altered physician prescribing behaviours resulting from perceived clinical 
management challenges, such as therapeutic nihilism in patients deemed too frail to benefit from 
therapy. Of particular concern is the possibility that the association of functional impairment and 
behavioural symptoms with underuse of therapies may to a certain extent reflect under-treated 
and unrecognized HF presenting with atypical symptoms. (41) Functional impairment and 
dementia have been found to predict mortality among older individuals hospitalized for HF. (42) 
This study has also demonstrated that functional impairment is associated with non-use of first-




which are often not taken into account in clinical trials or studies using administrative data, are 
important considerations. The ability to explore a breadth of clinical factors including key 
geriatric conditions using RAI-HC data is an important strength of this study. 
 The associations observed for CAD, diabetes mellitus, and airway disease are consistent 
with findings from other studies in older adults. (20,34,43)
 
ACE inhibitors and β-blockers are 
also used to treat CAD, diabetes mellitus and hypertension, and the co-occurrence of these 
conditions in older persons with HF may provide additional indications for physicians to 
prescribe these medications. Previous literature indicates that residence in long-term care 
facilities and cognitive impairment may be associated with underuse of HF therapy. (41)
 
In this 
study, all subjects were community-dwelling and cognitive impairment was not associated with 
non-receipt of therapy for HF. It may be that the co-occurrence of cognitive impairment in 
complex HF patients may pose too great a management challenge in a community setting, 
requiring transfer to more intensive LTC settings. In contrast to other studies, gender, health 
region, depressive symptoms and health instability were not associated with receipt of therapy 
for HF. (18,20,44,45) The consideration of other clinical and sociodemographic variables in 
multivariable analyses may have identified factors, particularly those related to frailty, that 
explained the gender effect.  
 While this study has begun to develop a profile of older clients with HF who are not 
receiving HF medications, it is not possible to determine how such profiles translate into 
prescribing practices. Primary care providers may be more concerned with adverse outcomes, 
such as falls or polypharmacy, or may be unaware of the potential benefits of first-line 
combination therapy on geriatric outcomes. (21,46,47) Further, physicians may be uncertain 




clinical trials, or may mismanage HF in the context of other comorbidities. (38) Whether clients 
had access to a physician or a chronic disease management program was not ascertainable from 
these data, nor were previous medication records. It is possible that other unmeasured patient 
factors, such as non-adherence to HF medications and intolerance to therapy could lead to 
discontinuation of therapy resulting in non-use. It is not possible to determine how much of the 
observed non-use could be explained by such factors. This study considered prevalent HF and 
did not have information about duration or severity of the syndrome, such as LVEF assessment 
and New York Heart Association functional class. However, the CHESS scale for health 
instability has been shown to be superior in predicting mortality in frail individuals with HF, 
indicating that disease severity is captured to some extent. (48) Patients with HF and preserved 
LVEF (HFPEF) may be less likely to receive these medications; although recommended for most 
patients with HFPEF by the CCS Guidelines, the recommendations for their use are strongest for 
HF with reduced LVEF. (2) While a large study of community-based patients found HFPEF 
prevalence to be 36% (49), it is possible that HFPEF affects a large subset of this sample. Other 
studies have shown that older females with HF, such as those in our study sample, are less likely 
to receive echocardiography to determine EF. (50) Thus it is unlikely that EF would have been 
known in most of our sample, reflecting true community practice. There is strong evidence for 
the reliability and validity of diagnostic items in the interRAI instruments, with positive 
predictive values and sensitivity of HF diagnosis being 0.83 and 0.80, respectively. (31,32) This 
sensitivity of HF diagnosis is high compared with other administrative databases. (51,52)  
Nonetheless, there is the potential that not all cases of HF were identified in this sample. The 
decision to consider medications in the same class as first-line, whether evidence-based or not, 




Guidelines. This inclusion of evidence-based and non-evidence-based therapies likely means that 
the proportion of clients receiving optimal therapy is overestimated. Lastly, the cross-sectional 
study design prevented exploration of dynamic factors associated with drug use. Others have 
demonstrated that long-term patient adherence to prescribed therapy could be improved through 
continuity of care and physician follow-up. (53) It is not possible to determine how many clients 
in this sample were receiving medications long-term. 
 This work shows that nearly 30% of home care clients with HF were not receiving first-
line therapies and that only 28% were receiving the first-line combination therapy recommended 
by national guidelines. These are both important findings and suggest that there is much room for 
improvement in HF care among older community-dwelling adults. Further, this study has begun 
to explore factors associated with non-use of medications and identified factors such as 
functional impairment and other comorbidity. This provides an important baseline upon which to 
develop future studies of potential barriers associated with optimal medication use and areas for 
targeted interventions to improve care. Investigating factors associated with combination therapy 
use would be an important follow-up study. For clinicians, this work serves as a potential 
reminder to follow guideline recommendations in HF management among older, vulnerable 
adults, particularly those with other comorbidities and functional impairment. Improving 
management in this population could improve disease outcomes, reduce hospitalizations, avoid 
long-term care placement and help promote independence. 
5.5 Conclusions 
 Novel patient-level factors associated with underuse of HF medications have been 
identified: whether and how these factors act as true barriers to prescribing remains to be 




care. Identifying ways to utilize existing services with the aim to improve HF management is a 
logical continuation of this work. Consideration of client characteristics and other potential 
barriers to medication use will be crucial in designing successful HF management programs for 
vulnerable home care clients. The RAI-HC, now in widespread use across Canada (54) and in at 
least 12 other countries (26), may be particularly useful in conducting such work in order to 
better inform clinical practice among typical vulnerable seniors. (55) This work has 
demonstrated the utility of routinely collected health information in identifying factors associated 
with HF management. To make full use of such tools, strategies designed to link primary care 




6.0 OUTCOMES AMONG OLDER HOME CARE CLIENTS WITH HEART FAILURE: 
MORTALITY, LONG-TERM CARE ADMISSION, HOSPITALIZATIONS, 







 HF is a chronic condition affecting approximately 1 in 5 individuals over the age of 80. 
(1) It is associated with significant morbidity and mortality and individuals with HF experience 
mortality and frequent hospitalizations. (2-5) Annual mortality rates due to HF reach 50% (2), 
and among Canadians over 85 years, HF leads to more hospitalizations than ischemic heart 
disease or heart attack. (3) Effective management of HF includes dietary and fluid restrictions, 
symptom monitoring, exercise therapy and combination pharmacotherapy. (2)  
 According to the CCS guidelines, first-line pharmacotherapy, recommended for most 
individuals with HF, consists of ACE inhibitor or ARB therapy in conjunction with β-blocker 
therapy. (2) These recommendations are based on evidence from a large number of clinical trials. 
Such trials commonly examine the outcomes of mortality and hospitalization, but other outcomes 
such as LTC admission, functional decline or cognitive decline, which may also be relevant to 
older individuals, are often not studied. ACE inhibitor therapies have been shown to reduce 
mortality and improve the combined outcome of death or hospitalization, as well as improve 
disease severity in randomized trials of individuals with HF and reduced EF. (6,7) Some work 
indicates that ACE inhibitor therapy may also improve cognitive impairment in individuals with 
HF. (8) ARB therapy is used primarily in individuals who cannot tolerate ACE inhibitor therapy 
and has been shown to reduce hospitalizations, but not mortality. (9,10) β-blockers may also 
improve survival, as well as HF severity and exercise tolerance, but do not exhibit class effects 
like ACE inhibitors. (11,12) 
 While good evidence for pharmacotherapy exists from trials, its applicability to all HF 
patients is questionable. Although prevalence of HF increases with age, the majority of trials 




(13,14) Outcomes explored through such studies are primarily mortality and hospitalization and 
often these outcomes are combined to achieve enough events to detect differences between 
treatment groups (see Tables 1-3 in Appendix G). Such studies are necessary to determine the 
efficacy of pharmacotherapy, but may not be useful in informing management of HF in older 
individuals with multiple comorbidities, multiple medications and geriatric conditions. Further, 
for older individuals with HF, outcomes such as LTC admission, functional decline and 
cognitive decline may be outcomes of as much importance as mortality or hospitalizations. Only 
a few studies have examined the effectiveness of ACE inhibitor therapy on cognition and 
exercise tolerance, and β-blocker therapy on exercise capacity. (15-17) These studies 
predominantly enrolled younger men with less comorbidity and medication use than more typical 
HF populations. Arguably, outcomes that are under-studied, such as LTC placement and 
cognitive and functional decline, may be especially relevant to older HF patients.  
 Another discrepancy between most study populations and HF patients overall is the 
setting in which HF is managed. Many study populations are derived from acute or tertiary care 
settings, but approximately 90% of individuals with HF in Ontario are managed through primary 
care. (18) Therefore, outcomes observed in groups receiving specialist care may not be 
representative of typically managed HF patients. Most work on outcomes of HF has involved 
medication use as predictors of mortality and hospitalization. For older, frail populations with 
HF, such as long-stay home care clients, little is known about all outcomes, specifically those 
beyond mortality and hospitalizations. There is a dearth of information about factors associated 
with each outcome. 
 The purpose of this study was to examine mortality, LTC placement, long-stay 




community-dwelling long-stay home care clients with HF. Using the comprehensive 
sociodemographic, clinical, diagnostic and medication data available from the RAI-HC, factors 
associated with these outcomes were explored. 
6.2 Methods 
6.2.1 Study Design and Data Source 
 This was an observational study that examined five outcomes (mortality, LTC admission, 
long-stay hospitalization, functional decline and cognitive decline) among long-stay home care 
clients in Ontario with HF.  
 All data on sociodemographic and clinical characteristics, as well as home care and acute 
service use were obtained from the Ontario RAI-HC database. The RAI-HC was mandated for 
use in Ontario in 2003 to assess all long-stay (expected to receive service for 60 days or longer) 
home care clients (19) and the database now contains more than one million assessment records 
for all such clients receiving services in the province. Outcome data for mortality, LTC 
admission and long-stay hospitalizations were obtained from the OACCAC administrative 
database. This database contains home care service records for all long-stay home care clients in 
the province as well as discharge information. 
 The RAI-HC assessment has been described previously and consists of over 300 
questions covering sociodemographic, functional, cognitive and clinical domains. (20) The RAI-
HC database also contains information about medication use (both over-the-counter and 
prescription) in the seven days prior to assessment, as well as use of acute care and home care 
services in the 90 days prior to assessment. interRAI assessments are completed by assessors 
who receive intensive, standardized training. These assessors are often social workers or nurses, 




professionals. The assessors may also review medical records if necessary. interRAI assessments 
including the RAI-HC have been shown to be both reliable and valid for use in older home care 
populations. (20-23) The ability to link data from the RAI-HC to service records and discharge 
data from the OACCAC database allowed the outcomes of interest to be comprehensively 
examined. 
6.2.2 Sample 
 The sample was selected from all long-stay home care clients in Ontario aged 65 years 
and older who were assessed with the RAI-HC between January 1, 2005 and December 31, 2007. 
Outcomes of interest were captured from both the OACCAC and RAI-HC databases until 
September 30, 2008, allowing clients to be at risk for each outcome for a minimum period of 
nine months. Individuals were included for study regardless of functional or cognitive 
impairment or presence of comorbidity. Individuals were excluded if no medications were 
recorded during any assessment. To create a longitudinal data set from the RAI-HC database, 
individual assessments were coded as either a first, second, third or fourth assessment, and 
merged by unique, anonymized client identification codes. Individuals with only one assessment 
were not included in this longitudinal data set. For individuals with four or more assessments, 
only the first four assessments were included in the longitudinal data set. HF diagnosis was 
considered to be consistent if 1) all assessments had a diagnosis of HF recorded, 2) no 
assessment had a diagnosis of HF recorded, or 3) initial assessments did not contain a diagnosis 
of HF, but all subsequent assessments did (new HF). If HF status was inconsistent across 
assessments for an individual, the individual was excluded from this data set.  Individuals were 
also excluded if the gap between two consecutive assessments was not between 60-270 days. 




assessed more frequently) as well as those who were more healthy (and assessed less frequently). 
Figure 6.1 depicts the inclusion criteria for the sample. From Figure 6.1, it can be seen that the 
RAI-HC database included 219,957 long-stay home care clients older than 65 years assessed in 
the community between 2005 and 2007. From this sample, those with no medications recorded 
(n = 4,521), those with only one assessment (n = 99,681), those with assessment gaps of less than 
60 days or more than 270 days (n=47,738), and those with inconsistent HF diagnoses (n = 242) 











 Key sociodemographic and health-related variables were chosen as potential covariates of 
interest from items available on the RAI-HC assessment, based on previous research and clinical 
relevance. These were classified as sociodemographic, clinical, diagnostic, pharmacotherapy or 
service use characteristics. Most variables were categorized as either present or not present when 
examining their main effect on the outcomes of interest.  
 The sociodemographic variables examined were age, gender, marital status, living 
arrangement (living alone versus not) and caregiver stress. Age was collapsed into three groups: 
65-74 years (reference group), 75-84 years and 85+ years. Caregiver stress was indicated by 
caregivers reporting an inability to continue with caring activities or expressing feelings of 
distress, anger or depression.  
 Clinical characteristics explored included number of comorbid conditions, impaired 
medication management, behavioural symptoms, impairment with stairs, incontinence and non-
adherence to medications. Impaired medication management is an item captured in the physical 
function section of the RAI-HC and is recorded if individuals have difficulty remembering to 
take medications, opening medication containers, taking correct dosages, performing injections 
or applying ointments. The behavioural symptom variable was a composite measure of any of 
the following individual items on the RAI-HC: wandering, verbal or physical abuse, 
inappropriate or disruptive behaviour, or resisting care. Using the medication non-adherence 
item on the RAI-HC, non-adherence was defined as adherence less than 80% of the time.   
 Additional clinical characteristics explored were derived from summary scales, 
algorithms and CAPs embedded in the RAI-HC. Four scales were used in the analyses. The ADL 




measure of functional ability. (24) The IADL capacity scale is a hierarchical index that assesses 
difficulty with meal preparation, ordinary housework and phone use, and ranges from 0 – no 
difficulty in any task, to 6 – great difficulty in all tasks. (21) The CPS measures cognitive status, 
ranging from 0 – cognitively intact, to 6 – very severe impairment. (25,26) The CHESS scale 
measures health instability and is a composite measure across the following symptoms: 
vomiting, dehydration, loss of appetite, weight loss, shortness of breath and edema. Scores on the 
CHESS scale can range from 0 – no symptoms of instability, to 5 – high level of instability. (27) 
Additionally, the MAPLe algorithm was used, and is a measure of assigning priority level of 
clients based on function and cognition. (28) This algorithm assigns to individuals scores 
between 1 – low priority, to 5 – high priority. Scores from these clinical scales and algorithms 
were collapsed categorically for descriptive purposes, but were not collapsed during subsequent 
multivariate modeling. interRAI instruments also contain CAPs to help with care planning and 
trigger areas for further follow-up. Two CAPs, the falls and mood CAPs, were used in the 
analyses. The falls CAP is not triggered if individuals had no previous falls, is triggered at a low-
risk level for individuals with one previous fall, and is triggered at a high-risk level for 
individuals with two or more previous falls. (29) The mood CAP assesses depressive symptoms 
and is not triggered if individuals exhibit no indicators of depression, is triggered at a low-risk 
level if individuals have indicators of possible depression, and is triggered at a high-risk level if 
individuals exhibit indicators of probable depression. (29) CAP levels were reported in 
descriptive and longitudinal analyses, with the reference group being those who did not trigger 
the respective CAP. 
 Diagnostic covariates that were examined in all analyses were diabetes mellitus, stroke, 




Alzheimer‟s), cancer and airway disease (a measure that includes asthma, emphysema and 
COPD). These diagnoses, as well as HF, are recorded on the RAI-HC during assessment, and are 
routinely verified through discussions with clients, caregivers, health care professionals, and 
review of medical charts if needed. Previous work done using Canadian LTC populations has 
shown that sensitivity of interRAI tools in HF diagnosis is high (above 80 percent) when 
compared to provincial discharge data. (30) 
 The RAI-HC captures pharmacotherapy use in the seven days prior to assessment. 
Medications are recorded at the time of assessment and verified using medication containers, 
conversations with clients and caregivers, and medical records. Recorded medications are 
electronically entered into the database and a manual search for medication names and variants 
was done to identify medications in the three classes of interest. Covariates explored were use of 
any ACE inhibitor therapy (including benazepril, captopril, cilazapril, enalapril, fosinopril, 
lisinopril, perindopril, quinapril, ramipril, and trandolapril), ARB therapy (including candesartan, 
eprosartan, irbesartan, losartan, telmisartan and valsartan) or β-blocker therapy (including 
acebutolol, atenolol, bisoprolol, carvedilol, metoprolol, nadolol and propranolol). A continuous 
use variable was created for each of these classes of medications for individuals who reported 
use at every assessment. 
 Service use characteristics explored included home care services (home help, 
physiotherapy, nursing and homemaking) and acute care services (emergency department visits 
and hospitalizations). Clients with any service use were compared to those with none. A weekly 
cost variable was created based on total home care service costs. This variable was created using 
home care service records data from the OACCAC database. The number of hours of each type 




therapy, social work, homemaking and respite care) are recorded in this database. The total 
service hours were multiplied by the standard CCAC cost associated with each type of service. 
To create the weekly cost variable, the total cost of all services received in the one-week period 
prior to the most recent RAI-HC assessment were added and for the purposes of the analyses, 
this cost variable was converted to increments of $100.   
 The five outcomes of interest were mortality, LTC admission, long-stay hospitalization, 
functional decline and cognitive decline. In the OACCAC database, clients are assigned a 
discharge code and date when home care services are terminated. Mortality, LTC placement and 
long-stay hospitalizations (14 days or longer) are three of the discharge codes used. If a 
discharge for these reasons was recorded, the event was said to have occurred. The outcomes of 
functional and cognitive decline were derived from changes in the ADL hierarchy scale and CPS 
scale embedded in the RAI-HC assessment. The definitions of decline for both function and 
cognition were consistent with those described in the home care quality indicators for use with 
interRAI home care instruments. (31) New functional decline was defined as an increase of two 
or more points on the ADL hierarchy scale among individuals with no functional impairment at 
the first assessment (ADL hierarchy score = 0). This decline represents a change to at least 
limited functional impairment. For cognition, new decline was defined as a one or more point 
increase on the CPS among individuals who were initially cognitively intact (CPS = 0 at 
assessment 1). This change corresponds to at least a six point reduction in Mini Mental State 
Exam scores. (26)  
6.2.4 Analysis 
 Sociodemographic, clinical, functional, pharmacotherapy and service use characteristics 




compared to those with two or more assessments on all characteristics of interest. Differences 
between groups (by HF status, number of assessments and time between assessments) were 
examined using chi-square tests for categorical variables (significance level p<0.05). Potential 
predictors of each of the five outcomes of interest were initially identified using bivariate 
analysis. Discrete survival analysis was done using Cox proportional hazards modeling. For the 
outcomes of mortality, LTC admission and long-stay hospitalization, events that occurred in the 
nine months following assessment were recorded. If the individual did not experience the event 
following an assessment, and had a subsequent assessment, event occurrence in the nine months 
following the subsequent assessment was recorded (i.e., individuals were renewed in the at-risk 
set). Individuals were right-censored if they had not experienced the event following the final 
assessment. Time to mortality, LTC admission and long-stay hospitalization was calculated from 
the relevant assessment date to the discharge date for each outcome. For the outcomes of 
functional and cognitive decline, a different approach was necessary. Because RAI-HC 
assessments are repeated at approximately six-month intervals, the exact date of decline is 
unknown, but is known to have occurred between two consecutive assessments. This makes the 
functional and cognitive decline events interval censored and avoids problems associated with 
arbitrarily assigning a date (such as the midpoint of the interval). Time to decline was calculated 
as the number of days between the two assessment dates during which the decline occurred. For 
clients with no decline during the first interval, event occurrence in subsequent intervals was 
explored. However, only the first occurrence of decline was recorded.  Previous unpublished 
work done using RAI-HC data has shown that such interval censoring has minimal effect on 
odds ratio estimates, and this method has been used in analyses of time to first hip fracture using 




 Factors potentially associated with each of the respective outcomes were initially 
identified using bivariate analyses and evidence from the literature. Significant covariates were 
included in subsequent multivariate proportional hazards regression analyses, initially done using 
stepwise selection with the criterion for statistical significance for entry of variables into the final 
model set to alpha=0.05. Covariates for age, gender and medication use were forced into models 
to examine their main effects and allow for comparisons between models and to previous 
findings from the literature. The binary covariates for any ACE inhibitor, ARB or β-blocker use, 
as well as the weekly cost of services covariate were treated as time-dependent covariates, 
meaning that the value of the covariate at the assessment prior to the outcome date was used in 
the model. Exploration of alternate models was done using composite comorbidity measures 
substituted for individual comorbid conditions and the weekly cost variable in place of the four 
home care service covariates. To minimize the potential effects of collinearity, covariates for 
marital status and living alone were examined separately in models for each outcome. Further, 
the MAPLe algorithm incorporates both ADL hierarchy scale scores and CPS scores. MAPLe 
algorithm scores were examined in models separately from ADL hierarchy scale scores and CPS 
scores for each outcome. Alternate forms of the models were examined to ensure that entry and 
deletion effects were ruled out. Proportionality assumptions were checked for each covariate in 
the final models by creating dummy variables of each covariate multiplied by the log of the time 
to discharge or time to decline. Two-way interaction effects were tested at p<0.05. Examination 
of potentially influential outliers was done for all covariates and apart from some high weekly 
costs, none were identified. For models that included the weekly cost covariate, clients with costs 
in the highest one percentile were excluded to minimize the effect of these potentially influential 








 From the final sample of 67,725 individuals (see Figure 6.1), 1,842 individuals with new 
HF were identified, but not included in the longitudinal analyses. A total of 9,283 (14.1%) 
individuals with HF were identified from this sample. Of these individuals, 3.3% (n = 312) died, 
2.3% (n = 209) were admitted to long-term care, 8.5% (n = 793) had long-stay hospitalizations, 
11.9% (n = 1,105) experienced functional decline and 12.8% (n=1,191) experienced cognitive 
decline. Of those who experienced functional or cognitive decline, 429 and 680 individuals, 
respectively, experienced new decline. 
 Table 6.1 presents the sociodemographic, clinical, functional, pharmacotherapy and 
service use characteristics of older home care clients in Ontario by HF diagnostic status. The 
table includes individuals with one assessment only, who were excluded from further analyses. 
Differences between groups, by both assessment number (one versus two or more assessments) 
and HF diagnosis, were examined. All groups were significantly different except for presence of 
diabetes mellitus, any use of ACE inhibitor or ARB therapy, falls CAP scores and mood CAP 
scores, as indicated in the table. Overall, the group with HF was older and less likely to be 
female or married than the non-HF group. Individuals with HF also demonstrated lower priority 
level on the MAPLe algorithm, less cognitive impairment, more difficulty with IADLs, greater 
health instability (based on CHESS scale scores), more comorbidity, more medication use 
(including HF specific medications) and more homemaking and home help service use than their 
counterparts without HF. Compared to individuals with only one assessment, those with two or 




less functional impairment, cognitive impairment and health instability. However, the group with 
two or more assessments reported more comorbid conditions and medication use, higher rates of 
incontinence and more service use. Use of ACE inhibitor and ARB therapies was not different 
between individuals with one assessment compared to those with two or more.  
 Only individuals with two or more assessments and consistently diagnosed HF were 
included in further outcomes analyses (n= 9,283). Table 6.2 illustrates the characteristics of this 
sample with respect to key sociodemographic variables, clinical scales and medication use. The 
proportion of individuals with HF remained constant over time, with these individuals making up 
approximately 14% of the entire sample at each assessment. Over time, an increasing proportion 
of individuals lived alone and females made up a larger proportion of the group. Levels of 
functional and cognitive impairment remained relatively stable over time, and by the fourth 
assessment, individuals exhibited less health instability and lower rates of falls than at the first 
assessment. The number of comorbidities and medications increased over time, but the reported 
rates of ACE inhibitor, ARB and β-blocker use remained relatively stable.  
 Since individuals were excluded based on time between assessments, comparisons 
between individuals with 60-270 days between assessments and those with less or more time 
between assessments were done to explore potential differences between groups. Results of this 
analysis can be found in Table 1 of Appendix J. While differences between groups are 
statistically significant, there appears to be no evidence to suggest that the groups differ 
clinically in substantively meaningful ways.  
 Tables 6.3 – 6.7 provide the five proportional hazards regression models for mortality, 
LTC admission, long-stay hospitalization, new functional decline and new cognitive decline, 




variables were significant in any of the final models. The proportionality assumption was not 
violated for any of the chosen models.  In Appendix J, Tables 2 through 6 display the results of 
initial bivariate logistic regression analyses of associations between individual covariates with 
each outcome of interest. 
 Table 6.3 depicts the model for time to mortality. Living alone and female gender were 
associated with a lower risk of mortality in the nine months following assessment, while health 
instability and IADL impairments were associated with an increased risk. Age and any ACE 
inhibitor, ARB or β-blocker use were not found to be significantly associated with mortality.  
 Factors associated with LTC admission within nine months are shown in Table 6.4. Older 
age was associated with an increased risk of admission (HR = 1.95 for individuals older than 85 
years compared to those 65-74 years). Increasing MAPLe scores and IADL impairment also 
increased admission risk, while more comorbid conditions reduced the risk. Gender was not 
significantly associated with LTC admission. Any use of an ACE inhibitor showed a protective 
effect for placement, but use of ARB or β-blocker therapy did not.  
 The selected model for time to long-stay hospitalization within nine months is shown in 
Table 6.5. Females had a reduced risk of long-stay hospitalizations, with a HR of 0.85 compared 
to males with similar characteristics for other covariates. Increasing health instability, 
impairments with stairs, and, to a lesser degree, number of medications were associated with a 
higher risk of long-stay hospitalization. Use of any HF medications was not found to be 
associated with risk of long-stay hospitalization. 
 Table 6.6 provides the model for factors associated with new functional decline. Living 
alone, female gender and reported ACE inhibitor use were all associated with a reduced risk of 




care services were all found to increase the likelihood of new decline. Factors associated with 
any functional decline irrespective of baseline status were also explored and the proportional 
hazards regression model can be found in Table 7 of Appendix J. Similar to the model for new 
functional decline, older age and MAPLe score increased the likelihood of any functional 
decline, while living alone, female gender and ACE inhibitor therapy reduced the likelihood. 
 In Table 6.7, the selected model for new cognitive decline is shown. Being female was 
associated with a reduced risk of new cognitive decline. Increasing age, ADL impairment, 
history of falls, indicators of depression and impaired medication management were all 
associated with a higher risk of new decline. A diagnosis of dementia was the strongest predictor 
of new decline, with an associated HR of 4.06 compared to individuals with similar covariates, 
but no dementia. Use of any ACE inhibitor, β-blocker, and ARB therapy was not significantly 
associated with new decline. Investigation of factors associated with any cognitive decline 
irrespective of baseline status was also done and the final model can be found in Table 8 of 
Appendix J. Older age, ADL impairment, indicators of depression, impaired medication 
management and a diagnosis of dementia increased the risk of new cognitive decline, while 




Table 6.1: Sociodemographic, Clinical, Diagnostic, Pharmacotherapy and Service Use Characteristics of Older Home Care 
Clients by Heart Failure Diagnosis and Number of Assessments, Ontario 2005-2007 (N =165,564) 
 
  1 Assessment Only 
N = 99,681 
2+ Assessments 
N = 65,883 












Sociodemographic Characteristics      
Age 65-74 years 














Gender Female 57.9 (7,389) 63.4 (55,086) 66.7 (6,195) 69.1 (39,113) 
Married  39.2 (5,007) 41.3 (35,888) 35.3 (3,281) 39.0 (22,065) 
Living Alone  31.8 (4,054) 34.3 (29,836) 39.4 (3,658) 38.0 (21,479) 
Caregiver Stress  17.1 (2,180) 17.1 (14,835) 12.5 (1,164)    13.9 (7,839) 
Clinical Characteristics      











   10.4 (9,027) 
72.3 (6,711) 
20.0 (1,854) 




































       6.1 (569) 
50.5 (28,618) 
39.5 (22,326) 

















    8.7 (4,893) 
MAPLe Algorithm score
e



















  1 Assessment Only 
N = 99,681 
2+ Assessments 
N = 65,883 












Behavioural Symptoms  7.5 (952) 9.2 (7,949) 4.1 (376) 6.8 (3,857) 

















   12.4 (7,038) 
Mood CAP
†g































  11.0 (6,201) 
64.4 (36,444) 
24.6 (13,955) 
Diagnoses      
Hypertension  60.2 (7,683) 53.1 (46,208) 63.3 (5,876) 55.1 (31,181) 
Arthritis  50.3 (6,416) 46.5 (40,393) 60.7 (5,635) 54.8 (36,001) 
CAD  43.6 (5,569) 21.8 (18,957) 46.3 (4,301) 24.0 (13,568) 
Diabetes Mellitus
‡
  31.9 (4,071) 22.1 (19,166) 32.5 (3,019) 22.3 (12,594) 
Airway Disease
i
   27.0 (3,446) 13.9 (12,066) 28.3 (2,625)   14.5 (8,216) 
Stroke  18.5 (2,367) 15.9 (13,845) 20.7 (1,919) 19.4 (10,976) 
Osteoporosis  18.0 (2,293) 19.0 (16,539) 20.5 (1,902) 22.3 (12,647) 
Any Dementia  14.7 (1,871) 20.7 (17,963) 12.0 (1,115) 20.1 (11,374) 
Cancer  13.0 (1,654) 18.4 (15,965)      10.6 (981)    12.7 (7,206) 



















Impaired Medication Management  62.4 (7,962) 53.0 (46,048) 56.9 (5,277) 52.3 (29,584) 
Medication Non-Adherence
k





  1 Assessment Only 
N = 99,681 
2+ Assessments 
N = 65,883 












Pharmacotherapy      
Any ACE inhibitor use
‡
  48.7 (6,217) 32.6 (28,310) 48.9 (4,541) 33.5 (18,985) 
Any ARB use
‡
  11.4 (1,460) 9.1 (7,918) 12.0 (1,118) 9.0 (5,065) 
Any β–blocker use  46.8 (5,979) 26.4 (22,930) 42.9 (3,985) 25.4 (14,361) 
Service Use      






















Acute Care Service Use
m









  25.2 (14,268) 
 
Abbreviations: ACE = Angiotensin Converting Enzyme, ADL = Activities of Daily Living, ARB = Angiotensin Receptor Blocker, β-blocker =  
 β-Adrenergic Receptor Blocker, CAD = Coronary Artery Disease, CAP = Clinical Assessment Protocol, CHESS = Changes in Health, End-stage 
disease and Signs and Symptoms, CPS = Cognitive Performance Scale, ED  = Emergency Department, HF = Heart Failure, IADL = Instrumental 
Activities of Daily Living, MAPLe = Method for Assigning Priority Levels 
† indicates that differences between groups by HF diagnosis were not significant at p < 0.05 
‡
 indicates that differences between groups by assessment number (1 versus 2 or more) were not significant at p < 0.05 
a
 0 = no impairment; 1-2 = some functional impairment; 3+ = severe functional impairment 
b
 0 = no difficulty; 1-2 = some difficulty; 3+ = great difficulty 
c
 0 = cognitively intact; 1-2 = mild cognitive impairment; 3+ = cognitively impaired
  
d
 0 = no health instability; 1-2 = some health instability; 3+ = moderate to high health instability
 
e
 1 = low priority; 2-3 = mild/moderate priority; 4-5 = high priority  
f
 0 = no prior falls; 1 – 1 prior fall; 2 – multiple prior falls 
g  
0 = no indicators of depression; 1-2 = some indicators of depression; 3+ = indicators of probable depression
 
h
 excludes HF  
i
 includes chronic obstructive pulmonary disease (COPD), emphysema and asthma 
j 
excludes ACE inhibitor, β-blocker and ARB  therapies 
k
 adherent less than 80% of the time 
l 
measured in 7 days prior to assessment 
m




Table 6.2: Characteristics of Older Home Care Clients with Heart Failure over Time, 












  % (n) % (n) % (n) % (n) 
HF  14.1 (9,283) 14.1 (9,283) 14.3 (5,456) 14.5 (3,613) 
Sociodemographic Characteristics      
Age 65-74 years 














Gender Female 66.7 (6,195) 66.7 (6,195) 70.2 (3,828) 72.7 (2,625) 
Living Alone  39.4 (3,658) 39.9 (3,702) 42.9 (2,338) 44.8 (1,616) 
Clinical Characteristics      















 10.1 (549) 
70.5 (2,546) 
19.7 (712) 
  9.8 (355) 






















































































  7.8 (283) 
Mood CAP
g 
0   
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  3.1 (112) 
42.9 (1,551) 
54.0 (1,950) 



































  % (n) % (n) % (n) % (n) 
Pharmacotherapy      
Any ACE inhibitor use  48.9 (4,541) 48.4 (4,497) 48.5 (2,648) 47.3 (1,708) 
Any ARB use  12.0 (1,118) 12.7 (1,174) 13.6 (741) 14.7 (530) 
Any β-blocker use  42.9 (3,985) 43.7 (4,058) 45.3 (2,371) 43.9 (1,585) 
 
Abbreviations: ACE = Angiotensin Converting Enzyme, ADL = Activities of Daily Living, ARB = 
Angiotensin Receptor Blocker, β-blocker = β-Adrenergic Receptor Blocker, CAP = Clinical Assessment 
Protocol, CHESS = Changes in Health, End-stage disease and Signs and Symptoms, CPS = Cognitive 
Performance Scale, HF = Heart Failure, IADL = Instrumental Activities of Daily Living, MAPLe = 
Method for Assigning Priority Levels 
a
 0 = no impairment; 1-2 = some functional impairment; 3+ = severe functional impairment 
b
 0 = no difficulty; 1-2 = some difficulty; 3+ = great difficulty 
c
 0 = cognitively intact; 1-2 = mild cognitive impairment; 3+ = cognitively impaired
  
d
 0 = no health instability; 1-2 = some health instability; 3+ = moderate to high health instability
 
e
 1 = low priority; 2-3 = mild/moderate priority; 4-5 = high priority  
f
 0 = no prior falls; 1 = 1 prior fall; 2 = multiple prior falls 
g  




 excludes HF  
i 





Table 6.3: Proportional Hazards Regression Model of Time to Mortality among Older 






(95% CL) p value 





     
0.28 (0.18) 
0.33 (0.19) 
1.32 (0.92, 1.89) 
1.40 (0.97, 2.01) 
0.13 
0.07 
Female -0.51 (0.12) 0.60 (0.48, 0.76) <0.001 
Living Alone -0.47 (0.14) 0.62 (0.47, 0.83) 0.001 
Clinical Characteristics    
IADL Capacity Scale score 0.18 (0.05) 1.20 (1.09, 1.32) <0.001 
CHESS Scale score 0.22 (0.05) 1.24 (1.12, 1.38) <0.001 
Pharmacotherapy    
Any ACE inhibitor use -0.01 (0.12) 0.99 (0.79, 1.25) 0.95 
Any ARB use -0.21 (0.20) 0.81 (0.55, 1.20) 0.30 
Any β-blocker use -0.10 (0.12) 0.91 (0.72, 1.14) 0.39 
 
Individuals were followed for 9 months following each assessment. 312 individuals died. Abbreviations: 
ACE = Angiotensin Converting Enzyme, ARB = Angiotensin Receptor Blocker, β–blocker = β-
Adrenergic Receptor Blocker, CHESS = Changes in Health, End-stage disease, Signs and Symptoms, CL 
= Confidence Limit, IADL = Instrumental Activities of Daily Living, SE = Standard Error 
a 




Table 6.4: Proportional Hazards Regression Model of Time to Long-Term Care Admission 






(95% CL) p value 





     
0.30 (0.26) 
0.67 (0.26) 
1.34 (0.80, 2.25) 
1.95 (1.18, 3.22) 
0.26 
0.009 
Female 0.04 (0.15) 1.04 (0.78, 1.39) 0.79 
Clinical Characteristics    
IADL Capacity Scale score 0.21 (0.06) 1.23 (1.09, 1.40) 0.001 
MAPLe Algorithm score 0.40 (0.07) 1.50 (1.30, 1.73) <0.001 
Number of Comorbid Conditions
b 
-0.49 (0.23) 0.62 (0.39, 0.97) 0.04 
Pharmacotherapy    
Any ACE inhibitor use -0.40 (0.15) 0.67 (0.50, 0.89) 0.006 
Any ARB use 0.08 (0.21) 1.09 (0.72, 1.63) 0.69 
Any β-blocker use -0.02 (0.14) 0.99 (0.74, 1.30) 0.92 
 
Individuals were followed for 9 months following each assessment. 209 individuals were admitted to 
long-term care. Abbreviations: ACE = Angiotensin Converting Enzyme, ARB = Angiotensin Receptor 
Blocker, β–blocker = β-Adrenergic Receptor Blocker, CL = Confidence Limit, IADL = Instrumental 
Activities of Daily Living, MAPLe = Method for Assigning Priority Levels, SE = Standard Error 
a 
Reference Group: Age 65-74 years 
b 




Table 6.5: Proportional Hazards Regression Model of Time to Long-Stay Hospitalization 






(95% CL) p value 





     
-0.13 (0.10) 
-0.23 (0.10) 
0.88 (0.72, 1.06) 
0.79 (0.65, 0.98) 
0.18 
0.03 
Female -0.16 (0.07) 0.85 (0.73, 0.98) 0.03 
Clinical Characteristics    
CHESS Scale score 0.18 (0.03) 1.20 (1.12, 1.28) <0.001 
Impairment with Stairs 0.19 (0.08) 1.21 (1.04, 1.42) 0.03 
Pharmacotherapy    
Number of Medications
b
 0.03 (0.01) 1.04 (1.01, 1.06) <0.001 
Any ACE inhibitor use -0.05 (0.07) 0.95 (0.82, 1.10) 0.48 
Any ARB use -0.13 (0.12) 0.88 (0.70, 1.10) 0.27 
Any β-blocker use -0.01 (0.07) 1.02 (0.88, 1.17) 0.84 
 
Individuals were followed for 9 months following each assessment. 793 individuals had long-stay 
hospitalizations. Abbreviations: ACE = Angiotensin Converting Enzyme, ARB = Angiotensin Receptor 
Blocker, β–blocker = β-Adrenergic Receptor Blocker, CHESS = Changes in Health, End-stage disease, 
Signs and Symptoms, CL = Confidence Limit, SE = Standard Error 
a 
Reference Group: Age 65-74 years 
b 




Table 6.6: Proportional Hazards Regression Model of Time to New Functional Decline 






(95% CL) p value 





     
0.13 (0.17) 
0.31 (0.17) 
1.14 (0.82, 1.59) 
1.36 (0.98, 1.90) 
0.45 
0.07 
Female -0.24 (0.11) 0.79 (0.63, 0.98) 0.03 
Living Alone -0.61 (0.13) 0.54 (0.42, 0.70) <0.001 
Clinical Characteristics    
IADL Capacity Scale score 0.28 (0.05) 1.33 (1.20, 1.46) <0.001 
MAPLe Algorithm score 0.23 (0.05) 1.26 (1.14, 1.40) <0.001 
Pharmacotherapy    
Any ACE inhibitor use -0.25 (0.11) 0.78 (0.62, 0.96) 0.02 
Any ARB use -0.01 (0.17) 1.00 (0.72, 1.38) 0.98 
Any β-blocker use -0.02 (0.11) 0.98 (0.79, 1.21) 0.86 
Service Use    
Weekly Cost of Home Care
b 
0.21 (0.01) 1.24 (1.21, 1.27) <0.001 
 
Individuals were followed for 9 months following each assessment. 429 individuals experienced new 
functional decline. Abbreviations: ACE = Angiotensin Converting Enzyme, ARB = Angiotensin 
Receptor Blocker, β–blocker = β-Adrenergic Receptor Blocker, CL = Confidence Limit, IADL = 
Instrumental Activities of Daily Living, MAPLe = Method for Assigning Priority Levels, SE = Standard 
Error 
a 
Reference Group: Age 65-74 years 
b




Table 6.7: Proportional Hazards Regression Model of Time to New Cognitive Decline 






(95% CL) p value 





     
0.52 (0.13) 
0.65 (0.13) 
1.69 (1.32, 2.17) 
1.91 (1.49, 2.47) 
<0.001 
<0.001 
Female -0.26 (0.08) 0.77 (0.66, 0.91) 0.002 
Clinical Characteristics    
ADL Hierarchy Scale score 0.10 (0.04) 1.11 (1.03, 1.20) 0.009 
Falls CAP                                         1
b






1.34 (1.10, 1.63) 
1.92 (1.54, 2.38) 
0.003 
<0.001 








1.14 (0.94, 1.38) 
1.70 (1.34, 2.15) 
0.19 
<0.001 
Diagnoses    
Any Dementia 1.40 (0.26) 4.06 (2.45, 6.71) <0.001 
Pharmacotherapy    
Impaired Medication Management 0.34 (0.08) 1.40 (1.19, 1.64) <0.001 
Any ACE inhibitor use 0.03 (0.09) 1.03 (0.88, 1.21) 0.69 
Any ARB use 0.06 (0.12) 1.06 (0.84, 1.34) 0.61 
Any β-blocker use 0.01 (0.08) 1.01 (0.87, 1.18) 0.90 
 
Individuals were followed for 9 months following each assessment. 680 individuals experienced new 
cognitive decline. Abbreviations: ACE = Angiotensin Converting Enzyme, ARB = Angiotensin 
Receptor Blocker, ADL = Activities of Daily Living, β–blocker = β-Adrenergic Receptor Blocker, CAP 
= Clinical Assessment Protocol; CL = Confidence Limit, SE = Standard Error 
a 
Reference Group: Age 65-74 years 
b 
1 prior fall: Reference Group: Level 0 = no prior falls 
c
 2 or more prior falls: Reference Group: Level 0 = no prior falls 
d
 Depression Rating Scale Score of 1-2, indicating some depressive symptoms: Reference Group:      
  Level 0 = no depressive symptoms 
e 
Depression Rating Scale score of 3 or more, indicating probably depression: Reference Group:  







 This work has investigated factors associated with outcomes in a group of older, 
community-dwelling individuals receiving home care services. This population exhibits high 
rates of comorbidity, medication use and IADL impairment. Five outcomes relevant to this 
population were explored in this study – mortality, LTC admission, long-stay hospitalization, 
functional decline and cognitive decline. After exploration of a number of key covariates 
including sociodemographic characteristics, other diagnoses and conditions relevant to geriatric 
populations, including functional and cognitive ability and health instability, age and gender, as 
well as comprehensive health status indicators (CHESS and MAPLe scores) were associated 
with most outcomes. Interestingly, of the medications for HF examined, only ACE inhibitor 
therapy appeared to confer protective effects, for both LTC admission and functional decline. 
While these findings are novel, the absence of a protective effect for outcomes such as mortality 
and long-stay hospitalizations may raise some questions about the applicability of earlier RCT 
evidence to this population.  
 The sociodemographic characteristics examined were found to be associated with many 
of the studied outcomes.  Older age increased the risk of all outcomes except mortality and long-
stay hospitalization within nine months. In models where age was associated with the outcome, 
the 85 years and older group was at the highest risk of events, demonstrating that age remains a 
strong predictor of outcomes even among older individuals. However, age did not predict time to 
mortality. When other factors, such as health instability and functional decline are taken into 
account, the effect of age on these outcomes is diminished. Biological age, and not chronological 
age has been shown to be more highly associated with death in retrospective analyses of older 




predictor, with females being at lower risk of all outcomes except LTC placement. This sample 
was predominantly female, as is typical of older populations and two-way interaction effects 
with gender were explored, but not found to be significant in any of the final models. These 
findings are important as many studies into cardiovascular disease enroll predominantly male 
populations, although this is changing. Previous work from the Rotterdam Study (n=7,734) has 
shown that, unlike the current findings, gender did not affect five-year survival among older 
individuals with HF. (34) Females have been shown to have better adherence to HF therapies 
(35), possibly indicating better health behaviours overall, which could partly explain the current 
finding. Living alone was also a fairly consistent protective factor, with significant effects for 
mortality, functional decline and any cognitive decline. It is likely that once other factors impair 
the ability to live alone, individuals are transferred to more intensive care settings. The fact that a 
higher proportion of individuals are living alone by the fourth assessment also depicts the 
survivor effect in the sample, as those unable to continue on their own are lost from home care.  
 From the clinical characteristics explored, the CHESS scale and MAPLe algorithm scores 
were commonly associated with all outcomes except new cognitive decline. These composite 
indicators of health status may have particular use in identifying persons at risk of acute events. 
The CHESS scale has been shown to be a better predictor of mortality than NYHA functional 
class (36) and these results show that it may also be associated with long-stay hospitalization and 
functional decline. The MAPLe algorithm score has been shown to predict LTC placement in 
earlier work and these findings support this utility. (27)  
 The IADL capacity scale and ADL hierarchy scale scores, as well as impairments with 
stairs (all measures of functional impairment) predicted shorter time to outcomes. These 




individuals at risk of adverse outcomes. A history of falls was also associated with any functional 
decline and new cognitive decline. Increasing prevalence of falls may reflect a general increase 
in frailty that is also associated with functional and cognitive decline. (37,38) Depressive 
symptoms, as measured through the mood CAP, were associated with cognitive decline. This 
finding is consistent with that of other studies done in community-dwelling older adults, where 
depression has been associated with higher incidence of mild cognitive impairment and 
dementia. (39,40) Much recent literature has explored the potential disease continuum from 
depression to mild cognitive impairment to dementia (39-42), although  underlying mechanisms 
for such relationships remain under investigation. (42) Depressive symptoms may also indicate 
under-treated HF and could impair self-care abilities. 
 This study explored a number of medication-related covariates, some of which were 
strong predictors of cognitive and functional decline. ACE inhibitor therapy was found to be 
protective for LTC placement and functional decline. As functional decline is related to LTC 
placement, these findings indicate that ACE inhibitor therapy may protect from LTC admission 
through effects on functional decline. There is some previous evidence to indicate that ACE 
inhibitor therapy may improve function (15,16) and these results appear to support this. 
However, this is the first study to examine LTC placement in older community-dwelling 
individuals with HF, and the finding that ACE inhibitors may reduce placement risk is novel. β-
blocker or ARB therapies were not significant predictors of any outcomes studied. Unlike ACE 
inhibitors, there is not a recognized class effect for β-blocker therapy. By examining all β-
blockers, not only those considered to be evidence-based, there is the possibility that potential 
therapeutic benefits have been diluted. ARB therapies are newer, and used in individuals who are 




of all HF patients, minimizing the potential effectiveness of ARB treatment. It is also possible 
that a large proportion of the population studied had HF with preserved ejection fraction 
(HFPEF). If this was the case, associations with medication use may not be observed as evidence 
of effectiveness for such individuals is not established. (43) However, a large community-based 
study found that 66% of HF patients had reduced EF (44), making it possible that this sample 
included mostly individuals for whom therapies are recommended. Also, CCS HF guidelines 
recommend use of combination ACE inhibitor or ARB therapy in conjunction with a β-blocker. 
(2) Two-way interaction effects of the three medication classes were examined in all models. 
None were significant indicating that the baseline risk associated with ACE inhibitor therapy 
alone did not change if ARB or β-blocker therapies were also present. This could be explained in 
part by the potentially large number of individuals with HFPEF, for whom combination therapy 
may not be as effective. However, it may be that combination therapy confers no benefit over 
ACE inhibitor therapy alone in this population and trials to examine effectiveness of 
combination therapy in older, frail individuals may be warranted. Interestingly, ACE inhibitor 
therapy did not protect individuals from mortality, long-stay hospitalizations or cognitive 
decline. Many clinical trials have established that ACE inhibitors are helpful in reducing 
mortality, but these results indicate that this benefit may not apply to older individuals with other 
comorbidities and geriatric conditions. The study population is clearly different from those in 
clinical trials, in age as well as medication use and comorbidity profiles. Such differences may 
account for the lack of observed associations with ACE inhibitors. It is worth noting that the 
presence of continuous ACE inhibitor or ARB therapy (at all assessments) was protective of all 
outcomes in bivariate analyses (see Tables 2-6 in Appendix J). These protective effects were not 




associated with outcomes are considered. A large European study of older adults with HF also 
found that ACE inhibitor, ARB and β-blocker use reduced three-month and one-year mortality 
post-hospital discharge, but did not explore medication use in multivariate analyses. (45) The 
fact that these associations were not maintained in multivariate models could indicate that 
potential benefits of pharmacotherapy are not as strongly associated with these outcomes as other 
covariates. Alternately, it may be difficult to interpret prognostic roles of HF therapies from this 
study, as confounding factors driving prescribing could not be adjusted for. It is still important to 
recognize that clinical trial results may not be as relevant in more complex populations such as 
the one studied.  
 Increasing number of medications was found to be associated with a higher risk of long-
stay hospitalizations. While this study could not examine prevalence of adverse drug reactions, 
they are well-known risk factors for long-stay hospitalizations (46,47) and this could partially 
explain this finding. Impaired medication management increased the risk of both functional and 
cognitive decline. The inability to manage medications could potentially lead to reduced 
medication intake and adverse outcomes or act as a proxy for cognitive decline. 
 Overall, this work depicts a situation in which a core set of relatively strong predictors 
emerges for the outcomes studied. Medication use does not seem to emerge as a strong predictor 
though important results have been noted. 
6.4.1 Limitations 
 There are issues regarding potential biases with this work that need to be addressed as 
potential alternative explanations for the results. First, this is a sample of older, community-
dwelling HF patients receiving home care services. Such individuals are not necessarily 




introduce selection bias. As shown in Chapter 4.0, such individuals represent a more clinically 
complex population than home care clients without HF. It is possible that more outcomes were 
seen because a sicker population was studied. The potential for survivor bias to affect these 
findings is important to consider. In Table 6.2, individuals with four assessments appear to be 
better off in a number of clinical characteristics. This means that over time, healthier individuals 
were studied. These people may have better informal supports or have more health promoting 
behaviours than clients who are lost. However, if individuals no longer require home care 
services, they would not continue to be represented in this sample. So, while there is the potential 
for survivor bias to partially explain these findings, these individuals were still sick or impaired 
to some extent.  
 Other potential sources of selection bias arise from the exclusion criteria used. 
Individuals who were excluded due to having only one assessment or an assessment gap that was 
not between 60 and 270 days were explored. These clients did not appear to differ clinically from 
those with assessment times between 60 and 270 days. This is interesting, as RAI-HC 
assessments are supposed to be repeated at six-month intervals, or when significant clinical 
changes occur, possibly leading to a situation in which sicker clients are assessed more 
frequently than those in better health. This does not appear to be the case. Table 6.1 shows that 
individuals with only one assessment were different and generally sicker than those with two or 
more assessments. Again, this indicates a survivor effect and may mean that healthier home care 
clients with HF were included.  
The lack of continuous drug data could threaten the internal validity of this study. As data about 
medication use are only collected during assessments, patterns of medication use between 




in the continuous user group (therapy recorded at all assessments) or the never user group (no 
therapy recorded at any assessment) for each HF medication, as shown in Table 9 in Appendix J. 
Continuous users may represent a healthier subgroup than individuals who discontinue therapy 
due to worsening disease or medication intolerance. This discontinuation, initiated either by 
physicians or patients, could lead to protopathic bias since these former users may be at higher 
risk of adverse events. In this sample, only six, five and three percent of individuals with HF 
discontinued ACE inhibitor, β-blocker or ARB therapy, respectively. However, if a large number 
of events occurred in this group, it could lead to overestimates of therapeutic benefits since they 
were considered to be non-users. Outcomes among discontinuers were examined and the 
proportion of individuals in this group who experienced outcomes was similar or slightly higher 
than continuous or never users (see Tables 10-13 in Appendix J). While there is the potential that 
such individuals may be sicker and different from other clients, they represent a very small 
proportion of the sample, somewhat reducing the concern of such bias. There is also the potential 
that individuals who were said to be never users had prior use of HF medications, but this could 
not be verified using RAI-HC data. 
 Non-adherence in the sample was reported to be low. Nonetheless, with a lack of 
continuous drug data and a corresponding measure of adherence, it is possible that non-
adherence to medications could account for some of the observed results. Previous studies have 
found adherence with HF pharmacotherapy to range between 30-60%, with adherence to lifestyle 
modifications being lower. (48) However, early studies have shown that women, individuals 
older than 85 years, and those with multiple medications were more likely to be adherent. (35) 




 Analyses were done discretely, meaning that individuals were considered to be at risk for 
each outcome independently. There is the potential that competing risks could affect some of the 
observed relationships between covariates and outcomes of interest. However, in the cause-
specific models presented, once individuals were discharged due to mortality or LTC placement, 
they no longer appeared in the data set. Individuals hospitalized for 14 days or longer are 
considered to be discharged to hospital, and may return home and receive home care services. 
Such individuals may appear in more than one event group, but if LTC placement or death 
occurs, they are no longer in the data set. No overly protective effects for long-stay 
hospitalization or LTC placement were observed that were also strongly associated with 
mortality, so the potential for competing risks influencing these findings appears to be minimal. 
Functional and cognitive decline were not considered to be competing risks for the outcomes of 
mortality, LTC placement or long-stay hospitalizations. The inability to capture shorter hospital 
stays is another weakness of this study, making the prevalence of any hospitalization higher than 
reported. 
 Medication and diagnostic data were collected from RAI-HC assessments and there is the 
potential for misclassification bias. If individuals were incorrectly classified as having HF, it 
would overestimate HF prevalence, potentially reducing the magnitude of the observed 
associations. In an attempt to reduce such misclassification bias, individuals whose HF diagnosis 
was not consistent at all assessments were excluded. Only 242 individuals were excluded for this 
reason, giving some confidence in diagnostic accuracy. Further, previous work with interRAI 
instruments has demonstrated high consistency between interRAI diagnoses and administrative 
data. (30,49) As for medication data, there is the potential that not all medications were captured 




prevalence and weaker associations with outcomes. A bias towards exclusion of HF medications 
specifically would not be expected, but individuals for whom no medications were recorded were 
excluded from the study sample. As medication use among older adults is known to be high (50), 
no recorded medications could indicate potential data quality issues. Assessors may have 
neglected to record medications or may have attached a separate form that was not transcribed 
into electronic records. However, a record of no medications could have been accurate, meaning 
that some individuals were excluded without reason. It is possible that during the search for 
medications of interest, some medications were missed due to spelling errors that were not 
captured during searching. This could underestimate prevalence of ACE inhibitor, ARB and β-
blocker use, and is a limitation of the current Ontario RAI-HC medication data. As stated 
previously, most individuals in these analyses had consistent medication status for HF 
medications, with more than 85% being either continuous or never users of ACE inhibitor, ARB 
or β-blocker therapy. This gives some assurances about data quality. A further consideration is 
that some medications may exacerbate HF and lead to higher rates of adverse outcomes. Use of 
other types of medications was not explored and could affect these findings by reducing 
observed effectiveness of HF medications. 
6.4.2 Strengths 
 The population studied is an important, but often under-studied one. Individuals with HF 
receiving home care services are a frail, medically complex group. Until recently, this was a 
relatively inaccessible group to study, but mandatory introduction of RAI-HC assessments in the 
past decade allowed valuable data to be collected in Ontario. Earlier work has comprehensively 
described older adults with HF who are receiving home care services and explored prevalence of 




population is worthy of study as it represents individuals who are independent enough to remain 
at home, but have frequent contact with the health care system. Further, this group is particularly 
suited to interventions to improve care as the potential to avoid adverse outcomes and maintain 
independence at home can reduce burden on other areas of the health care system. 
Approximately 90% of individuals with HF in Ontario are managed by family physicians, not 
specialists. (18) However, most clinical trials and effectiveness studies examine individuals 
receiving care in specialty clinic settings. Thus, this sample likely provides a more realistic 
picture of community-dwelling HF patients. Lastly, as the RAI-HC is mandated for use in 
Ontario, this sample captures the entire long-stay home care population. 
 The size of the database allowed for a large sample to be followed over time, with 
enough events occurring to allow exploration of factors associated with each outcome 
independently. Clinical trials often use combined outcomes to achieve enough power to detect 
differences between treatment groups (Tables 1-3 in Appendix G), but this may mask effects on 
individual outcomes. The sample size also permitted exploration of interaction effects which is 
not always possible with smaller samples. 
 The exploration of multiple outcomes in this population is novel, but especially relevant 
to older adults are the outcomes of LTC admission, and cognitive and functional decline. The 
ability to explore a comprehensive set of factors potentially associated with these outcomes is a 
unique strength of this work. Little work has explored LTC placement, functional decline and 
cognitive decline in older adults. The Canadian Study of Health and Aging (n = 10,263) is one of 
the few studies to examine these outcomes in older adults, but was not specific to individuals 




Rates of mortality and LTC placement were high and decline in function and cognition occurred 
in more than two-thirds of participants. (51)  
 Individuals with HF are known to have high rates of cognitive impairment (52-54) and 
end-stage HF is characterized by long-term functional limitations. (55) Some work has examined 
the utility of ACE inhibitor and β-blocker therapy in functional decline (15-17) and ACE 
inhibitor therapy in cognitive decline (8), but did not examine the breadth of clinical factors 
explored in this study. Arguably, explorations of factors associated with outcomes in frail, 
elderly individuals should be done as inclusively as possible. Some argue that enrollment of 
older adults in clinical trials is feasible (13,56), but improving the evidence base through strong 
observational studies may also be of use.   
 Another important strength of this work is the potential to utilize the breadth of 
information captured in the RAI-HC. The comprehensive clinical characteristics available in the 
assessment, including key geriatric conditions such as dementia, cognition and functional ability, 
are attributes of this data set. Additionally, the ability to examine these factors as well as HF 
medication use concurrently is unique. In contrast to clinical trials, which commonly exclude 
individuals with other medication use, other comorbidities and functional and cognitive 
impairment, this sample was inclusive on these characteristics. This allows exploration of how 
these factors come into play in the context of each other. This study was also able to capture 
current medication use by treating HF medications as time-dependent covariates, allowing for 
changes in current exposures over time. Lastly, but importantly, this study is one of few to 
examine factors associated with functional and cognitive decline among older individuals with 
HF, outcomes which may particularly important to this population. The findings suggest that 




consistent with earlier work done on ACE inhibitor use and exercise capacity in non-HF 
populations (57) and early studies of ACE inhibitors in HF populations. (15,16) 
6.5 Conclusions  
 Individuals with HF who receive home care services are a unique group in which to study 
outcomes associated with the disease. They are an independent population that is able to remain 
at home, but is vulnerable enough to require home care services. Presumably, this delicate 
balance can be shifted towards either further independence or adverse outcomes. (38) Functional 
and cognitive decline are common in this group, and ACE inhibitor therapy may be protective of 
at least functional decline. A number of clinical and sociodemographic factors including age, 
gender, living arrangement, comprehensive health status indicators and medication use were 
found to be associated with outcomes examined. 
 Implications of this work are potentially important, especially for older individuals with 
HF. The results indicate that certain geriatric conditions like functional impairment are 
associated with adverse outcomes, while number of comorbid conditions is not. ACE inhibitor 
therapy may be of some utility in avoiding LTC placement and functional decline. Targeted 
interventions aimed at maintaining function and minimizing the effect of disability could have a 
large effect on reducing adverse outcomes. Also, while ACE inhibitor therapy seems to confer 
some benefit, this work points to the need for further study into use of ACE inhibitor, ARB and 
β-blocker therapy to determine if results from trials are relevant to older, frail individuals. 
Further, medications are only one component of comprehensive CDM programs for HF. This 
work can be used to inform the development of CDM programs that account for the functional 
and cognitive impairments common among older individuals, but further initiatives to promote 




necessary. Home care clients could lend themselves well to inclusion into future studies as they 
are routinely assessed, accessible and in contact with primary care. Future RCTs that examine 
treatment benefits of ACE inhibitor therapy, both alone and in combination with β-blocker 
therapy, would be invaluable in adding to the evidence base. Lastly, this work also demonstrates 
the utility of interRAI data in exploring outcomes over time in the context of other comorbidity 




7.0 GENERAL DISCUSSION AND SUMMARY 
 
 Heart failure was found to be a significant problem among the older community-dwelling 
home care client sample, with a prevalence of approximately 15%.  Individuals receiving home 
care services represent a clinically complex group with many care needs and high service use. 
Only 30% of individuals received recommended first-line combination therapy. This may 
represent underuse of HF medications, but this underuse may be due to dissimilarities between 
trial populations and the older, frail individuals studied here. However, the benefits of first-line 
therapies are not well established in older populations and individuals with poorly managed HF 
may be at risk for adverse events. Whether medications are beneficial in preventing adverse 
outcomes is not clear from this work. Overall, this research has implications for future research, 
clinical practice and policy.  
7.1 Descriptive Characteristics of Older Home Care Clients with Heart Failure 
 Using RAI-HC data, the prevalence of HF in Ontario‟s older long-stay home care 
population was found to be similar to that observed in population-based studies, and lower than 
the prevalence observed in long-term care populations. (1,2) Compared to home care clients 
without HF, individuals with HF were a more clinically complex population, with more 
hospitalizations, ED visits and use of emergent care. This is consistent with work done in Canada 
on the burden and outcomes of HF. (3) Importantly, comparisons between these individuals and 
those represented in clinical trials show great disparity. This disparity has been addressed in the 
literature (4), but the current work demonstrates that home care clients with HF are older, have 
many comorbid conditions, use many medications and have high rates of functional and 
cognitive impairment. Additionally, the high rates of health instability among individuals with 




abilities, and CDM programs must consider these care needs when developing new interventions 
to improve management in this population. As the majority of individuals studied have caregiver 
support, caregivers could be an important resource in such initiatives, but precautions to 
minimize potential caregiver distress should be taken. This is the first such comprehensive 
description of community-dwelling individuals with HF who receive home care services.  
7.2 Medication Use among Older Home Care Clients with Heart Failure 
 Only 28% of older home care clients with HF were receiving combination 
pharmacotherapy. A further 28% were receiving none of the recommended first-line 
pharmacotherapies for HF. Treatment of HF following new diagnosis has been shown to be 
suboptimal in vulnerable, community-dwelling older adults, with ACE inhibitor and β–blocker 
use being 65% and 48%, respectively. (5) However, whether the results of the current study 
indicate undertreatment is uncertain. The differences observed between trial participants and the 
study population may limit the applicability of the evidence of these medications and this 
underuse may be appropriate. Ageism may also play a role in the low rates of medication use 
observed, as has been shown with other work. (6) The current study also revealed that functional 
impairment, age, and comorbid conditions including hypertension, diabetes, coronary artery 
disease and airway diseases were all associated with non-use of pharmacotherapy. The 
association of comorbidities with use of HF pharmacotherapy has been shown previously. (7-9) 
These findings seem to indicate that with the co-occurrence of conditions like hypertension and 
diabetes mellitus, older individuals are more likely to receive appropriate care. The association 
of functional impairment with non-use of HF therapy is novel and the high rates of functional 




observed. Other factors including gender, depressive symptoms, and health instability were not 
associated with non-use in the present study, contrary to some previous work. (7,10-12)  
7.3 Outcomes among Older Home Care Clients with Heart Failure 
 Making use of the longitudinal nature of data collected using the RAI-HC, individuals 
with more assessments were found to be healthier on a number of summary scales, despite high 
rates of comorbidity and medication use. Health instability was associated with an increased risk 
of mortality within nine months and age, comorbidity and medication use were not associated 
with this outcome, contrary to some studies in older populations. (13) These results underline the 
fact that frailty, or biological age, may be more important in predicting mortality than 
chronological age. Studies examining mortality outcomes in older adults should try to account 
for contributors to biological age.  
 Age, MAPLe scores and IADL impairment all increased the risk of LTC admission in 
this cohort. Work from the Canadian Study on Health and Aging found that female gender, being 
unmarried, cognitive and functional impairment and some comorbidities were associated with 
institutionalized populations. (14) The MAPLe score accounts for functional and cognitive 
abilities, creating some parallels with this work. However, the current study modeled predictors 
of LTC placement among older home care clients, which could explain some of the remaining 
discrepancies. The finding that number of comorbidities was associated with lower risk of 
placement seems counterintuitive, but could indicate that individuals from home care are too 
complex and are preferentially referred to complex continuing care, not LTC facilities. This 
outcome could not be explored with the data available. ACE inhibitor therapy reduced the risk of 




 Health instability was also associated with shorter time to long-stay hospitalization, as 
was increasing number of medications. These are important findings because more than two-
thirds of the HF group reported use of more than nine medications in the week prior to 
assessment. With use of an increasing number of medications, the potential for adverse drug 
reactions and subsequent hospitalizations also rises. (15,16) It is very likely that some of the 
observed long-stay hospitalizations were due to adverse drug reactions and were potentially 
avoidable. It is worth noting that many individuals with HF were not receiving pharmacotherapy, 
the initiation of therapy could further increase the risk of adverse drug reactions and 
hospitalizations.  
 Time to new functional decline was increased for females, those who lived alone and 
those using ACE inhibitor therapies. Thus, the protective effect for ACE inhibitors and LTC 
admission may occur through benefits on function. The most important predictor of new 
cognitive decline was a diagnosis of dementia, but impaired medication management, older age 
and history of falls were also strong predictors. Functional impairment also reduced the time to 
new cognitive decline.  
 This work demonstrates that older individuals with HF in the home care setting are a 
clinically complex group with functional impairment and high levels of comorbidity and 
medication use. These individuals receive fewer optimal HF therapies than populations studied 
in hospitals or HF clinic settings. (17) Mortality, LTC admission, long-stay hospitalization, 
functional decline and cognitive decline were common in this sample. Taken together, this work 
depicts a population of HF patients who are very different from most study populations. It is 
important to note that a number of characteristics that were prevalent among older home care 




explored. This work highlights the importance of exploring geriatric conditions when studying 
outcomes in older populations. 
7.4 Considerations about the Study Population and Care Setting 
 RAI-HC assessments are done for all long-stay home care clients in Ontario and this 
work arguably provides an accurate picture of characteristics, medication use and outcomes 
among frail, community-dwelling individuals. The burden of HF in the home care population is 
similar to rates reported in previous work from population-based cohorts. (1) The home care 
population is important to study, as the potential to avoid adverse outcomes may be especially 
high in this community-dwelling group. However, the substantial rates of comorbidity, 
medication use, service use, and health instability make management challenging. As the home 
care sector continues to play a vital role in the continuum of care, strategies to improve 
management of chronic diseases like HF will become increasingly important.  
 It would appear that individuals with HF in the home care setting could be better 
managed. CCAC services, in their current form, may not be adequate for CDM in HF or other 
conditions. As the burden of HF is expected to rise substantially over the next three decades (18), 
strategies to improve management will be critical. Home care may be a more appropriate setting 
for HF management for a number of reasons. First, as HF burden is projected to increase 
substantially, individuals with HF could overwhelm acute care services if not adequately 
managed. Second, as demonstrated with this work, individuals with HF have high rates of 
functional impairment and frequently experience both functional and cognitive decline. These 
problems may make attending HF clinics for management difficult and underuse of clinic-based 
programs has been demonstrated. (19) Third, individuals in home care are routinely assessed, 




clients are managed by primary care (20) and links between primary care and the CCACs are 
already in place. Last, there are many new technologies that may help facilitate self-care, 
monitoring and management of HF that could be used in the home setting. Structured telephone 
support programs and telemonitoring may reduce all-cause mortality, HF hospitalizations and 
health care costs, as well as improve quality of life and use of evidence-based therapies. (21) 
Telemonitoring involves patients monitoring their vital signs at least once a day and sending this 
information to health providers through telephone or internet connections. This form of follow-
up engages patients in self-care and could facilitate discharge planning, as well as reduce 
hospital admissions, days spent in hospital and mortality. (21) However, some recent work 
suggests no benefit among recently hospitalized patients. (22) Encouragingly, satisfaction with 
this modality of care and learning to use the technology was evident even for older individuals. 
(21) Interventions like telemonitoring could provide specialized HF care and monitoring to many 
individuals who may not be able to access health care services.  
 This work examined pharmacotherapy, but did not explore other important components 
of CDM for HF. Exercise therapy, dietary and fluid restrictions, smoking cessation and education 
about self-care are recommended in addition to pharmacotherapy in comprehensive disease 
management. The home care setting may provide a unique setting in which to examine 
interventions designed to improve adherence to these other recommended treatment modalities. 
CDM programs linked with home care could ensure nursing visits to patients exhibiting 
difficulty and allow continued follow-up. Interventions examining ways to facilitate HF 
management by improving barriers to self-care, promoting functional abilities and checking 
medication adherence could be important initial steps. Integrating CDM programs into the home 




programs have been shown to be cost-effective and targeting more patients, not only those at 
high risk, may be helpful. However, identifying effective ways to incorporate CDM into home 
care will be challenging, and must take into account the complex needs identified in this 
population. 
7.5 Pharmacotherapy Considerations 
 This work has also highlighted a number of issues related to the pharmacotherapeutic 
management of HF. Older individuals with HF are less likely to report use of any HF 
medications (10, 24-27) and the findings from Chapter 5.0 also demonstrate that use of these 
medications is low in this older, frail population. However, this research was cross-sectional in 
nature and whether such low use reflects prescribing practices or appropriate care could not be 
examined. There are many reasons for which non-use of medications may be appropriate, 
including intolerance to therapy, declining health, contraindications and patient preferences. 
Other work has demonstrated that high rates of ACE inhibitor and β-blocker use are achievable 
(10,24,28,29), but the evidence for the use of these medications is strongest for younger, 
healthier patients.  Physicians may be reluctant to prescribe due to concerns over adverse events 
or lack of confidence in guideline recommendations. While this work has begun to build 
evidence about reasons for non-use among community-dwelling patients, further exploration of 
prescribing patterns is needed.   
 From Chapter 6.0, ACE inhibitor use was not associated with mortality or long-stay 
hospitalizations. However, work from clinical trials has previously established this benefit (see 
Appendix G: Table 3). Also, β-blocker and ARB therapies were not found to be associated with 
any of the outcomes measured here, again showing a disconnect with earlier work (see Appendix 




ARB or β-blocker therapies in the current study. Combination ACE inhibitor and β-blocker 
therapy is recommended for most individuals with HF by national guidelines (30) and these 
findings raise questions about the added benefit of β-blocker therapy for those taking ACE 
inhibitors. Rates of HFPEF were unknown in this sample. If a large proportion of the sample had 
HFPEF, this could partially explain the lack of observed therapeutic benefit, as first-line 
therapies are less effective in treating this type of HF. Continuous medication data were not 
available, making patterns of medication use and adherence difficult to establish. However, this 
work at least raises the possibility that results from clinical trials are not as applicable in older, 
frail, clinically complex populations who are followed less frequently. Some observational work 
and subgroup analyses have also found that survival benefits of ACE inhibitor therapy may not 
be as great among those older than 65 years. (31) The current study and observational studies 
lack the controls associated with randomized trials, but inconsistent results about therapeutic 
effectiveness between such studies and randomized trials are important when considering HF 
management in older individuals. The novel associations of ACE inhibitor use and reduced risk 
of LTC admission and functional decline could indicate other benefits in older populations. 
These outcomes may be particularly relevant to older, frail individuals. However, the current 
study did not show benefits of ACE inhibitor therapy for cognitive decline, another potentially 
relevant outcome for geriatric populations. This finding is inconsistent with early work into 
potential benefits of ACE inhibitor therapy, but such work was done among older adults with 
hypertension, not HF. (32) Further studies of therapeutic benefits in older adults should explore 







 There are some high-level limitations of this work that are worthy of mention. Perhaps 
most important are the issues of potential selection bias and uncertainties surrounding diagnostic 
and medication information on the RAI-HC. By studying home care clients, including sub-sets 
with prevalent HF and multiple assessments, selection bias as a contributor to the findings cannot 
be ruled out. Including prevalent cases of HF means that individuals with severe, rapidly 
progressing disease may be under-represented. Similar problems could arise from the decision to 
perform longitudinal analyses on individuals with two or more assessments, but this was 
necessary for some of the outcomes of interest. As such, a healthier subset of community-
dwelling home care clients may have been included, making the findings less generalizable to all 
home care clients with HF. 
 Another important limitation is that most data were obtained from RAI-HC assessments. 
While this instrument contains comprehensive clinical information, issues of diagnostic 
uncertainty may arise. While HF diagnoses could have been under-reported, earlier work has 
demonstrated relatively high agreement between RAI diagnostic data and administrative 
databases. (33,34) Creating linkages to other databases such as the CIHI Discharge Abstracts 
Database or National Ambulatory Care Reporting System Database, or use of International 
Classification of Diseases codes on RAI assessments would help overcome this limitation. This 
was not possible in the current study. However, most individuals had consistently recorded HF 
(or non-HF), giving some indication of diagnostic reliability.  
 This study did not explore general risk factors for HF and other cardiovascular diseases 
such as smoking, alcohol use, physical activity and nutrition. It is possible that such risk factors 




Further work into prescribing patterns and outcomes in older HF populations should incorporate 
such risk factors.  
 For medication data, the RAI-HC as implemented in Ontario does not use standardized 
drug classification system codes and medications are manually recorded leading to many variants 
in medication names. This creates the possibility that some medications were missed, leading to 
underestimates of prevalence. Also, as data are collected at 6-month intervals, continuous drug 
data were not available. Thus, medication use at the time of assessment may not accurately 
reflect patterns of use between assessments.  
 This is the first study to examine medication use over time using interRAI data and while 
there is much potential for future pharmacoepidemiological work, improvements to data 
collection and recording are necessary. Linking RAI-HC data to provincial health care and 
pharmacy databases would be useful in facilitating strong future work. With implementation of 
the new suite of interRAI instruments, medication data will be recorded using standardized 
medication codes. This would facilitate wider access to the medication data, while maintaining 
core assessment items to allow continuation of the current work. Further, the new instruments 
will utilize existing scales and allow more sensitive measures to ease the detection of clinically 
meaningful changes. While data from RAI-HC assessments are comprehensive in some respects, 
information about certain clinical measures is unavailable. Knowledge about HF specific 
measures like ejection fraction, β-type natriuretic peptide levels and NYHA functional class were 
not available. This makes comparisons to other work difficult. The inability to determine NYHA 
functional class means that findings from this work cannot be related to disease severity. 
However, the CHESS scale on interRAI instruments may be a better predictor of mortality and 




unavailable, some disease severity was captured. Given the high rates of health instability shown 
in CHESS scores, it is likely that individuals with moderate to severe HF (NYHA class II-IV) 
made up a large proportion of the sample. This work was not a randomized study and the role of 
chance and other potential confounders in the results cannot be ruled out completely. Lastly, 
some of the work was cross-sectional in nature, limiting the potential to determine causality or 
explore dynamic factors associated with medication use.  
7.7 Strengths 
 The limitations of this work should not overshadow its unique and important strengths. 
Using the data available from RAI-HC assessments and OACCAC administrative records, this 
work has improved on many common exclusion criteria and controlled for many important 
potential confounders. The commonly used outcomes of mortality and hospitalizations were 
examined, as were LTC admission, functional decline and cognitive decline. Arguably these 
three latter outcomes may be of particular relevance to geriatric populations. There is a dearth of 
evidence about such outcomes for older individuals, particularly in community-dwelling 
populations. By exploring many covariates, including some especially pertinent to older 
populations, this work has begun to fill a large gap in current knowledge. This work has also 
demonstrated that pharmacotherapy use among this cohort is low. Whether this undertreatment is 
related to greater risk of adverse outcomes needs more attention.   
 The size of the data set allowed for all outcomes to be examined independently. This is 
an improvement over many clinical trial findings in which the use of combined endpoints is 
necessary to overcome inadequate power. By including age and gender in all longitudinal 
models, potential confounders have been controlled for, allowing comparisons with other studies. 




study and has shown the importance of many client characteristics in medication use and 
outcomes.  
7.8 Significance and Potential Implications 
 This work adds to current knowledge in many ways. It has examined an older, frail 
population representative of many home care clients across Ontario and possibly of other 
populations as well. This population is clinically complex and potential barriers to self-care 
abilities are present. The examination of medication use and outcomes in this population is 
unique. interRAI and OACCAC data allowed a comprehensive exploration of factors related to 
medication use and outcomes, including geriatric conditions. The importance of considering 
geriatric outcomes in underuse of cardiovascular medications is being recognized (36), and the 
current study extensively examined factors potentially related to underuse.  The longitudinal 
RAI-HC data have the potential to allow examination of outcomes, inform policy and improve 
clinical practice. The potential benefits of ACE inhibitor therapy in delaying LTC placement and 
functional decline are novel findings. These benefits could reduce health care costs associated 
with LTC admission and hospitalizations, but importantly, could improve quality of life and 
promote maintenance of independence for older adults. Further, such benefits may also be 
relevant to older individuals with HFPEF. 
 For clinicians, this work highlights the complexity of individuals receiving home care 
services as well as the uncertainties clinicians may have in managing older, complex individuals. 
Importantly, these findings raise questions about the potential benefits of such therapies in older 
individuals. There is little evidence about therapeutic effectiveness in older, complex patients, 
making treatment decisions and application of current guideline recommendations difficult. 




guideline recommendations. Nonetheless, adherence to guideline recommendations may help 
prevent LTC placement and function decline among older, frail individuals. Guideline panels 
could encourage greater exploration into benefits of therapy in older adults to provide better 
evidence to guide clinicians. Lastly, the utility of RAI-HC data in identifying under-treatment 
and characteristics potentially associated with adverse outcomes has been demonstrated. 
Engaging clinicians in ways to disseminate and use this information should be explored. 
 From a policy perspective, the burden of chronic disease among older home care clients 
potentially means that initiatives to promote better management in this specific population are 
warranted. Aligning with recent initiatives to promote independence and reduce acute health care 
service costs, such initiatives could have great potential benefit. The potential role of pharmacists 
and technologies in such strategies is also worthy of mention. Given the high rates of medication 
use among older home care clients, pharmacists are in a unique position to oversee all 
medications, identifying potentially inappropriate management and risk of adverse drug events. 
The relationship between number of medications and increased risk of hospitalizations could 
occur through adverse drug reactions, and pharmacists may be able to minimize the potential 
risks through medication reviews. Policies to promote access to pharmacist care should be 
explored. Telemonitoring and home base interventions using such technologies have the 
potential to improve care in the home setting and assist caregivers and service providers and 
specific funding priorities here may help improve management. All of these initiatives would 
align well with the provincial Aging at Home strategy, which strives to alleviate burden on 
inpatient and residential facilities. As this strategy comes to a close, building capacity across the 
research, home care and primary care sectors to promote more effective management of HF 




7.9 Recommendations for Future Research 
 This work has explored a vulnerable community-dwelling population and 
comprehensively described their needs, patterns of medication use and outcomes over time. A 
number of unanswered questions remain and there is much potential for future research to build 
on these findings.  
 Many important research questions have arisen from the current study. Whether the 
management of HF or other chronic conditions through home care varies by CCAC is unknown. 
Variations in HF prevalence by CCAC were observed, but were not found to correspond to age 
distributions. Exploration of CDM strategies by CCAC and identifying practices associated with 
improved outcomes could guide a standardized approach to chronic disease care throughout the 
province. Many factors potentially associated with non-use of HF medications were identified. 
However, this work was cross-sectional in nature and causal associations could not be 
established. Further exploration into the effect of such factors on prescribing patterns, as well as 
factors associated with non-use of combination therapy would be logical future research steps. 
 Two important research initiatives are obvious continuations of the current work. The 
examination of long-term therapeutic effectiveness and risks among older, complex populations 
is necessary. This would help provide an evidence base upon which to create care guidelines and 
improve management in the majority of individuals with HF. In the United States, the Sentinel 
program will use large insurance databases to measure outcomes of routine medication use in 
millions of patients (37), providing invaluable information about potential benefits of therapy in 
the context of other medications and comorbid conditions. Initiation of such a program in 
Canada, while daunting, could be facilitated through linking RAI data with administrative 




Canadians. However, such studies will not provide the rigour and quality of evidence associated 
with RCTs. The second proposed research strategy would be an RCT of ACE inhibitor therapy 
with or without β-blocker therapy in older, complex individuals with HF. Such an RCT should 
include the outcomes of functional and cognitive decline in addition to mortality and 
hospitalizations. This would contribute high quality evidence about the potential benefits of ACE 
inhibitor therapy and fill in the gap identified about whether combination therapy adds benefit. 
Identification of trial participants from the home care setting would make the outcome of LTC 
admission applicable of study, and allow the use of the comprehensive data about geriatric 
conditions from the RAI-HC to be utilized.  An extension of such an RCT could also examine 
the effectiveness of interventions that address other CDM components such as dietary and 
exercise recommendations. Such research initiatives would generate valuable evidence 
applicable to a population of HF patients currently under-represented in trials.  
 In the interim, investigation of interventions to improve HF management within the home 
care population could be explored. Finding effective ways to improve self-care skills, promote 
functional abilities and ensure appropriate medication management could help improve HF care. 
Effective communication with primary care providers could also play an important role in 
improving care. The ability to identify individuals who are inappropriately managed and 
potentially at risk of adverse events is possible through interRAI assessments. Feasibility studies 
examining the potential for interRAI data to identify individuals for follow-up in primary care is 
a potential research initiative. Linking such individuals with effective, tailored interventions 
could greatly improve outcomes.  
 In summary, HF management has benefitted from much past research. However, there 




populations, such as individuals receiving home care services. The current work has described 
client needs, patterns of medication use and outcomes over time. Building upon these findings to 
identify strategies to make full use of assessment data and improve outcomes would likely be 
invaluable, not only to individuals with HF, but those with other chronic conditions as well as the 
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APPENDIX F: Treatment Guidelines for Heart Failure Pharmacotherapy 
 
Table 1: Summary of Canadian, American and European Guidelines for Treatment of Heart Failure 
 






ACE inhibitor  use  Class I: 
1) all patients as soon as safe 
following MI; continued 
indefinitely if LVEF < 40% or 
acute HF is complicated by MI 
2) all asymptomatic patients with 
LVEF below 35% 
3) all patients with HF symptoms 
and LVEF < 40% 




1) patients older than 80 years with 
BP above 160/90 mmHg to reduce 
risk of HF depending on 
comorbidity and patient preference 
2) in patients with vascular disease 
or diabetes with end organ damage 
to reduce risk of HF development  
Class I: 
1) all patients with post-MI regardless 
of EF or with HF in combination with 
β-blocker therapy 
2) all asymptomatic patients with LVEF 
< 40%, even without MI 
3) all patients with current or prior 
symptoms of HF and reduced LVEF 
unless contraindicated 
Class IIa:  
1) patients at high risk for HF 
development (history of atherosclerotic 
vascular disease, diabetes, hypertension 
+ associated risk factors)  
2) asymptomatic patients with 
hypertension and LV hypertrophy  
Class IIb: 
1) symptom control in patients with 
HFPEF and controlled hypertension  
Class I: 
1) all patients with 
symptomatic HF and LVEF < 
40% 
 
Who Should get ACE 
inhibitors:  
 patients with LVEF < 
40%  irrespective of 
symptoms, based on 
RCTs 
β-Blocker use Class I: 
1) all HF patients with LVEF ≤ 
40%  (evidence-based β-blockers) 
2) NYHA class IV symptomatic 
patients with NYHA class IV, 
stabilized HF  
3) initiated therapy at low dose and 
titrate to target dose from trials, or 
maximum tolerated dose 
Class I:  
1) with ACE inhibitors in patients with 
recent MI despite EF or presence of HF  
2) asymptomatic patients with LVEF < 
40%  
3) bisoprolol, carvedilol and metoprolol 
recommended for all stable patients 
with current or prior HF symptoms and 
LVEF < 40%  with no contraindications   
Class I: 
1) all patients with 
symptomatic HF and LVEF < 
40%, unless contraindicated 
or not tolerated 
 
Who Should get β-Blocker:  












β-Blocker use Class I: 
4) not for use in patients with 
symptomatic hypotension despite 
adjustment of other therapies, 
severe airway disease, symptomatic 
bradycardia or significant AV block 
without permanent pacemaker 
(stable COPD is not a 
contraindication) 
Class IIb:  
1) symptom control in patients with HF 
and normal LVEF with controlled 
hypertension  
Who Should get β-Blocker:  
 NYHA class II-IV 
patients with 
asymptomatic systolic 
dysfunction post- MI 
(in combination with 
optimal dose of ACE 
inhibitor and ARB) 
 clinically stable 
patients 
ARB use Class I: 
1) patients intolerant to ACE 
inhibitor 
2) added to ACE inhibitor therapy 
for patients with persistent HF 
symptoms at increased risk of HF 
hospitalization despite optimal 
treatment with other drugs 
3) considered instead of ACE 
inhibitor therapy for patients with 
acute MI with acute HF or LVEF < 
40% 
Class IIa: 
1) adjunctive therapy to ACE 
inhibitors when β-blockers are 
contraindicated or not tolerated 
 




1) in patients with vascular disease 
or diabetes with end organ damage 
to reduce risk of HF development  
Class I:  
1) all patients post-MI without HF with 
intolerance to ACE inhibitors and 
LVEF < 40%  
2) evidence-based therapy (valsartan 
and candesartan) recommended in 
patients with current or prior HF 
symptoms, LVEF < 40% and ACE 
inhibitor intolerance  
Class IIa:  
1) preventatively in high risk patients 
(atherosclerotic vascular disease, 
diabetes, hypertension + associated  risk 
factors)  
2) asymptomatic patients with 
hypertension and LV hypertrophy 
3) as alternatives to ACE inhibitors as 
first-line therapy in mild to moderate 
HF with LVEF < 40% 
Class IIb: 
1) symptomatic patients with LVEF < 
40% receiving conventional therapy  
Class I: 
1) alternative to ACE 
inhibitor therapy in patients 
who are intolerant  
 
Who Should get ARB: 
 LVEF< 40% as 
alternate to ACE 
inhibitor in those with 
intolerance 
 LVEF< 40%  in 
patients with 
persisting symptoms 












ARB use  Class IIb: 
2) to minimize symptoms in patients 
with HF, normal LVEF and controlled 
hypertension  
 
AA use Class I: 
1) considered in patients with 
LVEF < 30% and severe 
symptomatic chronic HF despite 
optimization of other recommended 
treatments 
Class IIa: 
1) patients with acute HF and 
LVEF < 30% following acute MI 
(if serum creatinine is less than 
200µmol/L and potassium is less 
than 5.2 mmol/L) 
Class I:  
1) in select patients with moderate to 
severe HF symptoms and reduced 
LVEF who can be carefully monitored 
for renal function and potassium levels 
Class III: 
2) not recommended with ACE 
inhibitors and ARB for patients with 
current or prior symptoms of HF and 
LVEF < 40% 
Class I: 
1) considered at low dose in 
patients with LVEF < 35% 
and symptomatic HF (NYHA 
III-IV), unless contraindicated 
or not tolerated 
 
Who Should get AA:  
 LVEF < 35% 
 NYHA III-IV 
 those with optimal 
dose of β-blocker, 
ARB and/or ACE 
inhibitor 
Digoxin use Class I: 
1) patients in sinus rhythm with 
persistent symptoms despite 
optimized HF pharmacotherapy 
Class IIa: 
1) patients with chronic AF and 
poor control of ventricular rate 
despite β-blocker therapy, or when 
β-blocker cannot be used 
2) measure serum potassium and 
creatinine when increasing digoxin 




1) patients with current or prior 
symptoms of HF and reduced LVEF to 
decrease hospitalizations for HF  
Class IIb: 
1) symptom control in HF patients with 
normal LVEF is not established 
Class III: 
1) should not be used in asymptomatic 
patients with low EF and sinus rhythm  
Class IIa: 
1) consider in patients with 
symptomatic HF and AF 
 
Who Should get Digoxin: 
 patients with AF 
 patients with sinus 
rhythm and LVEF < 
40%, NYHA II-IV, on 















dinitrate  use 
Class IIa: 
1) considered in addition to 
standard therapy for African-
Americans with LVEF < 40% 
Class IIb: 
2) may be considered for other HF 
patients unable to tolerate other 
standard recommended therapy  
Class IIa: 
1) patients with LVEF < 40% on ACE 
inhibitor and β-blocker therapy for HF 
with persisting symptoms  
Class IIb: 
1) patients with current or prior 
symptoms of HF and reduced LVEF 
with intolerance to ACE inhibitors or 
ARBs, hypotension or renal 
insufficiency  
Class IIa: 
1) symptomatic patients with 
LVEF < 40% as alternative to 
both ACE inhibitor and ARB 
if intolerant 
 
Who Should get H-ISDN: 
 those intolerant to 
ACE inhibitor/ARB 
therapy 
 with ACE inhibitors if 
ARB or AA intolerant 
 
Abbreviations: AA  = Aldosterone Antagonist, ACE  = Angiotensin Converting Enzyme, AF  = Atrial Fibrillation, ARB = Angiotensin Receptor 
Blocker, β-Blocker = β-Adrenergic Receptor Blocker, BP = Blood Pressure, bpm = beats per minute, HF = Heart Failure, HFPEF = Heart 
Failure with Preserved Ejection Fraction, LV = Left Ventricle, LVEF = Left Ventricular Ejection Fraction, MI = Myocardial Infarction, NYHA = 
New York Heart Association (functional classification), RCT= Randomized Controlled Trials 
Class I Recommendation: Evidence or general agreement that a given procedure or treatment is beneficial, useful and effective. 
Class II Recommendation: Conflicting evidence/ divergence of opinion about usefulness or efficacy of procedure or treatment. 
Class IIa Recommendation: Weight of evidence is in favour of usefulness or efficacy. 
Class IIb Recommendation: Usefulness or efficacy is less well established by evidence or opinion. 
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Figure 1: Canadian Cardiovascular Society Treatment Guidelines for Heart Failure with 




Abbreviations: ACEI = Angiotensin Converting Enzyme Inhibitor, ARB = Angiotensin Receptor 
Blocker, CCS =Canadian Cardiovascular Society, CRT = Cardiac Resynchronization Therapy, EF = 
Ejection Fraction, ER = Emergency Room, HF = Heart Failure, LVEF = Left Ventricular Ejection 
Fraction, NYHA = New York Heart Association (functional classification), QRS = Cardiac QRS 
representing ventricular depolarization 
 
Source:  
Arnold JM, Liu P, Demers C, Dorian P, Giannetti N, Haddad H, et al. Canadian Cardiovascular 
Society consensus conference recommendations on heart failure 2006: diagnosis and 





 Figure 2: American Heart Association/American College of Cardiology Treatment Guidelines 




Abbreviations: ACC = American College of Cardiology, ACEi = Angiotensin Converting Enzyme 
Inhibitor, AHA = American Heart Association, ARB = Angiotensin Receptor Blocker, EF = Ejection 
Fraction, HF = Heart Failure 
 
Source: 
Hunt SA; American College of Cardiology, American Heart Association Task Force on Practice 
Guidelines. ACC/AHA 2005 guideline update for the diagnosis and management of chronic 
heart failure in the adult: a report of the American College of Cardiology/American Heart 





APPENDIX G: Treatment of Heart Failure with Reduced Ejection Fraction 
 
Table 1: Summary of ACE inhibitor Randomized Controlled Trials 
 
Study Description Sample Outcome(s) Results 
Captopril Multicenter 
Research Group  
 
Captopril Multicenter 
Research Group, 1983.  
- captopril or placebo in  
  patients on digoxin and   
  diuretic therapy 
- 13 US centers 
- 12 week follow-up  
- n = 92  
- NYHA class II-IV 
- mean age = 57 years 
- over 90% male 
1) clinical improvement,  
    improvement in  
    NYHA class, exercise  
    tolerance, EF effects 
- captopril improved  
  NYHA class, exercise  
  tolerance, and LVEF  






Consensus Trial Study 
Group, 1987.  
- enalapril or placebo in  
  patients on digoxin and  
  diuretics 
- 35 Scandinavian  
  centers 
- 188 day follow-up 
- n = 253  
- NYHA class IV 
- mean age = 71 years 
- 70% male 
1) prognosis of severe  
    HF (mortality, NYHA  
    class) 
- enalapril reduced 1- 
  year mortality by 31%,  
  significantly improved  
  NYHA class and  
  reduced need for other  









Group, 1988.  
- captopril or digoxin    
   plus diuretic therapy 
- 19 US centers 
- 6 month follow-up 
- n = 300  
- NYHA class I-IV 
- LVEF < 40% 
- mean age = 57 years 
- 83% male 
1) exercise tolerance 
2) changes in LVEF and  
    NYHA class,  
    frequency of  
    ventricular premature  
    beats, diuretic  
    requirements, ED use  
    and hospitalizations 
- captopril improved  
  exercise time, NYHA  
  class and reduced  
  premature beats 
- digoxin increased  
  LVEF 
- both therapies reduced  
  need for diuretic  
  therapy and  
  hospitalizations 





Investigators, 1991.  
- enalapril or placebo 
- 23 centers in US,  
  Canada and Belgium 
- 41.4 month follow up 
- n = 2,569  
- NYHA class I-IV 
- LVEF < 35% 
- mean age = 61 years 
- 80% male 
1) all-cause mortality 
2) HF hospitalizations,  
    MI incidence, specific 
    cause mortality,  
    combined mortality   
    and morbidity 
- enalapril reduced  
  mortality by 16% and  
  reduced the combined  
  endpoint of  mortality  





Study Description Sample Outcome(s) Results 
SOLVD-Prevention – 
Studies of Left 
Ventricular Dysfunction 
– Prevention Trial 
 
The SOLVD 
Investigators, 1992.  
- enalapril or placebo in  
  asymptomatic patients 
- 23 centres in the US,  
  Canada and Belgium 
- 37.4 month follow-up 
- n = 4,228  
- NYHA class I-II 
- LVEF < 35 % 
- mean age = 59 years 
- 89% male 
1) mortality 
2) HF incidence 
3) hospitalizations 
- enalapril reduced  
  deaths in those with  
  incident HF, mortality  
  or hospitalizations and   
  delayed HF progression  






Pfeffer et al., 1992.  
- captopril or placebo  
  post-MI 
- 45 centres in the US  
   and Canada 
- 42 month follow-up 
- n = 2,231  
- 3-16 days post-MI 
- LVEF < 40% 
- mean age = 59 years 
- 83% male 
1) mortality 
2) deterioration in  
    cardiac performance 
3) clinical deterioration  
4) hospitalizations 
 
- captopril reduced all- 
  cause and CV  
  mortality, clinical  
  deterioration,   
  hospitalizations and  
  risk of non-fatal MI   
  by 25%  




The AIRE Study 
Investigators, 1993.  
- ramipril or placebo  
  post-MI 
- 144 centers in 14  
  countries 
- 6 month follow-up 
- n = 1,986  
- 3-10 days post MI 
- mean age = 65 years 
- 74% male 
1) all-case, all-cause  
    mortality 
2) adverse events 
- ramipril reduced all- 
  cause mortality by 27% 
  and reduced death,  
  reinfarction, and  
  strokes 





Ambrosioni et al., 1995.  
- zofenopril or placebo 
post-MI 
- 154 Italian centers 
- 6 week follow-up 
- n = 1,556  
- 24 hours post-MI 
- mean age = 64 years 
- 73% male 
1) mortality or severe  
    congestive HF 
2) effect on clinical  
    signs, recurrent MI,   
    angina, cumulative  
    1-year mortality 
- zofenopril reduced risk  
  of death or severe HF  
  by 34 %  and 1-year  











Study Description Sample Outcome(s) Results 





Kober et al., 1995.  
- trandolapril or placebo  
  post-MI 
- 27 centers in Denmark 
- 24-50 month follow-up  
- n = 1,749  
- 2-6 days post-MI 
- EF < 35% 
- mean age = 67 years 
- 72% male 
1) all-cause mortality 
2) cardiovascular death,  
    sudden death,  
    recurrent MI,  
    progression to severe  
    HF 
- trandolapril reduced  
  all-cause and CV  
  mortality and HF  
  progression  
- no reduction in  
  recurrent MI 
 
Abbreviations: CV = Cardiovascular, ED = Emergency Department, EF = Ejection Fraction, HF = Heart Failure, MI = Myocardial Infarction, 





Table 2: Summary of ARB Randomized Controlled Trials 
 
Study Description Sample Outcome(s) Results 
Val-HeFT – Valsartan 
in Heart Failure Trial 
 
 
Cohn et al., 2001. 
- valsartan or placebo 
- 302 centers in 16  
  countries 
- 23 month follow-up 
- n = 5,010  
- NYHA class II-IV 
- LVEF < 40% 
- mean age = 62 years 
- 80% male 
1) mortality 
2) combined mortality  
    and morbidity 
- mortality similar  
  between groups 
- losartan reduced  
  combined endpoint of  
  mortality and morbidity 
OPTIMAAL – Optimal 
Trial in Myocardial 
Infarction with the 
Angiotensin II 
Antagonist Losartan 
Dickstein et al., 2002. 
- losartan (ARB) or  
  captopril (ACE  
  inhibitor) post-MI 
-329 centers in Europe 
- 2.7 year follow-up 
- n = 5,477  
- 1-10 days post-MI 
- LVEF < 35% 
- mean age = 67.4 years 
- 71% male 
1) total mortality  
2) sudden CV death or  
    resuscitated cardiac  
    arrest 
3) fatal or not-fatal MI 
- losartan therapy was  
  better tolerated and  
  associated with a trend  
  towards reduced  
  mortality 
VALIANT – Valsartan 




Pfeffer et al., 2003. 
- valsartan, captopril or  
  both post-MI 
- 931 centers in 24  
  countries 
- 25 month follow-up 
- n = 14,808  
- 0.5-10 days post-MI 
- LVEF < 40% 
- mean age = 65 years 
- 70% male 
1) all-cause mortality 
2) specific cause  
    mortality 
3) CV death, recurrent  
    MI, or HF 
    hospitalization 
- no difference in all- 
  cause mortality  
  between three groups 
- more adverse drug- 
  related events in  
  combination group 
CHARM-Alternative - 
Candesartan in Heart 
failure Assessment   of 




Granger et al., 2003. 
- candesartan or placebo  
  in HF patients with  
  ACE inhibitor  
  intolerance 
- 618 centers in 26  
  countries 
- 33.7 month follow-up 
- n = 2,028  
- NYHA class II-IV 
- LVEF < 40% 
- mean age = 67 years 
- 68% male 
1) CV death or 
    unplanned HF  
    hospitalization  
2) CV death, CV or HF  
    hospitalization, MI,  
    development of new  
    diabetes 
- candesartan reduced  
  CV death or unplanned  
  HF hospitalizations 
- similar discontinuation  










Study Description Sample Outcome(s) Results 
CHARM-Added – 
Candesartan in Heart 
failure Assessment   of 
Reduction in Mortality 
and morbidity- Added 
Trial 
 
McMurray et al., 2003. 
- candesartan or placebo  
  in patients on ACE  
  inhibitor therapy 
- 618 centers in 26  
  countries 
- 41 month follow-up 
- n = 2,548  
- NYHA class II-IV 
- LVEF < 40% 
- mean age = 64 years 
- 79% male 
1) CV death or  
    unplanned HF  
    hospitalization 
2) CV events or HF  
    hospitalization  
- candesartan reduced  
  CV deaths or  
  unplanned HF  
  hospitalizations,  
  improved CV events  
  and HF hospitalization  
 
Abbreviations: ACE = Angiotensin Converting Enzyme, ARB = Angiotensin Receptor Blocker, CV = Cardiovascular, HF = Heart Failure, MI = 





Table 3: Summary of β-Blocker Randomized Controlled Trials 
 
Study Description Sample Outcome(s) Results 
COMET – Carvedilol 
or Metoprolol European 
Trial 
 
Poole-Wilson et al., 
2003. 
- carvedilol or  
  metoprolol in chronic  
  HF 
- 15 European countries 
- 58 month follow-up 
- n = 3,029 
- NYHA class II-IV 
- LVEF < 35% 
- mean age = 62 years 
- 80% male 
 
1) all-cause mortality 
2) all-cause mortality or  
    hospitalizations 
- carvedilol improves  
  mortality beyond  
  metoprolol (seen by 6 
  months) 
- no differences in all- 
  cause hospitalizations 








Waagstein et al., 1993. 
- metoprolol or placebo  
  in patients with  
  symptomatic idiopathic  
  dilated cardiomyopathy 
- 33 centers in North   
  America and Europe 
- 12 -18 month follow-up 
- n = 383 
- LVEF < 40% 
- mean age = 49 years 
- 73% male 
1) all-cause mortality or  
    clinical deterioration  
    (need for cardiac  
    transplantation) 
2) effects on CV 
    function, exercise  
    capacity, quality of  
    life, hospitalizations  
    or ED visits for HF 
- metoprolol reduced all- 
  cause mortality by  
  34%, prevented clinical  
  deterioration, and  
  improved symptoms,  
  LVEF, quality of life  
  and exercise capacity 
RESOLVD – 
Randomized Evaluation 








- metoprolol-CR with  
  candesartan (ARB),  
  enalapril (ACE  
  inhibitor) or both in  
  patients with ischemic  
  and dilated  
  cardiomyopathy  
- multiple centers in  
  Europe and Canada  
- 24 week follow-up 
- n = 426  
- NYHA class II-IV 
- LVEF < 40% 
- mean age = 62 years 
- 83% male 
1) efficacy and safety of  
    metoprolol CR use in  
    addition to standard  
    therapy 
2) effects of metoprolol- 
    CR with standard  
    therapy on ventricular  
    volumes and function,  
    NYHA class and  
    quality of life 
- metoprolol-CR added   
  to ACE inhibitor and/or  
  ARB therapy improves  
  LVEF, reduces RAA  
  activation, and reduces  
  mortality 
- no changes in exercise  
  capacity, quality of life  
  scores, NYHA class or  














Intervention Trial in 
Congestive Heart Failure  
 
 
Hjalmarson et al, 2000. 
- metoprolol-CR/XL or  
  placebo 
- 313 centers in 14  
  countries 
- 1 year follow-up 
 
- n = 3,991  
- NYHA class II-IV 
- LVEF < 40% 
- mean age = 64 years 
- 77% male 
 
1) total mortality  
2) total mortality or HF  
    hospitalization  
2) substudy examined  
    quality of life 
- metoprolol-CR/XL  
  improved survival,  
  NYHA class, HF  
  hospitalizations, patient   
  well-being and reduced  
  total mortality or all- 
  cause hospitalizations  




CIBIS Investigators  
and Committees, 1994. 
- bisoprolol or placebo 
- multiple centers in   
  Europe 
- 1.9 year follow-up 
- n = 961 
- NYHA class III - IV 
- LVEF < 40% 
- mean age = 60 years 
- 83% male 
1) mortality 
2) tolerability of  
    bisoprolol and  
    analysis of all critical  
    events 
- bisoprolol reduced HF  
  progression 
- no significant reduction  
  in mortality or mode of  
  death 
CIBIS II –  
Cardiac Insufficiency 
Bisoprolol Study II 
 
CIBIS-II Investigators 
and Committees, 1999. 
- bisoprolol or placebo 
- 18 European countries  
- 1.3 year follow-up 
 
- n = 2,647  
- NYHA III - IV 
- LVEF < 35% 
- mean age = 61 years 
- 80% male 
1) all-cause mortality 
2) all-cause  
    hospitalizations, all  
    CV deaths, permanent  
    treatment withdrawals 
- bisoprolol reduced all- 
  cause mortality, CV  
  mortality and  
  hospitalizations 
 
CIBIS III – 
Cardiac Insufficiency 
Bisoprolol Study III 
 
 
Dobre et al., 2008 
- bisoprolol or enalapril  
  (ACE inhibitor)  
  monotherapy prior to  
  combination 
- multi-center in Europe 
- 5.4 month follow-up 
- n = 1,010 
- NYHA II and III 
- LVEF < 35% 
- mean age = 72 years 
(all were 65+ years) 
- 68% male 
1) all-cause mortality or  
    hospitalization 
2) HF hospitalizations 
- bisoprolol showed  
  trend to lower mortality  
- similar rates of CV  
  hospitalizations, but  
  more HF-related  






Packer et al., 2001. 
- carvedilol or placebo in  
  severe chronic HF 
- 334 centres in 21  
  countries 
- 10.4 month follow-up 
- n = 2,289 
- LVEF < 25% 
- mean age = 63 years 
- 80% male 
1) all-cause mortality  
2) mortality or HF  
    hospitalization 
- carvedilol therapy  
  reduced mortality by  
  35%, and mortality or   






Study Description Sample Outcome(s) Results 
PRECISE – Prospective 
Randomized Evaluation 
of Carvedilol on 
Symptoms and Exercise 
 
Packer et al., 1996. 
- carvedilol or placebo 
- 31 centers in the US 
- 12 month follow-up 
- n = 278 
- NYHA class II-IV  
- LVEF < 35% 
- mean age = 62 years 
- 80% male 
1) exercise tolerance  
2) changes in NYHA  
    class, LVEF, quality  
    of life 
3) CV hospitalizations 
- carvediol improved  
  NYHA class, LVEF  
  and morbidity and   
  mortality risk, but not  
  exercise tolerance or  
  qualtity of life   
US Carvedilol Heart 
Failure Study Group 
 
 
Colucci et al., 1996. 
Packer et al., 1996. 
Cohn et al., 1997. 
- carvedilol or placebo 
- 54 centers in the US 
- 12 month follow-up 
- n = 366  
- NYHA II-IV 
- LVEF < 35% 
- mean 60 = years 
- 70% male 
 
1) HF death or  
    hospitalization, need  
    to increase HF meds 
2) LVEF, NYHA class,  
    quality of life,  
    exercise tolerance and  
    heart size 
- carvedilol reduced  
  clinical progression by  
  21% , reduced all-cause  
  mortality, and  
  improved NYHA class  
  and HF symptoms  
MOCHA – Multicenter 





Bristow et al., 1996. 
- carvedilol or placebo in  
  symptomatic patients  
  on stable doses of  
  diuretics and ACE  
  inhibitors before entry 
- multiple US centers  
- 6 month follow-up 
- n = 345 
- NYHA II – III 
- LVEF < 35% 
- mean age = 60 years 
- 83% male  
1) exercise tolerance 
2) changes in quality of  
    life, NYHA class,  
    LVEF,  
    hospitalizations, and  
    signs/symptoms of HF 
- dose-related  
  improvements in LV  
  function, mortality and    
  hospitalizations with  
  carvedilol, but no  
  change in exercise  
  tolerance 
CAPRICORN – 
Carvedilol Post-Infarct 




Dargie et al., 2001. 
- carvedilol or placebo  
   post-MI 
- 163 centers in 17  
   countries  
- 1.3 year follow-up 
- n = 1,959  
- LVEF < 40% post-MI 
- mean age = 63 years 
- 74% male 
1) all-cause mortality or  
    CV hospitalization  
2) sudden death and HF   
    hospitalization 
- no difference in  
  combined primary  
  endpoint  
- carvedilol reduced all- 
  cause mortality, CV  
  hospitalization and  
  combined endpoint 
 
Abbreviations: ACE = Angiotensin Converting Enzyme, ARB = Angiotensin Receptor Blocker, BP = Blood Pressure, CV = Cardiovascular, ED 
= Emergency Department, HF = Heart Failure, MI = Myocardial Infarction, LV = Left Ventricle, LVEF = Left Ventricular Ejection Fraction, 





Table 4: Summary of AA Randomized Controlled Trials 
 
Study Description Sample Outcome(s) Results 






Pitt et al., 1999. 
- spironolactone or  
  placebo with ACE  
  inhibitors and diuretics  
  in severe HF 
- 195 centres in 15  
  countries 
- 24 month follow-up 
- n = 1,663 
- NYHA class III - IV 
- LVEF < 35% 
- mean age = 65 years 
- 73% male 
1) all-cause mortality 
2) CV death, CV  
     hospitalizations,  
     combined CV death  
     or hospitalization and  
     change in NYHA  
     class 
- spironolactone reduced  
  all-cause mortality by  
  30%, CV death by  
  31%, and risk of CV  
  hospitalization by 30 %  
  and improved NYHA  




Heart Failure Efficacy 
and Survival Study 
 
Pitt et al., 2003. 
- eplerenone or placebo  
  with optimal  
  pharmacotherapy post- 
  MI 
- multiple centers  
  internationally 
- 16 month follow-up 
- n= 6,642  
- 3-14 days post-MI 
- LVEF < 40% 
- mean age = 64 years 
~70% male 
1) all-cause mortality,   
    CV mortality and  
    hospitalizations 
2) CV mortality, CV  
    hospitalizations, all- 
    cause mortality and  
    hospitalizations 
- eplerenone reduced all- 
  cause mortality and  
  CV mortality or  
  hospitalization (overall  
  reduction in mortality  
  and morbidity) 
 
Abbreviations: ACE = Angiotensin Converting Enzyme, CV = Cardiovascular, HF = Heart Failure, MI = Myocardial Infarction, LVEF = Left 





Table 5: Summary of Digoxin Randomized Controlled Trials 
 
Study Description Sample Outcome(s) Results 
PROVED – Prospective 
Randomized Study of 
Ventricular Failure and 




Uretsky et al., 1993. 
- digoxin or placebo in  
  stable HF 
- 29 centers in the US  
- 3 month follow-up 
- n = 88  
- NYHA II-III 
- LVEF < 35% 
- mean age = 64 years 
- 80% male 
1) exercise performance,  
    treatment failure, time  
    to treatment failure 
2) HF progression,  
    changes in HF signs/ 
    symptoms, LVEF,  
    vital signs, body  
    weight 
- digoxin improved  
  exercise performance,  
  treatment failure, time  
  to treatment failure, 
  LVEF and lowered HR  
  and body weight 
RADIANCE – 
Randomized Assessment 







Packer et al., 1993. 
- digoxin or placebo  
  with ACE inhibitors 
- 43 centers in the US  
  and Canada 
- 12 week follow-up 
- n = 178  
- NYHA II-III 
- LVEF <35% 
- mean age = 60 years 
- 68% male 
1) withdrawal rate for  
    worsening HF, time to  
    withdrawal, exercise  
    tolerance 
2) effects on HF  
    symptoms and  
    progression, quality of  
    life, NYHA class and  
    cardiac dimensions 
- remaining on digoxin  
  therapy associated with  
  stable HF, stable  
  exercise tolerance,  
  slower HF progression,  
  better quality of life 
- switch from digoxin to  
  placebo reduced quality  
  of life,  increased HR  
  and body weight 








- digoxin or placebo 
- 302 centers in the US  
  and Canada 
- 37 month follow-up 
- n= 7,788  
- NYHA I-IV 
- LVEF below 45% 
- mean age = 63 years 
- 78% male 
1) all-cause mortality 
2) HF hospitalizations 
- digoxin therapy did not  
  improve mortality, but  
  showed trend towards  
  lower HF mortality,  
  fewer hospitalizations  
  and lower combined  
  outcome of HF death   
  or hospitalization  
 
Abbreviations: ACE = Angiotensin Converting Enzyme, HF = Heart Failure, HR = Heart Rate, LVEF = Left Ventricular Ejection Fraction, 





APPENDIX H:  Treatment of Heart Failure with Preserved Ejection Fraction 
 
Table 1: Summary of Studies of Therapies for Heart Failure with Preserved Ejection Fraction 
 








Ezekowitz et al., 2008. 
- prospective cohort, HF  
  post-discharge 
- ACE inhibitor, β- 
  blocker, digoxin, 
  spironolactone, and  
  ARB therapy 
- 103 Ontario hospitals 
- 1 year follow-up 
- n=9,943 
- any NYHA class 
- any LVEF  
- mean age = 76 years 
- 36% male (HFPEF) 
1) 1-year mortality or 
    HF readmission 
- no difference in  
  survival with ACE  
  inhibitor, β-blocker,  
  spironolactone, digoxin  
  or ARB therapy 
I-PRESERVE: 
Irbesartan in Patients 




Massie et al., 2008. 
- irbesartan (ARB) or  
  placebo in HFPEF 
- 293 sites in Europe,  
  North and South  
  America, South Africa,  
  and Australia 
- 49.5 month follow-up 
- n = 4,563  
- NYHA class II-IV 
- LVEF > 45% 
- mean age = 72 years 
- 60% female 
1) all-cause mortality or  
    CV hospitalization  
2) HF death or  
    hospitalization, all- 
    cause or CV  
    mortality, quality of  
    life 
- irbesartan did not  
  improve primary or  
  secondary outcomes 
 
CHARM-Preserved – 
Candesartan in Heart 
Failure Assessment of 
Reduction in Mortality 
Preserved 
 
Yusuf et al., 2003. 
- candesartan (ARB) or  
  placebo in HFPEF 
- 618 centers in 28  
  countries 
- 36.6 month follow-up 
- n = 3,023  
- NYHA class II-IV 
- LVEF > 40% 
- mean age = 67 years 
- 60% male 
1) CV death or HF  
    hospitalization 
- candesartan did not  
  improve primary  
  outcome, but  
  moderately reduced HF  
  hospitalizations 
PEP-CHF – Perindopril 
in Older People with 
Chronic Heart Failure 
 
 
Cleland et al., 2006. 
- perindopril (ACE  
  inhibitor) or placebo in  
  HFPEF  with diuretic  
  therapy 
- 53 centers in Europe 
- 2.1 year follow-up 
- n = 850  
- NYHA class I-IV 
- LVEF > 40% 
- mean age = 76 years 
- 55% female 
1) all-cause mortality or  
    unplanned HF  
    hospitalization 
- insufficient power, but  
  perindopril therapy  
  showed a trend towards  
  improved symptoms,  
  exercise capacity and   





Study Description Sample Outcome(s) Results 





Ahmed et al., 2006. 
- digoxin or placebo  
  (subset with HFPEF) 
- 302 centers in the US  
  and Canada 
- 37 month follow-up 
 
- n= 988  
- NYHA class I-IV 
- LVEF > 45% 
- mean age = 65 years 
- 60% male 
1) HF mortality or  
    hospitalization 
2) cause-specific  
    mortality or  
    hospitalization 
- digoxin did not  
  improve primary or  
  secondary endpoints 
- showed towards  
  reduced HF  
  hospitalizations  
SENIORS - Study of 




Seniors with heart 
failure  
 
Flather et al., 2005. 
- nebivolol (β-blocker)  
  or placebo 
- 11 European countries 
- 21 month follow-up 
- n = 2,128  
- NYHA class I-IV 
- 35% enrolled with  
  LVEF > 35% 
- mean age = 76 years 
- 36% female 
1) all-cause mortality or  
    CV hospitalization 
2) all-cause mortality or 
    hospital admissions,   
    all-cause hospital 
    admissions, CV  
    hospitalizations and  
    mortality, exercise  
    tolerance 
- nebivolol therapy  
  achieved modest  
  reduction in primary  
  endpoints, reduced all- 
  cause mortality or  
  hospitalizations  
- similar findings in  
  subgroup analysis of  




Aronow and Kronzon, 
1993. 
- enalapril (ACE  
  inhibitor) or placebo in  
  HF post- MI 
- one US center 
- 3 month follow-up 
- n = 21  
- NYHA class III 
- LVEF > 50% 
- mean age = 80 years 
- 86% women 
1) NYHA class, BP,  
    exercise time and  
    LVEF 
- enalapril improved  
  NYHA class, BP,  
  exercise time and  





Parthasarathy et al., 
2009 
- valsartan (ARB)or  
  placebo 
- multiple centers in  
  Finland 
- 14 week follow-up 
- n = 152  
- LVEF > 40% 
- mean age = 62 years 
- 50% male 
1) exercise time 
2) echocardiography  
    results, quality of life  
    scores, exertion 
- valsartan did not  
  improve primary  
  outcome, but improved  
  peak exercise systolic  
  BP and perceived  
  exertion 
 
Abbreviations: ACE = Angiotensin Converting Enzyme, ARB = Angiotensin Receptor Blocker, β-blocker = β-Adrenergic Receptor Blocker, 
BP = Blood Pressure, CV = Cardiovascular, HF = Heart Failure, HFPEF = Heart Failure with Preserved Ejection Fraction, MI = Myocardial 





APPENDIX I: Ontario Drug Benefit Formulary 
 







Exceptions to Coverage 
ACE inhibitor benazepril None 
captopril Capoten not covered 
cilazapril None 
enalapril Only Vasotec is covered (2.5, 5, 10 and 20 mg) 
fosinopril None 
lisinopril 20mg lisinopril with 25 mg HCTZ (combination with 
diuretic) not covered 
perindopril Generic (apo-perindopril 8 mg) not covered 
quinapril None 
ramipril 15 mg not covered (Apo/Ratio-ramipril or Altace) 
trandolapril None 
β-blocker acebutolol Monitan not covered (100, 200 and 400 mg) 
atenolol None 
bisoprolol None 
carvedilol Coreg not covered (3.125, 6.25, 12.5 and 25 mg) 
metoprolol None 
nadolol Corgard not covered (40m 80 and 160 mg) 
propranolol Inderal not covered (10, 20, 40, 80, 120 mg) 
ARB
a







Abbreviations: ACE  = Angiotensin Converting Enzyme, ARB = Angiotensin Receptor Blocker, β-
blocker = β-Adrenergic Receptor Blocker, HCTZ = Hydrochlorothiazide
 
a 
ARB therapies are all under patent, no interchangeable medications are available 
 
Source: 
Ontario Ministry of Health and Long-Term Care. Ontario public drug programs: Formulary 






APPENDIX J: Supplementary Information from Chapter 6.0 
 
Table 1: Comparison of Baseline Characteristics among Older Home Care Clients with 
Heart Failure by Time between Assessments, Ontario 2005-2007 (N=115,755) 
 
  Assessment 
Gap Between 
60-270 days 









  % (n) % (n)  
HF
a
  14.1 (9,283) 12.9 (6,162)  
Sociodemographic Characteristics     
Age 65-74 years 











Gender Female 68.7 (46,737) 70.7 (33,728 <0.0001 
Living Alone  38.7 (25,995) 38.2 (18,472) 0.10 
Clinical Characteristics     
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Pharmacotherapy     
Any ACE inhibitor use 
Any ARB use 
Any β-blocker use 
 36.0 (24,453) 
     9.4   (6,419) 
28.1 (19,128) 
36.0 (17,168) 





Abbreviations: ACE = Angiotensin Converting Enzyme, ADL = Activities of Daily Living, ARB = 
Angiotensin Receptor Blocker, β-blocker = β-Adrenergic Receptor Blocker, CAP = Clinical 
Assessment Protocol, CHESS = Changes in Health, End-stage disease and Signs and Symptoms, CPS = 
Cognitive Performance Scale, HF = Heart Failure, IADL = Instrumental Activities of Daily Living, 
MAPLe = Method for Assigning Priority Levels 
a
 excludes new and inconsistent HF (n = 4,348) 
b
 0 = no impairment; 1-2 = some functional impairment; 3+ = severe functional impairment 
c
 0 = no difficulty; 1-2 = some difficulty; 3+ = great difficulty 
d
 0 = cognitively intact; 1-2 = mild cognitive impairment; 3+ = cognitively impaired
  
e
 0 = no health instability; 1-2 = some health instability; 3+ = moderate to high health instability
 
f
 1 = low priority; 2-3 = mild/moderate priority; 4-5 = high priority  
g
 0 = no prior falls; 1 – 1 prior fall; 2 – multiple prior falls 
h  




 excludes HF  
j 





Table 2: Summary of Bivariate Analyses for Mortality within 90 days among Older Home 
Care Clients with Heart Failure, Ontario 2005-2007 (N=9,283) 
 
 Point Estimate 
(SE) 
OR (95% CI) p value 
Sociodemographic Characteristics    
Age 0.10 (0.03) 1.11 (1.04, 1.18) 0.002 
Female -0.57 (0.05) 0.57 (0.52, 0.62) <0.0001 
Married 0.17 (0.02) 1.42 (1.30, 1.55) <0.0001 
Living Alone -0.55 (0.05) 0.58 (0.53, 0.64) <0.0001 
Caregiver Stress 0.41 (0.06) 1.51 (1.34,1.70) <0.0001 
Clinical Characteristics    
ADL Hierarchy Scale score
 
0.32 (0.01) 1.38 (1.35,1.42) <0.0001 
IADL Capacity Scale score 0.31 (0.02) 1.37 (1.32, 1.42) <0.0001 
CPS score 0.21 (0.02) 1.24 (1.20, 1.28) <0.0001 
CHESS Scale score 0.30 (0.02) 1.35 (1.30, 1.41) <0.0001 
MAPLe Algorithm score 0.27 (0.02) 1.31 (1.26, 1.36) <0.0001 
Behavioural Symptoms 0.55 (0.09) 1.74 (1.46, 2.08) <0.0001 
Impairment with Stairs 0.58 (0.05) 1.79 (1.61, 1.99) <0.0001 
Incontinence 0.09 (0.04) 1.10 (1.01, 1.20) 0.03 
Falls CAP 0.07 (0.03) 1.07 (1.01, 1.15) 0.03 
Mood CAP 0.10 (0.03) 1.11 (1.04, 1.18) 0.001 
Number of Comorbid Conditions
a
 -0.15 (0.10) 0.86 (0.70, 1.04) 0.12 
Diagnoses    
Hypertension -0.33 (0.05) 0.72 (0.66, 0.78) <0.0001 
Arthritis -0.36 (0.05) 0.70 (0.64, 0.76) <0.0001 
CAD -0.03 (0.04) 0.97 (0.89, 1.05) 0.44 
Diabetes Mellitus 0.08 (0.05) 1.09 (0.99, 1.19) 0.08 
Airway Disease
b
 0.27 (0.05) 1.30 (1.19, 1.43) <0.0001 
Osteoporosis -0.20 (0.06) 0.82 (0.73, 0.91) 0.0002 
Stroke 0.03 (0.05) 1.03 (0.93, 1.15) 0.53 
Any Dementia 0.28 (0.06) 1.33 (1.17, 1.50) <0.0001 
Cancer 0.35 (0.06) 1.43 (1.26, 1.61) <0.0001 
Pharmacotherapy    
Number of Medications
c
 -0.004 (0.01) 1.00 (0.98, 1.01) 0.57 
Impaired Medication Management 0.60 (0.05) 1.82 (1.66, 2.00) <0.0001 
Medication Non-Adherence
d
 -0.27 (0.27) 0.77 (0.46, 1.29) 0.32 
Any ACE inhibitor use -0.02 (0.04) 0.98 (0.90, 1.07) 0.69 
Any ARB use -0.32 (0.07) 0.73 (0.63, 0.84) <0.0001 
Any β-blocker use -0.09 (0.05) 0.91 (0.83, 0.99) 0.04 












 -0.13 (0.05) 0.88 (0.81, 0.96) 0.004 















 Point Estimate (SE) OR (95% CI) p value 
Service Use    
Any Nursing
h
 0.44 (0.05) 1.56 (1.43, 1.70) <0.0001 
Any Homemaking
h
 -0.19 (0.04) 0.83 (0.76, 0.90) <0.0001 
Any Physiotherapy
h
 -0.21 (0.11) 0.81 (0.66, 0.99) 0.04 
Any Home Help
h
 0.11 (0.06) 1.12 (1.00, 1.24) 0.05 
Weekly Cost of HC services
i 
0.07 (0.01) 1.07 (1.05, 1.10) <0.0001 
Any previous ED visit
j
 0.11 (0.04) 1.11 (1.03, 1.21) 0.008 
Any previous Hospitalization
j
 0.17 (0.04) 1.18 (1.10, 1.27) <0.0001 
 
Abbreviations: ACE  = Angiotensin Converting Enzyme, ADL = Activities of Daily Living, ARB = 
Angiotensin Receptor Blocker, β-blocker =  β-Adrenergic Receptor Blocker, CAD = Coronary Artery 
Disease, CAP = Clinical Assessment Protocol, CHESS = Changes in Health, End-stage disease and Signs 
and Symptoms, CI = Confidence Interval, CPS  = Cognitive Performance Scale, ED  = Emergency 
Department, HC = Home Care, HF = Heart Failure, IADL = Instrumental Activities of Daily Living, 
MAPLe = Method for Assigning Priority Levels, OR = Odds Ratio, SE = Standard Error 
a
 excludes HF 
b
 includes chronic obstructive pulmonary disease (COPD), emphysema and asthma 
c
 excludes ACE inhibitor, β- blocker and ARB therapies  
d
 adherent less than 80% of the time
  
e 
ACE inhibitor or ARB use recorded at every assessment  
f
 β-blocker use recorded at every assessment 
g
 ACE inhibitor, ARB or β-blocker use recorded at every assessment 
h 
measured in 7 days prior to assessment 
i
 measured in increments of $100 
j 





Table 3: Summary of Bivariate Analyses for Long-Term Care Admission within 90 days 
among Older Home Care Clients with Heart Failure, Ontario 2005-2007 (N=9,283) 
 






Sociodemographic Characteristics    
Age 0.60 (0.05) 1.83 (1.67, 2.00) <0.0001 
Female -0.03 (0.06) 0.98 (0.87, 1.10) 0.67 
Married -0.01 (0.03) 0.98 (0.87, 1.10) 0.73 
Living Alone -0.23 (0.06) 0.79 (0.71, 0.89) <0.0001 
Caregiver Stress 0.86 (0.07) 2.38 (2.09, 2.70) <0.0001 
Clinical Characteristics    
ADL Hierarchy Scale score
 
0.21 (0.02) 1.24 (1.19, 1.28) <0.0001 
IADL Capacity Scale score 0.35 (0.02) 1.42 (1.36, 1.49) <0.0001 
CPS score 0.39 (0.02) 1.48 (1.42, 1.53) <0.0001 
CHESS Scale score 0.19 (0.03) 1.21 (1.15, 1.27) <0.0001 
MAPLe Algorithm score 0.56 (0.03) 1.76 (1.67, 1.85) <0.0001 
Behavioural Symptoms 1.25 (0.09) 3.48 (2.93, 4.14) <0.0001 
Impairment with Stairs 0.71 (0.07) 2.03 (1.77, 2.32) <0.0001 
Incontinence 0.53 (0.06) 1.71 (1.53, 1.90) <0.0001 
Falls CAP 0.40 (0.04) 1.50 (1.40, 1.60) <0.0001 
Mood CAP 0.31 (0.04) 1.36 (1.27, 1.46) <0.0001 
Number of Comorbid Conditions
a
 -0.20 (0.12) 0.82 (0.65, 1.05) 0.11 
Diagnoses    
Hypertension -0.09 (0.06) 0.92 (0.82, 1.03) 0.13 
Arthritis -0.27 (0.06) 0.76 (0.68, 0.85) <0.0001 
CAD -0.19 (0.06) 0.82 (0.74, 0.92) 0.001 
Diabetes Mellitus -0.35 (0.06) 0.70 (0.62, 0.80) <0.0001 
Airway Disease
b
 -0.36 (0.07) 0.70 (0.61, 0.79) <0.0001 
Osteoporosis 0.05 (0.06) 1.05 (0.92, 1.19) 0.48 
Stroke 0.01 (0.07) 1.01 (0.88, 1.15) 0.93 
Any Dementia 1.14 (0.06) 3.13 (2.77, 3.54) <0.0001 
Cancer -0.18 (0.09) 0.84 (0.70, 1.01) 0.06 
Pharmacotherapy    
Number of Medications
c
 -0.05 (0.01) 0.95 (0.93, 0.96) <0.0001 
Impaired Medication Management 1.14 (0.07) 3.11 (2.72, 3.56) <0.0001 
Medication Non-Adherence
d
 0.97 (0.20) 2.63 (1.78, 3.87) <0.0001 
Any ACE inhibitor use -0.13 (0.06) 0.88 (0.79, 0.98) 0.021 
Any ARB use -0.19 (0.09) 0.83 (0.70, 0.99) 0.03 
Any β-blocker use -0.19 (0.06) 0.83 (0.74, 0.92) 0.001 












 -0.17 (0.06) 0.85 (0.76, 0.95) 0.003 





















Service Use    
Any Nursing
h
 0.13 (0.06) 1.14 (1.02, 1.28) 0.02 
Any Homemaking
h
 0.26 (0.06) 1.30 (1.16, 1.45) <0.0001 
Any Physiotherapy
h
 -0.04 (0.12) 0.96 (0.75, 1.22) 0.73 
Any Home Help
h
 0.09 (0.07) 1.10 (0.96, 1.26) 0.17 
Weekly Cost of HC services
i 
0.01 (0.003) 1.01 (1.00, 1.01) 0.08 
Any previous ED visit
j
 0.15 (0.05) 1.17 (1.06, 1.29) 0.002 
Any previous Hospitalization
j
 -0.10 (0.05) 0.91 (0.82, 1.00) 0.06 
 
Abbreviations: ACE  = Angiotensin Converting Enzyme, ADL = Activities of Daily Living, ARB = 
Angiotensin Receptor Blocker, β-blocker =  β-Adrenergic Receptor Blocker, CAD = Coronary Artery 
Disease, CAP = Clinical Assessment Protocol, CHESS = Changes in Health, End-stage disease and Signs 
and Symptoms, CI = Confidence Interval, CPS  = Cognitive Performance Scale, ED  = Emergency 
Department, HC = Home Care, HF = Heart Failure, IADL = Instrumental Activities of Daily Living, 
MAPLe = Method for Assigning Priority Levels, OR = Odds Ratio, SE = Standard Error 
a
 excludes HF 
b
 includes chronic obstructive pulmonary disease (COPD), emphysema and asthma 
c
 excludes ACE inhibitor, β- blocker and ARB therapies  
d
 adherent less than 80% of the time
  
e 
ACE inhibitor or ARB use recorded at every assessment  
f
 β-blocker use recorded at every assessment 
g
 ACE inhibitor, ARB or β-blocker use recorded at every assessment 
h 
measured in 7 days prior to assessment 
i
 measured in increments of $100 
j 





Table 4: Summary of Bivariate Analyses for Hospitalization within 90 days among Older 
Home Care Clients with Heart Failure, Ontario 2005-2007 (N=9,283) 
 






Sociodemographic Characteristics    
Age -0.06 (0.03) 0.94(0.90, 0.99) 0.02 
Female -0.11 (0.04) 0.90 (0.84, 0.97) 0.006 
Married 0.03 (0.02) 1.06 (0.98, 1.14) 0.15 
Living Alone 0.002 (0.04) 1.00 (0.93, 1.08) 0.96 
Caregiver Stress 0.08 (0.05) 1.08 (0.97, 1.20) 0.16 
Clinical Characteristics    
ADL Hierarchy Scale score
 
0.03 (0.02) 1.03 (1.00, 1.06 ) 0.46 
IADL Capacity Scale score 0.09 (0.01) 1.10 (1.07, 1.12) <0.0001 
CPS score 0.01 (0.02) 1.00 (0.97, 1.03) 0.74 
CHESS Scale score 0.20 (0.02) 1.22 (1.18, 1.26) <0.0001 
MAPLe Algorithm score 0.14 (0.02) 1.15 (1.12, 1.19) <0.0001 
Behavioural Symptoms -0.02 (0.09) 0.98 (0.82, 1.17) 0.80 
Impairment with Stairs 0.35 (0.04) 1.42 (1.31, 1.54) <0.0001 
Incontinence 0.12 (0.04) 1.13 (1.05, 1.21) 0.0009 
Falls CAP 0.18 (0.03) 1.19 (1.13, 1.25) <0.0001 
Mood CAP 0.12 (0.03) 1.13 (1.07, 1.18) <0.0001 
Number of Comorbid Conditions
a
 0.36 (0.10) 1.44 (1.18, 1.75) 0.0003 
Diagnoses    
Hypertension -0.02 (0.04) 0.99 (0.91, 1.06) 0.69 
Arthritis -0.02 (0.04) 0.98 (0.91, 1.06) 0.64 
CAD 0.10 (0.04) 1.10 (1.03, 1.18) 0.008 
Diabetes Mellitus 0.23 (0.04) 1.26 (1.17, 1.36) <0.0001 
Airway Disease
b
 0.22 (0.04) 1.25 (1.16, 1.35) <0.0001 
Osteoporosis -0.006 (0.04) 0.99 (0.91, 1.08) 0.88 
Stroke 0.05 (0.04) 1.05 (0.96, 1.14) 0.28 
Any Dementia -0.23 (0.06) 0.80 (0.71, 0.89) 0.0001 
Cancer 0.19 (0.06) 1.20 (1.08, 1.34) 0.0007 
Pharmacotherapy    
Number of Medications
c
 0.04 (0.005) 1.04 (1.03, 1.05) <0.0001 
Impaired Medication Management 0.21 (0.04) 1.23 (1.14, 1.32) <0.0001 
Medication Non-Adherence
d
 0.31 (0.17) 1.36 (0.97, 1.91) 0.08 
Any ACE inhibitor use -0.01 (0.04) 0.99 (0.92, 1.06) 0.80 
Any ARB use -0.08 (0.06) 0.92 (0.83, 1.03) 0.12 
Any β-blocker use -0.04 (0.04) 0.96 (0.89, 1.03) 0.27 












 -0.03 (0.04) 0.98 (0.91, 1.05) 0.50 




















Service Use    
Any Nursing
h
 0.40 (0.04) 1.49 (1.39, 1.60) <0.0001 
Any Homemaking
h
 -0.05 (0.04) 0.95 (0.89, 1.02) 0.17 
Any Physiotherapy
h
 0.24 (0.07) 1.27 (1.10, 1.47) 0.001 
Any Home Help
h
 0.14 (0.05) 1.15 (1.05, 1.25) 0.003 
Weekly Cost of HC services
i 
0.06 (0.01) 1.06 (1.04, 1.09) <0.0001 
Any previous ED visit
j
 0.28 (0.03) 1.32 (1.24, 1.41) <0.0001 
Any previous Hospitalization
j
 0.37 (0.03) 1.44 (1.37, 1.53) <0.0001 
 
Abbreviations: ACE  = Angiotensin Converting Enzyme, ADL = Activities of Daily Living, ARB = 
Angiotensin Receptor Blocker, β-blocker =  β-Adrenergic Receptor Blocker, CAD = Coronary Artery 
Disease, CAP = Clinical Assessment Protocol, CHESS = Changes in Health, End-stage disease and Signs 
and Symptoms, CI = Confidence Interval, CPS  = Cognitive Performance Scale, ED  = Emergency 
Department, HC = Home Care, HF = Heart Failure, IADL = Instrumental Activities of Daily Living, 
MAPLe = Method for Assigning Priority Levels, OR = Odds Ratio, SE = Standard Error 
a
 excludes HF 
b
 includes chronic obstructive pulmonary disease (COPD), emphysema and asthma 
c
 excludes ACE inhibitor, β- blocker and ARB therapies  
d
 adherent less than 80% of the time
  
e 
ACE inhibitor or ARB use recorded at every assessment  
f
 β-blocker use recorded at every assessment 
g
 ACE inhibitor, ARB or β-blocker use recorded at every assessment 
h 
measured in 7 days prior to assessment 
i
 measured in increments of $100 
j 








Table 5: Summary of Bivariate Analyses for New Functional Decline within 90 days among 
Home Care Clients with Heart Failure, Ontario 2005-2007 (N=9,283) 
 






Sociodemographic Characteristics    
Age 0.16 (0.06) 1.18 (1.05, 1.32) 0.006 
Female -0.23 (0.08) 0.80 (0.68, 0.94) 0.006 
Married -0.16 (0.04) 0.73 (0.62, 0.86) 0.0001 
Living Alone -0.72 (0.09) 0.49 (0.41, 0.59) <0.0001 
Caregiver Stress 0.26 (0.11) 1.29 (1.04, 1.61) 0.02 
Clinical Characteristics    
IADL Capacity Scale score 0.23 (0.03) 1.26 (1.19, 1.34) <0.0001 
CPS score 0.13 (0.03) 1.14 (1.07, 1.21) <0.0001 
CHESS Scale score 0.18 (0.04) 1.19 (1.11, 1.28) <0.0001 
MAPLe Algorithm score 0.25 (0.04) 1.29 (1.20, 1.38) <0.0001 
Behavioural Symptoms 0.20 (0.18) 1.22 (0.86, 1.73) 0.27 
Impairment with Stairs 0.27 (0.09) 1.31 (1.10, 1.57) 0.003 
Incontinence 0.20 (0.08) 1.22 (1.04, 1.42) 0.01 
Falls CAP 0.22 (0.05) 1.24 (1.12, 1.38) <0.0001 
Mood CAP -0.04 (0.06) 0.97 (0.86, 1.09) 0.56 
Number of Comorbid Conditions
a
 -0.52 (0.35) 0.60 (0.30, 1.18) 0.14 
Diagnoses    
Hypertension -0.06 (0.08) 0.94 (0.80, 1.11) 0.48 
Arthritis -0.26 (0.08) 0.77 (0.66, 0.90) 0.001 
CAD -0.06 (0.08) 0.95 (0.81, 1.11) 0.48 
Diabetes Mellitus -0.03 (0.09) 0.97 (0.82, 1.15) 0.73 
Airway Disease
b
 -0.15 (0.09) 0.86 (0.73, 1.03) 0.10 
Osteoporosis -0.11 (0.10) 0.90 (0.74, 1.09) 0.28 
Stroke -0.14 (0.10) 0.87 (0.72, 1.06) 0.18 
Any Dementia 0.13 (0.11) 1.14 (0.91, 1.42) 0.25 
Cancer 0.08 (0.12) 1.08 (0.85, 1.38) 0.53 
Pharmacotherapy    
Number of Medications
c
 0.01 (0.01) 1.01 (0.99, 1.03) 0.18 
Impaired Medication Management 0.48 (0.09) 1.61 (1.36, 1.91) <0.0001 
Medication Non-Adherence
d
 -0.27 (0.46) 0.77 (0.31, 1.87) 0.56 
Any ACE inhibitor use -0.04 (0.08) 0.96 (0.82, 1.13) 0.64 
Any ARB use -0.07 (0.13) 0.93 (0.72, 1.20) 0.57 
Any β-blocker use 0.06 (0.08) 1.06 (0.90, 1.24) 0.49 












 -0.04 (0.08) 0.96 (0.82, 1.13) 0.65 





















Service Use    
Any Nursing
h
 0.11 (0.08) 1.11 (0.95, 1.31) 0.19 
Any Homemaking
h
 -0.12 (0.08) 0.89 (0.76, 1.04) 0.14 
Any Physiotherapy
h
 0.10 (0.15) 1.10 (0.81, 1.49) 0.54 
Any Home Help
h
 -0.28 (0.09) 0.76 (0.64, 0.90) 0.001 
Weekly Cost of HC services
i 
0.27 (0.07) 1.31 (1.16, 1.49) <0.0001 
Any previous ED visit
j
 0.18 (0.07) 1.20 (1.05, 1.37) 0.008 
Any previous Hospitalization
j
 0.13 (0.06) 1.13 (1.00, 1.28) 0.047 
 
Abbreviations: ACE  = Angiotensin Converting Enzyme, ADL = Activities of Daily Living, ARB = 
Angiotensin Receptor Blocker, β-blocker =  β-Adrenergic Receptor Blocker, CAD = Coronary Artery 
Disease, CAP = Clinical Assessment Protocol, CHESS = Changes in Health, End-stage disease and Signs 
and Symptoms, CI = Confidence Interval, CPS  = Cognitive Performance Scale, ED  = Emergency 
Department, HC = Home Care, HF = Heart Failure, IADL = Instrumental Activities of Daily Living, 
MAPLe = Method for Assigning Priority Levels, OR = Odds Ratio, SE = Standard Error 
a
 excludes HF 
b
 includes chronic obstructive pulmonary disease (COPD), emphysema and asthma 
c
 excludes ACE inhibitor, β- blocker and ARB therapies  
d
 adherent less than 80% of the time
  
e 
ACE inhibitor or ARB use recorded at every assessment  
f
 β-blocker use recorded at every assessment 
g
 ACE inhibitor, ARB or β-blocker use recorded at every assessment 
h 
measured in 7 days prior to assessment 
i
 measured in increments of $100 
j 





Table 6: Summary of Bivariate Analyses for New Cognitive Decline within 90 days among 
Older Home Care Clients with Heart Failure, Ontario 2005-2007 (N=9,283) 
 






Sociodemographic Characteristics    
Age 0.28 (0.05) 1.32 (1.20, 1.45) <0.0001 
Female -0.18 (0.07) 0.83 (0.73, 0.95) 0.007 
Married -0.06 (0.03) 0.89 (0.78, 1.02) 0.09 
Living Alone -0.25 (0.07) 0.78 (0.68, 0.89) 0.0003 
Caregiver Stress 0.27 (0.09) 1.30 (1.09, 1.56) 0.003 
Clinical Characteristics    
ADL Hierarchy Scale score
 
0.06 (0.03) 1.06 (1.00, 1.11) 0.03 
IADL Capacity Scale score 0.07 (0.02) 1.07 (1.03, 1.12) 0.001 
CHESS Scale score 0.03 (0.03) 1.03 (0.97, 1.10) 0.32 
MAPLe Algorithm score 0.02 (0.03) 1.02 (0.97, 1.08) 0.43 
Behavioural Symptoms 0.34 (0.14) 1.41 (1.08, 1.84) 0.01 
Impairment with Stairs 0.11 (0.07) 1.11 (0.97, 1.28) 0.13 
Incontinence 0.07 (0.06) 1.07 (0.95, 1.22) 0.26 
Falls CAP 0.22 (0.04) 1.25 (1.14, 1.36) <0.0001 
Mood CAP 0.05 (0.05) 1.05 (0.96, 1.15) 0.28 
Number of Comorbid Conditions
a
 -0.26 (0.30) 0.78 (0.42, 1.44)` 0.42 
Diagnoses    
Hypertension -0.003 (0.07) 1.00 (0.87, 1.14) 0.97 
Arthritis -0.12 (0.07) 0.89 (0.78, 1.01) 0.07 
CAD -0.19 (0.07) 0.83 (0.73, 0.94) 0.003 
Diabetes Mellitus -0.08 (0.07) 0.92 (0.80, 1.06) 0.24 
Airway Disease
b
 -0.11 (0.07) 0.90 (0.78, 1.03) 0.12 
Osteoporosis -0.05 (0.08) 0.96 (0.82, 1.12) 0.57 
Stroke -0.10 (0.08) 0.90 (0.77, 1.05) 0.19 
Any Dementia 0.20 (0.09) 1.22 (1.02, 1.45) 0.03 
Cancer -0.14 (0.11) 0.87 (0.70, 1.07) 0.18 
Pharmacotherapy    
Number of Medications
c
 -0.01 (0.01) 0.99 (0.98, 1.01) 0.29 
Impaired Medication Management 0.40 (0.07) 1.49 (1.30, 1.71) <0.0001 
Medication Non-Adherence
d
 -0.01 (0.33) 0.99 (0.52, 1.87) 0.97 
Any ACE inhibitor use -0.04 (0.07) 0.96 (0.85, 1.09) 0.57 
Any ARB use -0.06 (0.10) 0.95 (0.77, 1.16) 0.59 
Any β-blocker use 0.005 (0.07) 1.01 (0.88, 1.14) 0.94 












 -0.06 (0.07) 0.94 (0.83, 1.08) 0.39 





















Service Use    
Any Nursing
h
 -0.03 (0.07) 0.97 (0.85, 1.10) 0.63 
Any Homemaking
h
 -0.19 (0.06) 0.83 (0.73, 0.94) 0.004 
Any Physiotherapy
h
 0.18 (0.12) 1.20 (0.94, 1.52) 0.14 
Any Home Help
h
 -0.30 (0.07) 0.74 (0.65, 0.85) <0.0001 
Weekly Cost of HC services
i 
0.17 (0.05) 1.18 (1.08, 1.30) 0.0005 
Any previous ED visit
j
 0.17 (0.06) 1.19 (1.06, 1.32) 0.003 
Any previous Hospitalization
j
 0.14 (0.05) 1.15 (1.04, 1.27) 0.006 
 
Abbreviations: ACE  = Angiotensin Converting Enzyme, ADL = Activities of Daily Living, ARB = 
Angiotensin Receptor Blocker, β-blocker =  β-Adrenergic Receptor Blocker, CAD = Coronary Artery 
Disease, CAP = Clinical Assessment Protocol, CHESS = Changes in Health, End-stage disease and Signs 
and Symptoms, CI = Confidence Interval, CPS  = Cognitive Performance Scale, ED  = Emergency 
Department, HC = Home Care, HF = Heart Failure, IADL = Instrumental Activities of Daily Living, 
MAPLe = Method for Assigning Priority Levels, OR = Odds Ratio, SE = Standard Error 
a
 excludes HF 
b
 includes chronic obstructive pulmonary disease (COPD), emphysema and asthma 
c
 excludes ACE inhibitor, β- blocker and ARB therapies  
d
 adherent less than 80% of the time
  
e 
ACE inhibitor or ARB use recorded at every assessment  
f
 β-blocker use recorded at every assessment 
g
 ACE inhibitor, ARB or β-blocker use recorded at every assessment 
h 
measured in 7 days prior to assessment 
i
 measured in increments of $100 
j 






Table 7: Proportional Hazards Regression Model of Time to Any Functional Decline 






(95% CL) p value 





     
0.21 (0.10) 
0.45 (0.10) 
1.23 (1.01, 1.49) 
1.56 (1.29, 1.89) 
0.04 
<0.001 
Female -0.27 (0.06) 0.76 (0.67, 0.86) <0.001 
Living Alone -0.51 (0.08) 0.60 (0.52, 0.70) <0.001 
Clinical Characteristics    
CHESS Scale score 0.08 (0.03) 1.08 (1.02, 1.14) 0.006 
MAPLe Algorithm score 0.24 (0.03) 1.27 (1.19, 1.35) <0.001 
Falls CAP                                         1
b






1.10 (0.94, 1.29) 
1.50 (1.27, 1.76) 
0.24 
<0.001 
Incontinence 0.16 (0.06) 1.17 (1.04, 1.32) 0.01 
Pharmacotherapy    
Impaired Medication Management 0.34 (0.08) 1.41 (1.21, 1.65) <0.001 
Any ACE inhibitor use -0.14 (0.06) 0.87 (0.77, 0.98) 0.02 
Any ARB use -0.04 (0.10) 0.96 (0.80, 1.16) 0.69 
Any β-blocker use -0.03 (0.06) 0.97 (0.86, 1.10) 0.67 
 
Individuals were followed for 9 months following each assessment. 1,105 individuals experienced any 
functional decline. Abbreviations: ACE = Angiotensin Converting Enzyme, ARB = Angiotensin 
Receptor Blocker, β–blocker = β-Adrenergic Receptor Blocker, CAP = Clinical Assessment Protocol; 
CHESS = Changes in Health, End-stage Disease, Signs and Symptoms, CL = Confidence Limit, MAPLe 
= Method for Assigning Priority Levels, SE = Standard Error 
a 
Reference Group: Age 65-74 years 
b 
1 prior fall: Reference Group = Level 0 (no prior falls) 
c





Table 8: Proportional Hazards Regression Model of Time to Any Cognitive Decline among 






(95% CL) p value 





     
0.46 (0.10) 
0.60 (0.10) 
1.58 (1.29, 1.93) 
1.83 (1.49, 2.23) 
<0.001 
<0.001 
Female -0.18 (0.06) 0.83 (0.74, 0.94) 0.004 
Living Alone -0.22 (0.07) 0.81 (0.71, 0.92) 0.001 
Clinical Characteristics    
ADL Hierarchy Scale score 0.05 (0.03) 1.06 (1.01, 1.11) 0.04 
MAPLe Algorithm score -0.10 (0.03) 0.90 (0.85, 0.96) 0.001 












Diagnoses    
Any Dementia 0.21 (0.09) 1.23 (1.03, 1.47) 0.02 
Pharmacotherapy    
Impaired Medication Management 0.34 (0.07) 1.41 (1.22, 1.63) <0.001 
Any ACE inhibitor use -0.03 (0.06) 0.97 (0.86, 1.09) 0.57 
Any ARB use -0.05 (0.10) 0.95 (0.79, 1.14) 0.57 
Any β-blocker use -0.08 (0.06) 0.92 (0.82, 1.04) 0.17 
 
Individuals were followed for 9 months following each assessment. 1,191 individuals experienced any 
cognitive decline. Abbreviations: ACE = Angiotensin Converting Enzyme, ARB = Angiotensin 
Receptor Blocker, ADL = Activities of Daily Living, β–blocker = β-Adrenergic Receptor Blocker, CAP 
= Clinical Assessment Protocol, CHESS = Changes in Health, End-stage disease, Signs and Symptoms, 
CL = Confidence Limit, MAPLe = Method for Assigning Priority Levels, SE = Standard Error 
a 
Reference Group: Age 65-74 years 
b
 Depression Rating Scale Score of 1-2, indicating some depressive symptoms: Reference Group =      
  Level 0 (no depressive symptoms) 
c 
Depression Rating Scale score of 3 or more, indicating probably depression: Reference Group =  





Table 9: Medication Use among Older Home Care Clients with Heart Failure Over Time 
(N=9,283) 
 
 Assessment 1 
n = 9,283 
Assessment 2 
n = 9,283 
Assessment 3 
n = 5,456 
Assessment 4 
n = 3,613 
ACE inhibitor Therapy 
Continuous Use 4,541 4,156 2,328 1,455 
Never Use 4,742 4,401 2,457 1,594 
New Use - 385 321 213 
Discontinued Use - 341 295 268 
Mixed Use
a
  - - 55 83 
β-blocker Therapy 
Continuous Use 3,985 3,711 2,022 1,305 
Never Use 5,298 4,951 2,847 1,840 
New Use - 274 227 162 
Discontinued Use - 347 218 239 
Mixed Use
a
  - - 42 26 
ARB Therapy 
Continuous Use 1,118 1,000 557 369 
Never Use 8,165 7,991 4,615 2,993 
New Use - 118 91 75 
Discontinued Use - 174 169 145 
Mixed Use
a
  - - 24 31 
 
Abbreviations: ACE = Angiotensin Converting Enzyme, ARB = Angiotensin Receptor Blocker, β-
blocker =  β-Adrenergic Receptor Blocker 
a





Table 10: Outcomes by ACE inhibitor Use Over Time among Older Home Care Clients 























Continuous Users 139 72 320 167 438 280 503 
Never Users 138 114 330 198 516 298 536 
New Users 13 10 65 24 65 46 66 
Discontinuers 

















  - 1 11 4 12 7 11 
 
Abbreviations: ACE = Angiotensin Converting Enzyme, ADL = Activities of Daily Living, ARB = 
Angiotensin Receptor Blocker, β-blocker = β-Adrenergic Receptor Blocker, CPS = Cognitive 
Performance Scale 
a
 use of ACE inhibitor therapy was inconsistent over all assessments 
 
 
Table 11: Long-Term Care Admission among Older Home Care Clients by ACE inhibitor 






















































































Table 12: Any Functional Decline among Older Home Care Clients by ACE inhibitor Use, 



















































































Table 13: New Functional Decline among Older Home Care Clients by ACE inhibitor Use,  











































































 use of ACE inhibitor therapy was inconsistent over all assessments 
 
 
